

ZIKA VIRUS VACCINE

FIELD OF INVENTION

5 The disclosure relates to methods for the purification of Zika viruses for use in vaccines and in particular relates to an improved sucrose gradient process step allowing the separation of impurities such as protamine sulphate. The disclosure also relates to Zika virus vaccines and compositions and methods for producing said vaccines and administering the vaccines to subjects for the generation of an anti-Zika virus immune response.

BACKGROUND OF THE INVENTION

Adverse responses to protamine sulfate have been known for many years. Previous exposure to protamine can induce a humoral immune response and predispose susceptible individuals to the development of untoward reactions from the subsequent use of this drug. Patients exposed to protamine through the use of protamine-containing insulin or during heparin neutralization may experience life-threatening reactions and fatal anaphylaxis upon receiving large doses of protamine intravenously. Severe reactions to intravenous protamine can occur in the absence of local or systemic allergic reactions to subcutaneous injection of protamine-containing insulin. Although there is no clear evidence for hypersensitivity reactions of protamine sulphate linked to vaccination, vaccines containing protamine impurities have a precaution and contraindication warning in their labels stating that a serious allergic reaction after a previous dose of such a protamine containing vaccine (e.g. IXIARO®, see CDC site <http://www.cdc.gov/japaneseencephalitis/vaccine/>) is a contraindication to further doses. Thus elimination of said impurity is a medical request for an improved safety profile. On the other hand protamine sulphate is an excellent tool (and often better than other tools such as benzonase) to purify crude harvests of viruses grown on cell substrates.

In 2007, Zika virus was detected for the first time outside of the endemic regions of Asia and Africa since its discovery in a Rhesus monkey in Uganda in 1947. Since then, the virus has caused a large epidemic in French Polynesia, spreading through islands in the Pacific and into South and Central America by 2015 (WHO “Zika Situation Report” February 5, 2016). Evidence suggests that in addition to being transmitted by *Aedes* species mosquitos, other vectors may exist, and the virus may be transmitted by blood transfusion, transplacentally, and through sexual transmission (WHO Zika Virus Fact Sheet, Feb. 2016). Though the symptoms of Zika virus infection include mild fever, rash, and conjunctivitis, there is a likely correlation between infection and neurological disorders, including

Guillain-Barré syndrome and microcephaly in fetuses/neonates subsequent to infection during pregnancy. There is currently no specific treatment or vaccine for Zika virus and the only preventative measures involve control of the mosquito vector. Zika virus presents a substantial public health threat due to the wide circulation of the *Aedes* mosquito, multiple routes of transmission, and potentially severe neurological effects of infection.

A preventative vaccine against Zika virus is a pressing medical need in endemic areas and in geographical areas where the vector is spreading. Furthermore, as Zika infection has dire consequences on embryonic and fetal development, a safe and effective vaccine for women of child-bearing potential or pregnant women is needed. Vaccines administered during pregnancy must be very safe for both the mother and the developing fetus. While live attenuated viral vaccines are highly effective, they are often not considered safe enough for administration to pregnant women. In this regard, inactivated viral vaccines, which lack the ability to propagate in the vaccinated subject, are considered much safer. Development of an inactivated Zika virus vaccine for administration to at-risk patients would fill this need.

SUMMARY OF THE INVENTION

During the course of virus purification, it was observed that addition of protamine sulfate to a virus harvest produced on a cell substrate removed not only contaminating DNA derived from host cells, as expected, but surprisingly also virtually eliminated immature and otherwise non-infectious virus particles from the preparation. This finding provided a streamlined, gentle, reproducible and broadly-applicable process for obtaining highly-purified infectious virus particles for applications such as vaccine preparation. In addition, it was surprisingly found that said protamine sulfate can be very efficiently separated from the virus fraction allowing for a safer vaccine produced at high yields.

Disclosed herein are virus vaccines and compositions comprising an inactivated Zika virus, and related methods of producing said vaccines and compositions. Also provided are methods of administering said Zika virus vaccines for the prevention of Zika virus infection and/or for the production of an anti-virus immune response in subjects, for example subjects at risk of being exposed to Zika virus. In particular, the invention is directed to a virus vaccine comprising an optimally inactivated Zika virus particle, wherein the Zika virus particle in an appropriate dose is able to seroconvert a subject that is administered the virus vaccine with at least a 70% probability, preferably an 80% probability. Another advantage of the invention is that related methods of producing said vaccines and compositions are very efficient and provide pure compositions largely

devoid of impurities, in particular protamine sulphate, allowing for high volume production of vaccines. Detail experimental examples to the above are provided for Zika virus.

The herein disclosed in vivo data regarding immunogenicity of the inactivated Zika virus vaccine of the current invention indicates that the virus is surprisingly potently immunogenic and also highly cross-protective (very similar immunogenicity in African and Asian strains). Data indicate that immunogenicity was unexpectedly higher than the recently reported inactivated Zika virus vaccine candidate (Larocca, et. al, 2016, Nature doi:10.1038/nature18952.). Inactivated viruses are among the safest vaccines and especially preferred for delivery to populations where safety is especially concerning, such as pregnant women, children and immunocompromised individuals, which makes the herein disclosed inactivated Zika virus particularly suitable. Obtaining a high titer of inactivated virus is a challenge in the field. The herein disclosed process for purifying inactivated Zika virus results in not only a high yield, but also a very pure drug substance.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention. This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings are not intended to be drawn to scale. The figures are illustrative only and are not required for enablement of the disclosure. For purposes of clarity, not every component may be labeled in every drawing, alignments were performed with the multi alignment package Jalview (Waterhouse et al., 2009, Bioinformatics 25 (9) 1189-1191). In the drawings:

Figure 1: Average distance tree (by % identity, nt), complete genomes.

Figure 2: Neighbor joining tree (by % identity, nt), complete genomes.

Figure 3: Pairwise alignment-Jalview (% identity, nt), complete genomes.

Figure 4: Average distance tree (by % identity, aa), E-protein.

Figure 5: Neighbor joining tree (by % identity. aa), E-protein.

Figure 6: Pairwise alignment-Jalview (% identity, aa), E-protein.

Figure 7: Alignment (shading: % identity, aa), E-protein.

Figure 8: An example of virus particle maturation in the host cell. As observed in flaviviruses, full maturation of the particles requires proteolytic cleavage of the precursor membrane glycoprotein (prM) by the host protease furin. Not all prM molecules are cleaved, resulting in the release of mature, mosaic or immature-like conformations from the cells. Mosaic and immature forms are generally not infectious—only mature virions are infective and have hemagglutinin (HA) / TCID50 activity. (Figure adapted from Plevka, et al., Maturation of flaviviruses starts from one or more icosahedrally independent nucleation centres, EMBO reports (2011) 12, 602–606).

Figure 9: An exemplary downstream virus purification process from the crude harvest to formulation of the drug substance (vaccine), a preferred embodiment of the process of the invention (**A**). A flow-chart of an exemplary virus inactivation process is shown in (**B**).

Figure 10: PS treatment results in selective removal of Zika virus aggregates and Vero HCP and LMW impurities (SEC-HPLC of 30x concentrated Zika Virus harvest day 5).

Figure 11: SEC-HPLC of individual 30x concentrated Zika harvest prior to PS treatment at different time points.

Figure 12: SEC-HPLC of individual 30x concentrated Zika harvest post PS treatment at different time points. The smaller graph indicates the observed cytopathic effect (CPE) over time.

Figure 13: Preparation of the sucrose gradient.

Figure 14: Representative SDS-PAGE from the sucrose gradient harvest of a Zika purification is shown.

Figure 15: Comparison of JEV and ZikaV harvest schedules/yields.

Figure 16: SEC-HPLC elution profile of ZikaV NIV. Data were processed on Dionex Ultimate 3000 / Superose 6 Increase column. Both panels are from the same chromatogram. The upper graph is the complete elution profile; the lower graph is an enlargement of the ZIKAV elution peak.

5 **Figure 17:** SEC-MALLS analysis of inactivated ZikaV.

Figure 18: Cumulative particle size distribution of Zika NIV.

10 **Figure 19:** Graphical representation of the neutralization of the Zika virus H/PF/2013 with pooled mouse sera. The number of plaques without serum was set to 100%. The EC50 was calculated using the 3-parameter method.

15 **Figure 20:** Graphical representation of the neutralization of the Zika virus MR766 with pooled mouse sera. The number of plaques without serum was set to 100%. The EC50 was calculated using the 3-parameter method.

Figure 21: Correlation between JEV antigen content in neutralized inactivated virus (NIV) analysed by ELISA and SEC-HPLC (Dionex Ultimate 3000, Superose 6 column).

20 DETAILED DESCRIPTION OF THE INVENTION

Disclosed herein are Zika virus vaccines and compositions comprising an inactivated Zika virus, and related methods of producing said vaccines and compositions. Also provided are methods of administering said virus vaccines for the prevention of virus infection and/or for the production of an anti-virus immune response in subjects, for example subjects at risk of being exposed to virus. In particular, the invention is directed to a virus vaccine comprising an optimally inactivated virus particle, wherein the virus particle in an appropriate dose is able to seroconvert a subject that is administered the virus vaccine with at least a 70% probability, preferably an 80% probability. Another advantage of the invention is that related methods of producing said vaccines and compositions are very efficient and provide pure compositions largely devoid of impurities, in particular protamine sulphate, allowing for high volume production of vaccines. Examples to the above are provided for Zika virus.

Disclosed herein are downstream processes for purifying Zika virus particles from a crude preparation. The downstream process can be applied to either a virus which has not adapted for

propagation on a particular cell substrate or for a partially / fully cell substrate adapted Zika virus particle.

Aspects of the invention provide processes for the purification of infectious Zika virus particles comprising the steps of (a) providing a crude harvest (a) comprising virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate; (b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising a protamine salt, preferably a protamine sulphate, to obtain a virus preparation (b); and further purifying the virus preparation (b) by an optimized sucrose density gradient centrifugation to obtain a virus preparation (c) comprising the infectious virus particles.

In some embodiments, the concentration of protamine sulphate in step (b) is about 1 to 10 mg/ml, more preferably about 1 to 5 mg/ml, more preferably about 1 to 2 mg/ml. In one embodiment, the concentration of protamine sulphate in step (b) is about 2 mg/mL. In one embodiment, the concentration of protamine sulphate is 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml. In a preferred embodiment, the concentration of protamine sulphate in step (b) is about 2 mg/ml.

In some embodiments, the residual host cell DNA of the virus preparation (c) is less than 1 µg/mL, especially less than 900, 800, 700, 600, 500, 400, 300 or 200 ng/mL, preferably less than 100 ng/mL.

In a preferred embodiment, the residual host cell DNA of the virus preparation (c) is less than 10 ng/mL. In some embodiments, the residual host cell protein of the final virus preparation (c) is less than 10 µg/mL, especially less than 9, 8, 7, 6, 5, 4, 3 or 2 µg/mL, preferably less than 1 µg/mL. In a preferred embodiment, the residual host cell protein of the virus preparation (c) is less than 100 ng/mL. In some embodiments, the residual non-infectious virus particles of the final virus preparation (c) is less than 10 µg/mL, especially less than 9, 8, 7, 6, 5, 4, 3 or 2 µg/mL, preferably less than 1 µg/mL. In a preferred embodiment, the content of residual non-infectious virus particles of the virus preparation (c) is less than 100 ng/mL.

In some embodiments, the residual protamine is less than 1 µg/mL, especially less than 900, 800, 700, 600, 500, 400, 300 or 200 ng/mL, preferably less than 100 ng/mL, more preferably is below the detection limit of HPLC, in particular below the detection limit in the final drug substance. In some embodiments, the PS content is tested by HPLC or size exclusion chromatography (SEC). For example, HPLC is validated for PS determination in JEV sucrose gradient pool samples as a routine release assay and is very sensitive (i.e., LOQ 3 µg/mL; LOD 1 µg/mL). In the current invention, PS content in in Zika virus DS samples was <LOD. In one embodiment, the HPLC assessment of PS

content can be performed on a Superdex Peptide 10/300GL column (GE: 17-5176-01) using 30% Acetonitrile, 0,1% Trifluoroacetic acid as solvent with a flow rate of 0,6 ml/min at 25°C and detection at 214 nm. A more sensitive method of measurement for residual protamine in a purified virus preparation is mass spectrometry (MS). In some embodiments, the residual PS levels in a Zika virus preparation are tested by MS or other such highly sensitive method, e.g. nuclear magnetic resonance (NMR). With this method, residual PS, as well as fragments and/or break-down products of PS, can be detected at trace amounts, such as levels as low as, for example, 10^6 , 10^7 or 10^8 molecules per typical sample load. In some embodiments, the PS levels are tested in the sucrose gradient pool. In some embodiments, the PS levels are tested in the drug product. In some embodiments, the PS levels are tested in the drug substance.

In some embodiments, the crude harvest (a) comprising the virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b). In some embodiments, the one or more pre-purification step(s) comprises digesting host cell genomic DNA in the crude harvest (a) comprising the virus particles and impurities by enzymatic treatment. In some embodiments, the one or more pre-purification step(s) comprises filtration, ultrafiltration, concentration, buffer exchange and/or diafiltration. In some embodiments, the one or more pre-purification steps is filtration using a filter having a pore size equal to or less than 1 μm . In some embodiments, the filter has a pore size equal to or less than 0.2 μm . In a preferred embodiment, the filter has a pore size of 0.2 μm . In some embodiments, the concentration and/or ultra/diafiltration and/or buffer exchange is performed by tangential flow filtration (TFF). In some embodiments, ultra/diafiltration of the crude harvest (a) comprising the virus particles and impurities is performed using a hollow fiber membrane having a cut-off of equal to or less than 300 kDa. In a preferred embodiment, the hollow fiber membrane has a cut-off of about 100 kDa.

The process according to the current invention may also comprise the use of a sucrose gradient, preferably an optimized sucrose gradient. The sucrose gradient is preferably optimized for the removal of protamine sulfate, also for the removal of immature viral particles or other viral particles which are non-infectious or host cell proteins or nucleic acids (DNA, RNA, mRNA, etc) or other host cell debris. In the current invention the optimized sucrose gradient comprises at least two, at least three, at least four layers of sucrose solutions with different densities. In one embodiment, the virus preparation to be purified is provided in a sucrose solution which has a density of about 8%, about 9%, about 10%, about 11%, about 12% sucrose (w/w), preferably about 10%. In one embodiment, one sucrose solution in the gradient has a density of about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55% sucrose (w/w),

preferably about 50%. In one embodiment, one sucrose solution in the gradient has a density of about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40% sucrose (w/w), preferably about 35%. In one embodiment, one sucrose solution in the gradient has a density of about 10%, about 11%, about 12%, about 13%, about 14%,
5 about 15%, about 16%, about 17%, about 18%, about 19%, about 20% sucrose (w/w), preferably about 15% sucrose. In a preferred embodiment, the sucrose gradient comprises three layers of sucrose solutions of about 50%, about 35% and about 15% (w/w) sucrose and the virus composition to be purified is contained in about 10% (w/w) sucrose. Because the invention provided for means to not only test for host cell DNA but also immature viral particles, the skilled person in the art is able to
10 more precisely optimize the sucrose gradient for most efficient purification and include additional tools such as PRNT assay to monitor purification success.

In some embodiments, the virus particle is a live virus, a chimeric virus, an attenuated live virus, a modified live virus, or a recombinant live virus. In a further step, the virus particles of the invention
15 may be optionally inactivated. In some embodiments, the virus particle is an attenuated form of the virus particle. For example, the virus may have reduced infectivity, virulence, and/or replication in a host, as compared to a wild-type virus. In some embodiments, the virus is a mutated or modified virus, for example the nucleic acid of the virus may contain at least one mutation relative to the wild-type virus. In some embodiments, the virus is a recombinant live virus, meaning a virus that is
20 generated recombinantly and may contain nucleic acid from different sources.

In some embodiments, the Zika virus particle is a live virus, an attenuated live virus, a modified live virus, or a recombinant live virus. In preferred embodiments, the Zika virus is a Zika virus from the Asian lineage.

In some embodiments, the relative reduction of impurity of the final virus preparation relative to the liquid medium (a) comprising the virus particles and impurities is in a range from 60 to 95%. In some
25 embodiments, the residual impurity of the final virus preparation is less than 1%.

In some embodiments, the Zika virus is propagated in a cell line selected from the group consisting of an EB66 cell line, a Vero cell line, a Vero- α His cell line, a HeLa cell line, a HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a diploid avian cell line. In some
30 embodiments, said cell line is a duck cell line. In some embodiments, said cell line is a diploid avian

cell line. In some embodiments, said cell line is an EB66 cell line. In a preferred embodiment, said cell line is a Vero cell line.

Aspects of the invention provide a use of any of the processes described herein for manufacturing a composition for immunization against a viral infection. In a preferred embodiment, the composition or vaccine is directed against Zika virus such as e.g. a Zika virus of the Asian lineage.

Other aspects provide compositions comprising the Zika virus particles obtainable by any of the processes described herein for treating and/or preventing (i.e. protecting from) a viral infection. In a preferred embodiment, the viral infection is caused by Zika virus such as e.g. a Zika virus of the Asian lineage.

Furthermore, disclosed herein are Zika virus vaccines and compositions comprising an inactivated Zika virus, and related methods of producing said vaccines and compositions. Also provided are methods of administering the Zika virus vaccines for the prevention of Zika virus infection and/or for the production of an anti-Zika virus immune response in subjects, for example subjects at risk of being exposed to Zika virus.

Zika virus is a flavivirus closely related to Dengue virus and is similarly transmitted by the *Aedes* species mosquito, although other arthropod vectors for Zika virus are possible. Since it was first isolated from a Rhesus monkey in the Zika forest of Uganda in 1947, there were very few reported incidents of human infection, especially outside of the endemic regions of Africa and Asia until a large outbreak in French Polynesia in 2007 (Haddow *et al. PLoS Neglected Tropical Diseases* (2012) 6(2), Malone *et al. PLoS Neglected Tropical Diseases* (2016) 10(3),). The virus has since spread through islands of the Pacific, including Oceania, and into South and Central America (WHO “Zika Situation Report” February 5, 2016).

In addition to being spread by the bite of an infected mosquito, evidence also suggests transmission may occur between individuals, such as from the blood of an infected individual, *in utero*/transplacental transmission from an infected mother to the fetus, sexual transmission between sexual partners, and possibly by other local transmission routes. There is a possible association between Zika virus infection during pregnancy and microcephaly in the fetus/neonate. Microcephaly is a rare condition in which a baby’s head circumference is significantly less than expected based on the average for their age, sex, and ethnicity. This is a result of the brain failing to undergo proper

embryonic development, and in 90% of cases is associated with mental retardation (Rocha *et al.* (2016) *Bull World Health Organ* 8 Feb. 2016).

There is a probable association between individuals having had a prior Zika virus infection and the incidence of Guillain-Barré syndrome, a neurological disorder in which the individual's immune system destroys the myelin sheath surrounding axons of the peripheral nervous system (WHO "Zika Situation Report" February 5, 2016).

No specific treatments or vaccines for Zika virus currently exist, and the only measures at this time to prevent infection are through vector control and avoiding travel to regions experiencing outbreaks.

Described herein are Zika virus vaccines and compositions comprising inactivated Zika virus that provide a safe method for generating an immune response to Zika virus, including virus-neutralizing antibodies, that may help prevent against Zika virus infection.

Any strain of Zika virus may be used in the methods and compositions described herein. In some embodiments, the Zika virus is an isolate from an infected subject during a Zika virus outbreak. In some embodiments, the Zika virus is a strain isolated from Africa or from the African virus lineage. In some embodiments, the Zika virus is a strain isolated from Asia or from the Asian lineage (includes also strains from French Polynesia). In some embodiments, the Zika virus is a strain isolated from the Americas (South America, Central America, or North America), such as a Suriname Zika virus strain. In some embodiments, the Zika virus has an RNA genome corresponding (but not limited) to the DNA sequence provided by GenBank Accession No. AY632535.2, KU321639.1, KU497555.1, KU501215.1, KU509998.1, KU527068.1, KU681081.3, KU681082.3, KU707826.1, KU744693.1, or LC002520.1 or RNA genome disclosed partially or fully herein (SEQ ID NO: 2 to 69).

In some embodiments, the process of the invention results in an enrichment of infectious Zika virus particles from the crude harvest comprising infectious Zika virus particles and non-infectious virus particles and other virus products such that the enrichment of the infectious virus particles is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, preferably at least 80%, especially at least 85% relative to the total virus particle content of the crude harvest (a) comprising the virus particles and impurities.

In some embodiments, the residual impurity of the final virus preparation with respect to all impurities in the crude harvest is less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, preferably less than 5% as determined by SEC-HPLC (Size Exclusion Chromatography – HPLC).

- 5 A unique aspect of the current invention is the realization that know-how related to the vaccine design and purification approach used for the Japanese Encephalitis Vaccine (JEV) IXIARO® (see Srivastava A.K. et al., 2001, Vaccine 19, 4557-4565, WO99/11762) may be employed and improved upon in order to expedite the development of a Zika virus vaccine and provide it to the subjects in need as soon as possible. The industrial process as disclosed for IXIARO®, providing a very effective
- 10 vaccine against JEV, was complemented by further significant improvements disclosed herein in order to provide a more efficient (higher yield) and safer (less or no protamine sulphate with its allergic potential) Zika vaccine compared to the available JEV vaccine. A particular innovation of the herein disclosed vaccines is their greatly reduced protamine salt (SEQ ID NO: 1) content in the final drug substance facilitated by the development of an improved sucrose gradient. Said sucrose gradient
- 15 not only allowed the separation of protamine sulphate but also allowed for a very effective inactivation by formaldehyde and resulted in the case of Zika with over 90% yield with the improved process disclosed herein vs about 35% yield with the published JEV process, see experimental part for comparison).
- 20 Aspects of the disclosure relate to methods of producing a virus in Vero tissue culture cells. Vero cells are a commonly used tissue culture cell line derived from the kidney of an African green monkey. The Vero cells used in the methods described herein are the Vero (WHO) cell line, obtained from the Health Protection Agency general cell collection under catalogue number 88020401.
- 25 Vero cells can be grown to confluent monolayers, for example in tissue culture flasks; in suspension (on microcarriers), for example in roller bottles; or in any other cell culture system for viral production. In some embodiments, the Vero cells are grown in a bioreactor for viral production. For plaque assays or the plaque reduction neutralization test (PRNT), Vero cells are grown in monolayers in tissue culture flasks, dishes, or wells of a plate. To infect the Vero cells with the virus, the culture
- 30 medium is inoculated with virus and the cells are incubated with the virus for a period of time. The cells may be washed after inoculation to remove any virus that did not adsorb to the cells in a given amount of time.

- The methods provided herein involve passaging the virus in Vero cells. As used herein, the terms
- 35 “passage” or “passaging” refer to infecting a population of Vero cells with virus and subsequently

inoculating a second population of Vero cells with virus produced by infection of the first Vero cell population. In some embodiments, a portion of the culture medium from the infected Vero cells (containing virus that was released from the infected cells) is used to inoculate a second population of Vero cells. This is referred to as one passage or one round of passaging. The passaging may be performed serially, for example, a portion of the culture medium from the infected second population of Vero cells is used to inoculate a third population of Vero cells, and so on. In some embodiments, virus obtained from a single plaque is used to inoculate another population of cells.

In some embodiments, the virus is passaged in Vero cells several times, such as at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 times. In some embodiments, the virus is passaged in Vero cells at least 4 times or 5 times. In some embodiments, the virus is passaged in Vero cells at least 30 times. It is important that the virus population, i.e. the virus sequences, stays as much as possible constant over said passaging. If adaption of the virus occurs (i.e. appearance of mutated viruses in the original virus population), it is preferred that said passages are not used in the context of manufacturing of said virus, e.g. for Zika it was found that up to passage 3 and culturing to day 7 can be used without major shifts in virus population, i.e. introduction of virus population with mutations. However this observation needs to be done for each virus strain and may be different.

In some embodiments, the Vero cells are incubated for at least 2 days after inoculation with the virus at e.g. a typical 0.01 MOI (multiplicity of infection) to allow for viral production prior to passaging. In some embodiments, the Vero cells are incubated for at least 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 days e.g. at least 7 days after inoculation with the virus prior to passaging. The number of days the Vero cells are incubated after viral inoculation may depend on factors such as the multiplicity of infection used to inoculate the cells and the viral titer desired in the culture medium. Serial passaging of the virus in Vero cells may result in generation of a Vero cell adapted virus strain.

The culture medium from the infected Vero cells may be harvested (collected) to obtain the virus. In some embodiments, the culture medium is harvested from infected Vero cells and is replaced with fresh culture medium, which is then harvested after another period of time. In some embodiments, the culture medium harvested from infected Vero cells is pooled from independent Vero cell cultures and/or from independent days. Harvesting can be repeated up to 4 times by 7 or 9 days post infection, for example, and result in a high yield of virus per unit cell culture. In order to minimize the adaption of Zika virus strain to Vero cells, it was found that Vero cells could be incubated for at least 7 days, more preferably 5 days, prior to passaging and subsequently supernatants could be harvested at days

2, 3, 5 and 7 or 2, 3, and 5 (see also experimental part). The harvested culture medium can be stored at +4°C prior to purification of the virus from the culture medium up to 2 weeks.

In some embodiments, debris from infected and lysed Vero cells may be removed from the harvested culture medium, referred to as a “clarification” of the culture medium. The harvested culture medium may be clarified by common methods known in the art, such as low-speed centrifugation, for example, at 1500 g for 10 min, and/or by filtration through a filter of pore size of 0.45 µm. The harvested culture medium can be stored at +4°C prior to concentration.

To concentrate the titer of the Zika virus in the harvested culture medium, it may be subjected to concentration by any method known in the art. For example, the harvested culture medium may be concentrated by methods including, without limitation, ultrafiltration, ultracentrifugation, centrifugal concentrator, vacuum centrifugation, and lyophilization. In some embodiments, the harvested culture medium is concentrated by ultrafiltration and the retentate containing the Zika virus is collected. In some embodiments, the harvested culture medium is concentrated by precipitation in which polyethylene glycol (PEG) 8000 is dissolved in the culture medium (up to 10%) and the precipitate is dissolved in a buffer, for example phosphate-buffered saline (PBS, pH 7.0).

The harvested culture medium may be precipitated to produce a virus supernatant. In some embodiments, the harvested culture medium is precipitated to remove Vero cell DNA and other undesired material, such as Vero cell debris, from the harvested culture medium. In some embodiments, the harvested culture medium is concentrated prior to precipitation. In some embodiments, the harvested culture medium is precipitated by adding protamine sulfate (e.g. SEQ ID NO: 1) to the harvested culture medium and incubating the mixture, for example at +4°C or on ice. In some embodiments, the harvested culture medium is treated with benzonase to remove Vero cell DNA and other undesired material, such as Vero cell debris, from the harvested culture medium. However, it was found that the treatment with protamine sulfate is preferred (see experimental part). In some embodiments, the precipitated culture medium is centrifuged to collect precipitated material and the supernatant containing the virus, referred to as a “virus supernatant”, is collected.

The virus supernatant may be further purified after precipitation, for example density gradient ultracentrifugation. In some embodiments, the virus supernatant is further purified by sucrose gradient. Fractions may be collected from the sucrose gradients and assayed for presence of the virus. Methods for assaying for virus positive fractions include plaque assay, hemagglutination assay, polyacrylamide gel electrophoresis, and antigen assays such as Western blotting and ELISA. The

fractions containing virus may be pooled based on titer of the virus and level of other impurities. The level or amount of impurities present in the virus supernatant can be estimated by testing for Vero cell DNA, virus aggregates and/or Vero cell protein (see experimental part). A particular embodiment of the invention is the improved sucrose gradient that allows for an efficient protamine separation as shown in the experimental part. It was surprisingly found that the addition of a virus-containing fraction with 10% (w/w) sucrose to a simple three layer sucrose density gradient (e.g. a gradient comprising a 15% (w/w) sucrose solution, a 35% (w/w) sucrose solution, and a 50% (w/w) sucrose solution) resulted in efficient separation of protamine sulphate without much loss of virus. Thus a particularly preferred embodiment of the invention is the use of a sucrose density gradient that is able to efficiently separate protamine sulphate, wherein said sucrose density gradient is used in the purification of virus such as the viruses described herein, i.e. a Zika virus.

To achieve a safe vaccine or composition for the administration to subjects, the virus supernatant may be inactivated (see experimental part for Zika virus). As used herein, the terms “inactivated” and “optimally inactivated” may be used interchangeably and refer to a process (or its result) by which the virus is rendered unable to infect a host cell (non-infectious), but that does not affect or substantially affect the antigenicity of the virus, for example, the immunogenic antigens exposed on the surface of the virus are able to stimulate an immune response in a subject (*e.g.*, antigen-specific antibodies). By “does not affect or substantially affect the antigenicity of the virus” is meant that the inactivated virus retains at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or even essentially 100% of the antigenicity of a virus that is not subjected to inactivation.

A variety of methods are known in the art for inactivating viruses. In some embodiments, the virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

In some embodiments, the inactivating is by chemical inactivation and involves contacting the virus with one or more chemical inactivation agents for a period of time under conditions such that the virus is inactivated but the antigenic epitopes are substantially intact. In some embodiments, the virus is inactivated for a period of time that is longer than is required to completely inactivate the virus. In some embodiments, the virus supernatant is inactivated for the number of days required to inactivate the virus plus at least one additional day. Samples of the virus supernatant may be taken at one or more times throughout the inactivation process and assessed for viral viability (infectivity) by any method known in the art, such as by infecting a monolayer of host cells (*i.e.*, plaque assay). Using

such a procedure, the period of time that is required to completely inactivate the virus can be determined, and a longer period of time is selected to ensure complete inactivation.

5 In some embodiments, the virus is contacted with a chemical inactivation agent for between 1 day and 50 days, between 2 days and 40 days, between 2 days and 30 days, between 2 days and 20 days, between 2 days and 10 days, between 3 days and 9 days, between 4 days and 8 days, between 5 days and 7 days, between 2 days and 5 days, or between 5 and 10 days. In some embodiments, the virus is contacted with one or more chemical inactivation agents for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 days, 49 days, or at least 50 days.

15 In some embodiments, the chemical inactivation is performed at about +5°C, +10°C, +15°C, +20°C, +25°C, +30°C, +35°C, +40°C, or about +45°C. In some embodiments, the chemical inactivation is performed at about +4°C. In some embodiments, the chemical inactivation is performed at about +22°C.

20 Any chemical inactivation agent known in the art may be suitable for inactivating the virus in the methods described herein. It will be appreciated by one of skill in the art that factors such as the chemical inactivation agent and the temperature at which inactivation is performed may affect the length of time (number of days) required to completely inactivate the virus. Examples of chemical inactivation agents include, without limitation, formaldehyde, enzymes, β -propiolactone, ethanol, trifluoroacetic acid, acetonitrile, bleach, urea, guanidine hydrochloride, tri-n-butyl phosphate, ethyleneimine or a derivatives thereof, and organic solvents such as Tween, Triton, sodium deoxycholate, and sulphobetaine. A preferred inactivation is inactivation with formaldehyde at 22°C $\pm$ 2°C for about 10 days.

30 In some embodiments, the inactivating agent is neutralized after chemical inactivation of the virus. In some embodiments, the inactivating agent is formaldehyde and is neutralized after chemical inactivation using sodium thiosulphate or sodium metabisulfite.

35 In some embodiments, the virus is inactivated by thermal inactivation. In some embodiments, the thermal inactivation involves exposing the virus to heat, such as dry heat or vapor heat, for a period of

time. In some embodiments, the thermal inactivation involves exposing the virus to temperatures of about +40°C, +45°C, +50°C, +55°C, +60°C, +65°C, +70°C, +75°C, +80°C, +85°C, +90°C, +95°C, or about +100°C. In some embodiments, the virus is exposed to heat for at least 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, about 96 hours, or longer. A preferred thermal inactivation involves exposing the virus to temperatures of about +56°C for 60 minutes.

In some embodiments, the virus is inactivated by exposing the virus to acidic or alkaline conditions for a period of time such that the virus is completely inactivated. The pH of a virus preparation may be adjusted to a desired pH, for example by the addition of an acid, a base, or a buffer with a particular pH to the virus preparation. In some embodiments, the virus is inactivated at an acidic pH of about 2, 2.5, 3, 3.5, 4, 4.5, 5 or about 5.5. In other embodiments, the virus is inactivated at an alkaline pH of about 8, 8.5, 9, 9.5, 10, or about 10.5.

In some embodiments, the virus is inactivated using UV inactivation. UV inactivation involves exposing the virus to energy-rich radiation, such as UV-A, UV-B, or UV-C light for a period of time. It will be appreciated that any two or more methods of inactivation may be combined and performed concurrently or serially.

The inactivated virus may be subsequently dialyzed to remove any undesired material, including the inactivating agent and any neutralizing agent, and/or to replace the buffer with a buffer that is pharmaceutically acceptable for administration to subjects. In some embodiments, the inactivated virus is dialyzed with PBS. In addition or alternatively, the inactivated virus may be filtered, such as sterile filtered, through a 0.22 µm filter.

Any of the methods or uses described herein may be for the prevention of a Zika virus infection in a subject. As used herein, the terms “prevent,” “preventing” and “protection from” include the administration of a virus vaccine or composition to a subject to reduce, or delay the onset of the manifestation of clinical or subclinical symptoms, complications, pathologies or biochemical indicia of a disease or infection, or to reduce or inhibit the spread/transmission of the Zika virus. As used herein, antigen(s), such as an inactivated Zika virus, that is administered to a subject prophylactically (e.g., prior to infection) may be referred to as a vaccine.

Zika Vaccine

As described herein Zika virus may cause any of a variety of symptoms upon infection of a subject, and is generally characterized by mild fever; rash (exanthema) on face, neck, trunk, upper arms; headache; sensitivity to light; non-inflammatory joint pain; conjunctivitis; lack of appetite; diarrhea; abdominal pain; and/or dizziness. Zika virus infection during pregnancy is associated with microcephaly in the fetus/neonate. There is also a probable association between the onset of Guillain-Barré syndrome or symptoms thereof. Diagnosis of Zika virus infection in subjects exposed to Zika virus or suspected of being exposed to Zika virus involves detecting the presence of virus-specific antibodies and/or molecular testing, such as PCR or real-time PCR detection of Zika virus.

Provided herein are methods for administering a dose of a therapeutically effective amount of a Zika virus vaccine to a subject in need thereof. In some embodiments, the subject is a mammalian subject, such as a human, non-human primate, rodent, rabbit, sheep, dog, cat, horse, or cow. In some embodiments, the subject is a mouse. In some embodiments, the subject is a human subject, such as a child, an adult, or an elderly adult. In some embodiments, the subject is a female subject. In some embodiments, the subject is pregnant or planning on becoming pregnant. In some embodiments, the subject is at risk of being exposed to Zika virus. In some embodiments, the subject is living in or traveling to an area where Zika virus is present or is thought to be present. In some embodiments, the subject has been previously infected with or vaccinated against Dengue virus; i.e., at risk for antibody-dependent enhancement of disease. In some embodiments, the subject is living in or traveling to an area that is experiencing a Zika virus infection outbreak. In some embodiments, the subject is living in or traveling to an area where an arthropod vector capable of transmitting the Zika virus vector is present or is thought to be present.

Any of the Zika virus vaccines or compositions described herein may be administered to a subject in a therapeutically effective amount or a dose of a therapeutically effective amount. As used herein, a “therapeutically effective amount” of vaccine is any amount that results in a desired response or outcome in a subject, such as those described herein, including but not limited to prevention of infection, an immune response or an enhanced immune response to Zika virus, or prevention or reduction of symptoms associated with Zika disease.

In some embodiments, the therapeutically effective amount of a Zika virus vaccine or composition described herein is an amount sufficient to generate antigen-specific antibodies (*e.g.*, anti-Zika virus antibodies). In some embodiments, the therapeutically effective amount is sufficient to provide seroprotection in a subject; i.e., to generate sufficient antigen-specific antibodies to prevent/protect

from infection. In some embodiments, seroprotection is conferred on at least 75%, 80%, 90%, 95%, 96%, 97%, 98%, or at least 99% of vaccinated subjects. In some embodiments, seroprotection is defined by a reduction in the number of Zika virus plaques by 50% or more in a plaque reduction neutralization test (PRNT) by a 1:10 or higher dilution of sera from a vaccinated subject. In some
5 embodiments, an effective amount of the Zika vaccine is sufficient to seroconvert a subject with at least 70% probability. In some embodiments, the therapeutically effective amount is sufficient to seroconvert a subject with at least 75%, 80%, 85% 90%, 95%, 96%, 97%, 98%, or at least 99% probability. Whether a subject has been seroconverted can be assessed by any method known in the art, such as obtaining a serum sample from the subject and performing an assay to detect anti-Zika
10 virus antibodies. In some embodiments, a subject is seroconverted if a serum sample from the subject contains an amount of anti-Zika virus antibodies that surpasses a threshold or predetermined baseline. A subject is generally considered seroconverted if there is at least a 4-fold increase in anti-Zika virus antibodies (*i.e.*, anti-Zika E protein IgG antibodies) in a serum sample from the subject as compared to a serum sample previously taken from the same subject.

15 In some embodiments, seroconversion of a subject is assessed by performing a plaque reduction neutralization test (PRNT). Briefly, PRNT is used to determine the serum titer required to reduce the number of Zika virus plaques by 50% (PRNT50) as compared to a control serum/antibody. The PRNT50 may be carried out using monolayers of Vero cells or any other cell type/line that can be
20 infected with Zika virus. Sera from subjects are diluted and incubated with live, non-inactivated Zika virus. The serum/virus mixture may be applied to the Vero cells and incubated for a period of time. Plaques formed on the Vero cell monolayers are counted and compared to the number of plaques formed by the Zika virus in the absence of serum or a control antibody. A threshold of neutralizing
25 antibodies of 1:10 dilution of serum in a PRNT50 is generally accepted as evidence of protection (Hombach *et. al.* Vaccine (2005) 23:5205-5211).

30 In some embodiments, the Zika virus may be formulated for administration in a composition, such as a pharmaceutical composition. The term “pharmaceutical composition” as used herein means a product that results from the mixing or combining of at least one active ingredient, such as an inactivated Zika virus, and one or more inactive ingredients, which may include one or more pharmaceutically acceptable excipient.

Pharmaceutical compositions of the invention, including vaccines, can be prepared in accordance with methods well known and routinely practiced in the art (see *e.g.*, Remington: The Science and Practice
35 of Pharmacy, Mack Publishing Co. 20th ed. 2000; and Ingredients of Vaccines – Fact Sheet from the

Centers for Disease Control and Prevention, e.g., adjuvants and enhancers such as alum to help the vaccine improve its work, preservatives and stabilizers to help the vaccine remain unchanged (e.g., albumin, phenols, glycine)). Pharmaceutical compositions are preferably manufactured under GMP conditions. Typically a therapeutically effective dose of the inactivated Zika virus preparation is employed in the pharmaceutical composition of the invention. The inactivated Zika virus is formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art. Dosage regimens are adjusted to provide the optimum desired response (e.g., the prophylactic response).

Dosages of the active ingredients in the pharmaceutical compositions of the present invention can be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired pharmaceutical response for a particular subject, composition, and mode of administration, without being toxic to the subject. The selected dosage level depends upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the subject being treated, and like factors.

A physician, veterinarian or other trained practitioner, can start doses of the inactivated Zika virus vaccine employed in the pharmaceutical composition at levels lower than that required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect (e.g., production of anti-Zika virus antibodies) is achieved. In general, effective doses of the compositions of the present invention, for the prophylactic treatment of groups of people as described herein vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and the titer of anti-Zika virus antibodies desired. Dosages need to be titrated to optimize safety and efficacy. In some embodiments, the dosing regimen entails subcutaneous or intramuscular administration of a dose of inactivated Zika virus twice, once at day 0 and once at about day 7. In some embodiments, the dosing regimen entails subcutaneous administration of a dose of inactivated Zika virus twice, once at day 0 and once at about day 14. In some embodiments, the dosing regimen entails subcutaneous administration of a dose of inactivated Zika virus twice, once at day 0 and once at about day 28. In some embodiments, the inactivated Zika virus is administered to the subject once.

Any of the Zika virus vaccines or compositions described herein may be administered to a subject with, prior to, or after administration of one or more adjuvants. An adjuvant is a molecule that enhances a response in a subject, such as an immune response, to an antigen or other molecule. In some embodiments, an adjuvant may stabilize an antigen or other molecule. Determining whether a Zika virus vaccine or compositions thereof are administered with an adjuvant depends on various factors (e.g., type and extent of response desired) and will be evident to one of skill in the art. In some embodiments, administering any of the Zika virus vaccines or compositions described herein with, prior to, or after administration of an adjuvant may enhance the production of virus neutralizing (anti-Zika virus) antibodies. In some embodiments, a subject that is administered any of the Zika virus vaccines or compositions described herein with, prior to, or after administration of an adjuvant may only require a single administration of the Zika virus vaccine or composition to be seroconverted (produce a level of anti-Zika virus antibodies). Examples of adjuvants may include, without limitation, aluminium salt (aluminium hydroxide or aluminium phosphate), calcium phosphate hydroxide, paraffin oil, killed bacteria, bacterial toxins, toxoids, subunits of bacteria, squalene, thimerosal, detergents, IL-1, IL-2, IL-12, 2-component adjuvants, such as 2-component adjuvants containing an antibacterial peptide and a TLR9 agonist (*e.g.*, IC31®), and combinations such as Freund's complete adjuvant and Freund's incomplete adjuvant. In some embodiments, the Zika virus vaccines or compositions is administered with aluminium hydroxide. In some embodiments, the inactivated Zika virus vaccine or composition is administered with aluminium phosphate salt. A preferred aluminium salt is the aluminium hydroxide with reduced Cu content, *e.g.* lower than 1,25ppb based on the weight of the Zika composition, an adjuvant described in detail in WO 2013/083726 or Schlegl et al., Vaccine 33 (2015) 5989-5996.

In some embodiments, the adjuvant is comprised of two components. In some embodiments, the 2-component adjuvant comprises an antibacterial peptide and a TLR9 agonist. In some embodiments, the antibacterial peptide is provided by the amino acid sequence KLKL₅KLK (SEQ ID NO: 71). In some embodiments, the TLR9 agonist is a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN). In some embodiments, the I-ODN comprises the nucleic acid sequence (dIdC)₁₃ (SEQ ID NO: 70). In some embodiments, the adjuvant is IC31®. In some embodiments, the adjuvant is in nanoparticle form (See, *e.g.*, US Patent No. 8,765,148 B2, incorporated by reference in its entirety). In some embodiments, the adjuvant is IC31®, *i.e.* KLKL₅KLK (SEQ ID NO: 71) and the nucleic acid sequence (dIdC)₁₃ (SEQ ID NO: 70), in combination with an aluminium salt such as aluminium hydroxide.

The Zika virus vaccines or compositions described herein may be administered to a subject concomitantly with one or more vaccines to another infectious agent, such as another infectious agent is that present or thought to be present in the same geographic area as Zika virus. In some embodiments, the other infectious agent is one that the subject is also at risk of being in contact with.

5 In some embodiments, the other infectious agent is transmitted by the same arthropod vector as Zika virus. In some embodiments, the other infectious agent is Japanese Encephalitis virus, Yellow Fever virus, Dengue virus and/or Chikungunya virus.

Also within the scope of the present disclosure are kits for use in prophylactically administering to a subject, for example to prevent or reduce the severity of Zika virus infection. Such kits can include one or more containers comprising a composition containing inactivated Zika virus, such as an inactivated Zika virus vaccine. In some embodiments, the kit may further include one or more additional containing comprising a second composition, such as a second vaccine. In some embodiments, the second vaccine is a vaccine for another arbovirus. In some embodiments, the second vaccine is a Dengue virus vaccine and/or a Chikungunya virus vaccine.

In some embodiments, the kit can comprise instructions for use in accordance with any of the methods described herein. The included instructions can comprise a description of administration of the composition containing inactivated Zika virus to prevent, delay the onset, or reduce the severity of Zika virus infection. The kit may further comprise a description of selecting a subject suitable for administration based on identifying whether that subject is at risk for exposure to Zika virus or contracting a Zika virus infection. In still other embodiments, the instructions comprise a description of administering a composition containing inactivated Zika virus to a subject at risk of exposure to Zika virus or contracting Zika virus infection.

The instructions relating to the use of the composition containing inactivated Zika virus generally include information as to the dosage, dosing schedule, and route of administration for the intended treatment. The containers may be unit doses, bulk packages (*e.g.*, multi-dose packages) or sub-unit doses. Instructions supplied in the kits of the invention are typically written instructions on a label or package insert (*e.g.*, a paper sheet included in the kit), but machine readable instructions are also acceptable.

The kits of the present disclosure are in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging, and the like. Also contemplated are packages for use in combination with a specific device, such as a syringe or an infusion device. The container may

have a sterile access port, for example the container may be a vial having a stopper pierceable by a hypodermic injection needle. At least one active agent in the composition is an inactivated Zika virus, as described herein.

5 This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including”, “comprising”, or “having,” “containing”, “involving”,
10 and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art.

15 Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. The methods and techniques of the present disclosure are generally performed according to conventional methods well-known in the art. Generally, nomenclatures used in connection with, and techniques of biochemistry, enzymology, molecular and cellular biology, microbiology, virology, cell or tissue culture, genetics and protein and nucleic chemistry described
20 herein are those well-known and commonly used in the art. The methods and techniques of the present disclosure are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated.

25 The present invention is further illustrated by the following examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference, in particular for the teaching that is referenced hereinabove. However, the citation of any reference is not intended to be
30 an admission that the reference is prior art.

Table 1. Overview of process buffers and stock solutions.

Buffer	Composition	Final pH	Final conductivity [mS/cm]
A	0.5 M NaOH		n.a.
B	0.1 M NaOH		n.a.

C	25 mM Tris, 150 mM NaCl	7.4±0.2	16.5
D	1 M Tris	7.4±0.2	n.a.
E	4,5 M NaCl	n.a.	n.a.
F	1 M NaCl	n.a.	n.a.
G	1 % SDS	n.a.	n.a.
H	50 % (w/w) Sucrose in 25 mM Tris, 150 mM NaCl	7.4±0.2	n.a.
I	35 % (w/w) Sucrose in 25 mM Tris, 150 mM NaCl	7.4±0.2	n.a.
J	15 % (w/w) Sucrose in 25 mM Tris, 150 mM NaCl	7.4±0.2	n.a.
K	10 x PBS	7.4±0.2	n.a.
L	50 mg/mL Protamine sulphate	7.4±0.2	n.a.
M	Drug substance formulation buffer (10mM Tris(hydroxymethyl)-aminomethan, 5 % Sucrose, 1% (10 mg/mL) rHSA)	7.4±0.2	1.3

Table 2. Abbreviations.

°Bx	Degrees Brix = sugar content (w/w) of an aqueous solution*
BSA	Bovine serum albumin
CC700	Capto™ Core 700
CPE	Cytopathic effect
EtOH	Ethanol
EU	Endotoxin units
DS	Drug Substance
DP	Drug Product
DSP	Downstream Process
HCP	Host cell protein
hcDNA	Host cell DNA
hpi	Hours post infection
HPLC	High Performance Liquid Chromatography
ID	Inner diameter
JEV	Japanese Encephalitis virus
LAL	Limulus amoebocyte lysate
LDS buffer	Lithium dodecyl sulfate sample loading buffer
LOD	Limit of detection
LOQ	Limit of quantitation
MALLS	Multiangle light scattering
mAU	Milli absorbance units
MS	Mass spectroscopy
NIV	Neutralized inactivated virus
PBS	Phosphate buffered saline
PD	Process development
PFU	Plaque forming units
p.i.	Post-infection
PS	Protamine sulphate or protamine sulfate
rcf	Relative centrifugal force
rHSA	Recombinant human serum albumin
Rms radius	Root mean square radius
rMSB	Research master seed bank
RSD	Relative standard deviation
SEC	Size exclusion chromatography
SGC	Sucrose gradient centrifugation
SGP	Sucrose gradient purified
SDS	Sodium dodecyl sulphate

TBS	Tris buffered saline
TFF	Tangential flow filtration
TCID50	Tissue culture infectious dose 50%
UF/DF	Ultrafiltration/diafiltration
WFI	Water for injection
ZikaV	Zika virus

*Degrees Brix (°Bx) is the sugar content of an aqueous solution. One degree Brix is 1 gram of sucrose in 100 grams of solution and represents the strength of the solution as percentage by mass. °Bx corresponds to the sucrose content in percent (w/w), e.g., 45 °Bx equals 45 % (w/w) sucrose.

5

Table A. Primers for Zika virus sequencing: lower case letters indicate bases not included in ZIKA but containing restriction sites for later cloning when needed (therefore, two Tms provided).

Primer Pair	Oligoname	Primer sequence (5'-3') restriction sites (lower case)	Tm (gene-specific)	Tm (entire primer)	Amplicon size [bp]
1	9320_Zika_PF_1F	SEQ ID NO: 74 ttaggatccGTTGTTGATCTGTGTGAAT	69.9	74.6	707
	9321_Zika_PF_1R	SEQ ID NO: 75 taactcgagCGTACACAACCAAGTT	69.3	75.6	
2	9322_Zika_PF_2F	SEQ ID NO: 76 ttaggatccTCACTAGACGTGGGAGTG	70	73.9	704
	9323_Zika_PF_2R	SEQ ID NO: 77 taactcgagAAGCCATGTCYGATATTGAT	69.8	73.7	
3	9324_Zika_PF_3F	SEQ ID NO: 78 ttaggatccGCATACAGCATCAGGTG	72.3	74.5	712
	9325_Zika_PF_3R	SEQ ID NO: 79 taactcgagTGTGGAGTTCCGGTGTCT	72	76.4	
4	9326_Zika_PF_4F	SEQ ID NO: 80 ttaggatccGAATAGAGCGAARGTTGAGATA	70.9	74	712
	9327_Zika_PF_4R	SEQ ID NO: 81 taactcgAGTGGTGGGTGATCTTCTTCT	70.5	73.7	
5	9328_Zika_PF_5F	SEQ ID NO: 82 ttaggatccCAGTCACAGTGGAGGTACAGTAC	70.3	75	704
	9329_Zika_PF_5R	SEQ ID NO: 83 taactcgagCRCAGATACCATCTTCCC	71.5	77.3	
6	9330_Zika_PF_6F	SEQ ID NO: 84 ttaggatCCCTTATGTGCTTGGCCTTAG	70.7	72.7	698
	9331_Zika_PF_6R	SEQ ID NO: 85 taactcgagTCTTCAGCCTCCATGTG	70.4	76.9	
7	9332_Zika_PF_7F	SEQ ID NO: 86 ttaggatccAATGCCCACTCAAACATAGA	71.9	75	716
	9333_Zika_PF_7R	SEQ ID NO: 87 taactcgagTCATTCTCTTCTTCAGCCCTT	71	74	
8	9334_Zika_PF_8F	SEQ ID NO: 88 ttaggatccAAGGGTGATCGAGGAAT	70.9	75.2	703
	9335_Zika_PF_8R	SEQ ID NO: 89 taactcgagTTCCTTCAGAGAGAGGAGC	71.9	73.4	
9	9336_Zika_PF_9F	SEQ ID NO: 90 ttaggatccTCTTTTGCAAACCTGCGATC	71.9	75	699
	9337_Zika_PF_9R	SEQ ID NO: 91 taactcgagTCCAGCTGCAAAGGGTAT	71	74.9	
10	9338_Zika_PF_10F	SEQ ID NO: 92 ttaggatccGTGTGGACATGTACATTGA	71.4	75.8	706
	9339_Zika_PF_10R	SEQ ID NO: 93 taactcgagCCCATTTGCCATAAAGTC	70.4	75.8	

Primer Pair	Oligoname	Primer sequence (5'-3') restriction sites (lower case)	Tm (gene-specific)	Tm (entire primer)	Amplicon size [bp]
11	9340_Zika_PF_11F	SEQ ID NO: 94 ttaggatccTCATACTGTGGTCCATGGA	71.6	78.1	692
	9341_Zika_PF_11R	SEQ ID NO: 95 taactcgagGCCCATCTCAACCC'TTG	74	78	
12	9342_Zika_PF_12F	SEQ ID NO: 96 ttaggatccTAGAGGGCTTCCAGTGC	70.9	74	707
	9343_Zika_PF_12R	SEQ ID NO: 97 taactcgagATACTCATCTCCAGGTTTGTG	70.2	72.2	
13	9344_Zika_PF_13F	SEQ ID NO: 98 ttaggatccGAAAACAAAACATCAAGAGTG	70.6	75.4	726
	9345_Zika_PF_13R	SEQ ID NO: 99 taactcgagGAATCTCTCTGTCATGTGTCCT	71.9	75.6	
14	9346_Zika_PF_14F	SEQ ID NO: 100 ttaggatccTTGATGGCAGCACCAAC	73.1	75.6	715
	9347_Zika_PF_14R	SEQ ID NO: 101 ttaggatccGTTGTTGATCTGTGTGAAT	70.8	77.9	
15	9348_Zika_PF_15F	SEQ ID NO: 102 taactcgagCAGGTCAATGTCCATTG	71.9	75.4	719
	9349_Zika_PF_15R	SEQ ID NO: 103 ttaggatccTGTGTGTTCTTATTGCTGGT	73.9	77.2	
16	9350_Zika_PF_16F	SEQ ID NO: 104 taactcgaGTGATCAGRGCCCCAGC	72.3	75.4	703
	9351_Zika_PF_16R	SEQ ID NO: 105 ttaggatccTGCTGCCCAGAAGAGAA	72	76.3	
17	9352_Zika_PF_17F	SEQ ID NO: 106 taactcgaGCACCAACAYGGGTTCTT	73.6	76	705
	9353_Zika_PF_17R	SEQ ID NO: 107 ttaggatccCTCAAGGACGGTGTGGC	72	75.5	
18	9354_Zika_PF_18F	SEQ ID NO: 108 taactcgagCAATGATCTTCATGTITGGG	71.7	75.8	699
	9355_Zika_PF_18R	SEQ ID NO: 109 ttaggatccTATGGGGGAGGACTGGT	71	74.1	
19	9356_Zika_PF_19F	SEQ ID NO: 110 taactcGAGCCCAGAACC'TTGATC	73.3	75.5	711
	9357_Zika_PF_19R	SEQ ID NO: 111 ttaggatccCAGACCCCCAAGAAGGC	71.3	76.9	
20	9358_Zika_PF_20F	SEQ ID NO: 112 taactcgagCCCCTTTGGTCTTGTCT	71.7	75	706
	9359_Zika_PF_20R	SEQ ID NO: 113 ttaggatccAGGAAGGATGTATGCAGATG	71.9	73.9	
21	9360_Zika_PF_21F	SEQ ID NO: 114 taactcgagACATTGCGCATATGATTTTG	70.4	75.7	709
	9361_Zika_PF_21R	SEQ ID NO: 115 ttaggatccAGGAAGGACACACAAGAGT	71.8	75	
22	9362_Zika_PF_22F	SEQ ID NO: 116 taactcgagACAGGCTGCACAGCTTT	70	79.1	581
	9363_Zika_PF_22R	SEQ ID NO: 117 ttaggatccTCTCTCATAGGGCACAGAC	74.8	81.1	

SEQUENCES

- 5 SEQ ID NO: 1
A typical form of protamine
PRRRSSSRP VRRRRRPRVS RRRRRRGGR RR

Provided below are examples of nucleic acid sequences of the genomes of Zika viruses that may be used in the methods, compositions, and/or vaccines described herein.

SEQ ID NO: 2

5 KU321639.1 Zika virus strain ZikaSPH2015, Brazil, complete genome
GTTGTTACTGTTGCTGACTCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTGG
ATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAACG
CGGAGTAGCCCGTGTGAGCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTCTATGGGCCATCAGG
10 ATGGTCTTGGCAATTCTAGCCTTTTGGAGATTACCGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTG
GGGAAAAAGAGGCTATGGAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGGA
AGGAGAAGAAGAGACGGGGCGCAGATACTAGTGTGGAATTGTTGGCCTCCTGCTGACCACAGCTATGGCAGCGGAGG
TCACTAGACGTGGGAGTGCATACTATGTACTTGGACAGAAACGATGCTGGGGAGGCCATATCTTTTCCAACCACATTG
GGGATGAATAAGTGTTATATACAGATCATGGATCTTGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCT
15 GGATGAGGGGGTGAACCATGACGTCGATTGTTGGTGCAACACGACGTCAACTGGGTTGTGTACGGAACCTGCCAT
CACAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCTCCATTCCACTAGGAAGCTGCAAACGCGGT
CGCAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTTGGCTTC
GCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCT
GATTGCCCCGGCATACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGG
20 GTTGATATTGCTTGAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTCGACATAGAGCTGGTTAC
AACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCT
GCCCCAACAAAGGTGAAGCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGACAGAGGC
TGGGGAAATGGATGTGGACTTTTTGGCAAAGGGAGTCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAAATGACCG
GGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTGATGCTGGCTCCAGCACAGTGGGATGATCGT
TAATGACACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACC
25 CTGGGGGGTTTTGGAAGCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGTATTACTTGACTATG
AATAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCCACGACATTCATTACCTTGGCACGCTGGGGCAGACACCGGAAC
TCCACACTGGAACAACAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACCTGTCGTGTTCTAGGG
AGTCAAGAAGGAGCAGTTCACACGGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCCT
CTGGCCACTTGAAATGTCGCCTGAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCTTGTGTACCGCAGCGTTCA
30 CATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGCAGGGACAGATGGACCTTG
CAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACCTTGACCCCAAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCA
CTGAAAGCACTGAGAACTCTAAGATGATGCTGGAACCTTGATCCACCATTTGGGGACTCTTACATTGTCATAGGAGTCGGG
GAGAAGAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAGGCACTTTGAAGCCACTGTGAGAGGTGCCA
AGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTATTGGGCAAGGGCAT
35 CCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTGGAGGAATGTCCTGGTTCTCACAATTTCTATTGGAACGTTGCTG
ATGTGGTTGGGTCTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCC
ACAGCCGTCTCTGCTGATGTGGGTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGCT
ATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAAGCA
AGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAAGAACATCATGTGGAGATCAGTAGAAGGGGAG
40 CTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTC
CACAGAGATTGCCCGTGCCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGCACTTCGTGAGAGCAGC
AAAGACAAATAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACAGCTTTC
TTGTGGAGGATCATGGGTTCGGGGTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGAT
CCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAGTATCTAGGCTACTGGATTGAGAGTGAGAAGA
45 ATGACACATGGAGGCTGAAGAGGGGCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGAC
AGATGGAATAGAAGAGAGTGTATGATCATACCAAGTCTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCT
ACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAATTCGGTTTGAAGGAATGCCAGGCACTAAGGTCCA
CGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTG
CTGCAGGGAGTGCACAATGCCCCACTGTGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCAGG
50 AAAGAACCAGAAAGCAACTTAGTAAGGTCAATGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGGAGT
GCTTGTGATTCTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATATAAGCACATCAATGGCA
GTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGTGGGTGCCACCTTCGC

GGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTATCTT
TCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTTGCAAACCTGCGATCTCCG
CCTTGGAAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCA
CTGATAACATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCCGGGGCACACTGCTTGTGGCGTGGAGAGCAGGC
5 CTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTGTAAGGGAAAAAGGCAGTGTGAAGAAGAACTTACCATTGTGTCATGGC
CCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGGGCTGCTGTTGCTCACAAGGAGTGGGAAGCGG
AGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGA
GATGGCTGGGCCCATGGCCGCGGTGCGTCTGCTAATTGTGAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTG
AAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAACAGTCCCCGGCTCGATGTGGCGCTAGATG
10 AGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGATGACCATC
TGTGGCATGAACCAATAGCCATACCCCTTTCAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTG
CTCTATGGGATGTGCTCTGCCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAG
ACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTACAAAAAGGA
TCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGAGATGTCAAGCAGGATCTGGTGTCTACTGTGGTC
15 CATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGGAGGA
ACATCCAGACTCTGCCCGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAAC
TTCAGGATCTCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGATCAAAAATGGGAGT
TATGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGCTGAAGAAGA
AGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACCAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATA
20 AAAACAAGACTCCGTACTGTGATCTTAGCTCCAACCAGGGTTGTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCC
AGTGCGTTATATGACAACAGCAGTCAATGTACCCACTCTGGAACAGAAATCGTCGACTTAATGTCCATGCCACCTTCAC
TTCACGTCTACTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCACTTCACAGATCCCTCAAGT
ATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACCAG
GAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACACCGAAGTGAAGTCCCAGAGAGAGCCTGGAGCTCA
25 GGCTTTGATTGGGTGACGGATTATTCTGGAAAAACAGTTTGGTTTGTTCGAAGCGTGAGGAACGGCAATGAGATCGCAGC
TTGTCTGACAAAAGGCTGGAAAACGGGTGCATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATC
AAGAGTGGGACTTTGTCGTGACAACCTGACATTTAGAGATGGGCGCCAACCTTAAAGCTGACCGTGTCTAGATTCCAGG
AGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGACCCATGCCTGTACACATGCCAGCGCTGC
CCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGAC
30 TGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCT
CTATCGACCTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTG
GAACTCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAGATAGAAG
ATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAGACACGGAGA
GAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTT
35 GCCGCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATT
CAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCGGCCCAAT
TGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTGTGGGAACAGTCTCGCTGGGAATCTTTTTCGTCTTGATGAGG
AACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTG
AGCCAGCCAGAATTGCATGTGTCTCATTGTTGTGTTCTATTGCTGGTGGTGTCTATACCTGAGCCAGAAAAGCAAAGAT
40 CTCCCCAGGACAACCAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGAT
GGTTGGAGAGAACAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGAGGGGGCAACCATGGGATTCTCAATGG
ACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACCTTTCATTACCCAGCCGTCCAACATGCAGT
GACCACTTCATAACAACACTACTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGC
CATTCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACGCCCCGTGACCCTAATAGTGG
45 CCATCATTTTGTCTGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCCAGAAGAGA
ACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCA
AGTGGAGAAAAAGATGGGACAGGTGCTACTCATGGCAGTAGCCGTCTCCAGCGCCATACTGTGCGGACCGCCTGGGGG
TGGGGGGAGGTGGGGCCCTGATCACAGCCGCAACTTCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTC
TACAGCCACTTCACTGTGTAACATTTTTAGGGGAAGTACTTGGCTGGAGCTTCTAATCTACACAGTAACAAGAAACGC
50 TGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTC
GGCCCTGGAGTTCTACTCTACAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCGCCCTCAAGGAC
GGTGTGGCAACGGGAGGCCATGCTGTGTCCGAGGAAGTGAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAG
CCCTATGGAAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGA
AGTGAAAGGATACAAAAAGGAGGCCCTGGTCATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGT

CTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATC
 TAGTCCTGAAGTGGAAAGAAGCACGGACGCTCAGAGTCTCTCCATGGTGGGGGATTGGCTTGAAAAAGACCAGGAGCC
 TTTTGTATAAAAGTGTTGTGCCCATACACCAGCACTATGATGGAAACCTGGAGCGACTGCAGCGTAGGTATGGGGGAG
 5 GACTGGTCAGAGTGCCACTCTCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAAGCAACACCATAAAA
 AGTGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCTAGGAGGCCAGTGAAATATGAGGAGGATGTGA
 ATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGTGAAGCTCCCAACATGAAGATCATTGGTAACCGATTGAAAGG
 ATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGA
 GGCCCCACACAAGGGTCAGCGTCCTCTCTAATAAACGGGGTGTGAGGCTCCTGTCAAAACCTGGGATGTGGTGACTG
 10 GAGTCACAGGAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTCAAGGAAAAAGTGGACACTAGGGT
 GCCAGACCCCCAAGAAGTACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAAGAGCTAGGCAACACAAAC
 GGCCACGAGTCTGTACCAAGAAGAGTTCATCAACAAGGTTCTGTAGCAATGCAGCATTAGGGGCAATATTTGAAGAGGA
 AAAAGAGTGAAGACTGCAGTGAAGCTGTGAACGATCCAAGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCA
 CCTGAGAGGAGAGTGCCAGAGTTGTGTACAACATGATGGGAAAAAGAGAAAAGAAACAAGGGGAATTTGAAAGGC
 CAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTCTTGAACGAGG
 15 ATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATGTCCTAGAAG
 AGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCT
 GGAGAATGAAGCTCTAATACCAACCAAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATAC
 CAAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAAACAGTTATGGACATTATTCGAGACAAGACCAAA
 GGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTGGAATATGGAGGCT
 20 GAGGAAGTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGA
 TGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCT
 CAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAACCCCTCACTGGATGGGACAACCTGGGAA
 GAAGTTCGTTTTGCTCCCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCAA
 GATGAAGTATTGGCCGGGCGCGTCTCTCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAAAATCAT
 25 ATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAG
 TTGACTGGGTTCCAACCTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGT
 GGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTTCC
 TATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGGCTGAGAACATTA
 AAAACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAAGTTTCGCTAC
 30 TTGGGTGAAGAAGGTCTACACCTGGAGTGCTGTAAGCACCAATCTTAATGTTGTGAGGCTGCTAGTCAGCCACAGCTT
 GGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGG
 CACGGAAGAAGCCATGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGAT
 GGGAAAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCCAGAAGAGG
 GACTAGTGGTTAGAGGAGA

35

SEQ ID NO: 3

KU497555.1 Zika virus isolate Brazil-ZKV2015, Brazil, complete genome

CCAATCTGTGAATCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTTGGATTTG
 GAAACGAGAGTTTTCTGGTCATGAAAAACCCAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAAACGCGGA
 40 GTAGCCCGTGTGAGCCCCCTTGGGGGCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTCTATCAATAGATGGGGTTCAGTGGGGA
 TCTTGGCGATTCTAGCCTTTTTGAGATTACGGAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGA
 AAAAGAGAGGCTATGGAAATAATAAAGAAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCCAGGAAGGA
 GAAGAAGAGACGAGGCGCAGATACTAGTGTGGAATCGTTGGCCTCCTGCTGACCACAGCTATGGCAGCGGAGGTCACT
 AGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACGATGCTGGGGAGGCCATATCTTTTCAACCACATTGGGGAT
 45 GAATAAGTGTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATG
 AGGGGGTGGAAACAGATGACGTGATTGTTGGTGAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCACAA
 AAAAGGTGAAGCACGAGATCTAGAAGAGCTGTGACGCTCCCTCCCTTCCACTAGGAAGCTGCAAACGCGGTGCGAA
 ACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAAATTGGATATTAGGAACCTGGCTTCGCGTT
 AGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGC
 50 CCCGGCATACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGAT
 GTTGTCTTGGAAATGGGGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTCGACATAGAGCTGGTTACAACAAC
 AGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCTGCCCAA
 CACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAAGCTTAGTGGACAGAGGCTGGGG
 AAATGGATGTGGACTTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAG

AGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTCAAGTTCATGGCTCCCAGCACAGTGGGATGATCGTTAATGA
 CACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTACCAAGAGCCGAAGCCACCCTGGGG
 GTTTTGGAAGCTTAGGACTTGATTGTGAACCGAGGACAGGCCCTTGACTTTTCAGATTTGTATTACTTGAATAAC
 AAGCACTGGTTGGTTCACAAGGAGTGGTTCACGACATTCCATTACCTTGGCACGCTGGGGCAGACACCGGAACTCCACA
 5 CTGGAACAACAAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCGTGGTTCTAGGGACTCAA
 GAAGGAGCAGTTACACGGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCCTCTGGCC
 ACTTGAAATGTCGCCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCACTCCTTGTGTACCGCAGCGTTCACATTCA
 CCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGCAGGGACAGATGGACCTTGCAAGGT
 10 TCCAGCTCAGATGGCGGTGGACATGCAAACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAA
 GCACTGAGAACTCTAAGATGATGCTGGAACCTGATCCACCATTGGGGACTCTTACATTGTCATAGGAGTCGGGGAGAAG
 AAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGAAAAAGCATTTGAAGCCACTGTGAGAGGTGCCAAGAGAA
 TGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTCATTGGGCAAGGGCATCCATCAA
 ATTTTTGGAGCAGCTTTCAAATCATTGTTGGAGGAATGCTCTGGTTCTCAAAATTCTCATTGGAACGTTGCTGATGTGGT
 15 TGGGTCTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTGATCTTCTTATCCACAGCCG
 TCTCTGCTGATGTGGGGTGTCTGGTGGACTCTCAAAGAAGGAGACGAGATGTGGTACAGGGGTGTTCTGTATAACGA
 CGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCTGACTCTCCCGTAGATTGGCAGCAGCAGTCAAGCAAGCCTGG
 GAAGATGGTATCTCGGGATCTCTCTGTTTCAAGAATGGAAAACATCATGTGGAGATCAGTAGAAGGGGAGCTTAACG
 CAATCCTGGAAGAGAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAG
 20 ATTGCCGTGCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTGAGAGCAGCAAAGACA
 AATAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACAGCTTTCTGTGGA
 GGATCATGGGTTGGGGTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGATCCAGCCG
 TTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAGTGTCTAGGCTACTGGATTGAGAGTGAGAAGAATGACAC
 ATGGAGGCTGAAGAGGGCCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGA
 25 ATAGAAGAGAGTGATCTGATCATACCAAGTCTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTACAGGAC
 CCAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCAGGCACTAAGGTCCACGTGGAG
 GAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTGTGCAGG
 GAGTGCACAATGCCCCACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAAC
 CAGAAAGCAACTTAGTAAGGTCAATGGTGAAGTGCAGGATCAACTGATCAGATGGATCACTTCTCCCTGGAGTGCTTGTG
 30 ATTCTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATATAAGCACATCAATGGCAGTGCTGG
 TAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGCGGAAATG
 AACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTC
 AGAGCTAATTGGACACCCCGTGAAGCATGCTGCTGGCCTTGGCCTCGTGTTTTTGCAAACTGCGATCTCCGCCTTGAA
 GGCGACCTGATGGTTCTCATCAATGGTTTTGCTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGACAAC
 35 ATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGAGAGCAGGCCCTTGCTAC
 TTGCGGGGGTTTATGCTCCTCTCTGAAGGGAAAAGGCAGTGTGAAGAAGAACTTACCATTGTGATGGCCCTGGGAC
 TAACCGCTGTGAGGCTGGTGCACCCCATCAACGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCC
 CCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCT
 GGGCCCATGGCCGCGGTGGTCTGCTAATTGTCAAGTACGTTGGTCTCAGGAAAGAGTGTGGACATGTACATTGAAAGAG
 CAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAACAGTCCCCGGCTCGATGTGGCGCTAGATGAGAGTG
 40 GTGACTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGATGACCATCTGTGGC
 ATGAACCCAATAGCCATACCCTTTCAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAGAGGAGTGGTGTCTATG
 GGATGTGCTGCTCCCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTA
 GGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTACAAAAGGATCCGCGC
 TGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGAGATGTCAAGCAGGATCTGGTGTCTACTGTGGTCCATGGAA
 45 GCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCA
 GACTCTGCCCGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTTCAGGA
 TCTCCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCGTGATAAAAAATGGGAGTTATGTTA
 GTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGCTGAAGAAGAAGCAGCT
 50 AACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACCAGGAGAGTTCCTGAAATAGTCCGTGAAGCCATAAAAAACA
 GACTCCGTACTGTGATCTTAGCTCAACCAAGGGTGTGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCGT
 TATATGACAACAGCAGTCAATGTACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACTTCAGT
 CTAACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCAAGCATAGCA
 GCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACCAGGAACCC
 GTGACGCATTTCCGGACTCCAACCTACCAATTATGGACACCGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTT

GATTGGGTGACGGATCATTCTGAAAAACAGTTTGGTTTGTTCAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCT
 GACAAAGGCTGAAAAACGGGTATACAGCTCAGCAGAAAGACTTTTGAAGACAGAGTTCCAGAAAAACAAACATCAAGAG
 TGGGACTTTGTCTGTGACAACTGACATTTAGAGATGGGCGCAACTTTAAAGCTGACCGTGTATAGATTCCAGGAGATG
 5 CCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCACTTCTGGCTGGACCCATGCCTGTCACACATGCCAGCGCTGCCAGAG
 GGAGGGGGCGCATAGGCAGGAATCCCAACAACTGGAGATGAGTACCTGTATGGAGGTGGGTGCGCAGAGACTGACG
 AAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATC
 GACCTGAGGCGGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTGGAAC
 TCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAGATAGAAGATGG
 10 TGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAGACACGGAGAGAAAA
 AGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCCG
 TGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGA
 AGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCGGCCCAATTGCCG
 GAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAATCTTTTTCGTCTTGATGAGGAACAA
 GGGCATAGGGAAGATGGGCTTTGGAATGGTGAAGTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCA
 15 GCCAGAATTGCATGTGTCCTCATTGTTGTGTTCTATTGCTGGTGGTGTCTACCTGAGCCAGAAAAAGCAAAGATCTCCC
 CAGGACAACCAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAAGTCGGATGGTT
 GGAGAGAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATAGGATTCTCAATGGACAT
 TGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACCTTTCATTACCCAGCCGTCACATGCAGTGAC
 CACTTCATACAACAATACTCCTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGCCAT
 20 TCTACGCATGGGACTTTGGAGTCCCGTCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATAGTGGCCA
 TCATTTTGTCTGTGGCGCACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGTGCCAGAAAGAGAACG
 GCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGAAGTGAACATGACAATTGACCCCAAGT
 GGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTCGCGGACCGCTGGGGGTGG
 GGGGAGGCTGGGGCCCTGATCACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAAGTCTCTAC
 25 AGCCACTTCACTGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACGCTGG
 CTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCTGGGAGAGAAATGGAAGGCCCGCTGAACCATGTCGGC
 CCTGGAGTTCTACTCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGCGCCCTCAAGGACGGT
 GTGGCAACGGGAGGCCATGCTGTGTCCGAGGAAGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCC
 30 TATGGAAGGTCAATTGATCTTGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAG
 TGAAAGGATACAAAAAGGAGGCCCTGGTCATGAAGAACCCTGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGTCT
 TAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATCTA
 GTCCTGAAGTGAAGAAGCACGGACGCTCAGAGTCTCTCCATGGTGGGGGATTGGCTTGAAAAAGACCAGGAGCCTT
 TTGCATAAAAGTGTGTGCCATACACCAGCACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGA
 35 CTGGTCAGAGTGCCACTCTCCCGCAACTCTACACATGAGATGTAAGTGGTCTCTGGAGCGAAAAAGCAACACCATAAAAAAG
 TGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCTAGGAGGCCAGTGAAATATGAGGAGGATGTGAAT
 CTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGTCCCAACATGAAGATCATTGGTAACCGCATTGAAAGGAT
 CCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAAAAACCCCATATAGGACATGGGCTTACCATGGAAGCTATGTG
 GCCCCACACAAGGTCAGCGTCTCTCTAATAAACGGGGTTGTACAGGCTCTGTCAAAACCTGGGATGTGGTGACTGG
 AGTCACAGGAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTAGGGTG
 40 CCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAAGAGCTAGGCAAACACAAACG
 ACCACGAGTCTGTACCAAAGAAGAGTTTCATCAACAAGGTTCTGAGCAATGCAGCATTAGGGGCAATATTTGAAGAGGAA
 AAAGAGTGGAAGACTGCAGTGGAAGCTGTGAACGATCCAAGGTTCTGGGCTCTAGTGGAACAAGGAAAGAGAGCACCAC
 CTGAGAGGAGAGTGCCAGAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAGGCC
 AAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTGGAAGCCCTTGGATTCTTGAACGAGGA
 45 TCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATGTCCTAGAAGA
 GATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTG
 GAGAATGAAGCTCTAATACCAACCAAAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACC
 AAAACAAAGTGGTAAAGTCTTAGACCAGCTGAAAAAGGGGAAACAGTTATGGACATTATTTGAGACAAGACCAAAG
 GGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTATTGGAATATGGAGGCTG
 50 AGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGAT
 GGGATAGGCTCAAACGAATGGCAGTCAGTGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTC
 AGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAACCCCTCAACTGGATGGGACAACTGGGAA
 GAAGTTCCGTTTTGCTCCACCACTTCAACAAGTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCA
 GATGAAGTATTGGCCGGGCGCGTCTCTCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAAAATCAT

ATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAG
 TTGACTGGGTTCCAACCTGGGAGAACTACCTGGTCAATCCATGGAAGGGGAGAATGGATGACCACTGAAGACATGCTTGT
 GGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCCAAGTTACGAAATGGACAGACATTTCCC
 5 TATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCCACCTGGGCTGAGAACATTA
 AAAATACAGTCAACATGGTGGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAAGTTTCGCTAC
 TTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTGAGACCAATCTTAATGTTGTCAGGCCTGCTAGTCAGCCACAGCTT
 GGGGAAAAGCTGTGCAGCCTGTGACCCCTCCAGGAGAAGCTGGGTAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGC
 ACGGAAGAAGCCATGCTGCCTGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGATG
 10 GGAAAAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCCAGAAGAGGG
 ACTAGTGGTTAGAGGAGACCCCCGAAAACGCAAAACAGCATATTGACGCTGGGAAAGACCAGAGACTCCATGAGTTT
 CCACCACGCTGGCCGCCAGGCACAGATCGCCGAATAGCGGCGGCCGGTGTGGGGAATCCA

SEQ ID NO: 4

KU501215.1 Zika virus strain PRVABC59, Puerto Rico, complete genome

15 GTTGTGATCTGTGTAATCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAAGCTAGCAACAGTATCAACAGGTTTTATTTTG
 GATTTGGAACGAGAGTTTCTGGTCATGAAAAACCAAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAAC
 GCGGAGTAGCCCGTGTGAGCCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTCATGGGCCATCAG
 GATGGTCTTGCGGATTCTAGCCTTTTTGAGATTACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGT
 GGGGAAAAAAGAGGCTATGGAACAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGG
 20 AAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGGAATTGTTGGCCTCCTGCTGACCACAGCTATGGCAGCGGAG
 GTCCTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACGATGCTGGGGAGGCCATATCTTTTCAACCACATT
 GGGGATGAATAAGTGTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGC
 TGGATGAGGGGGTGAACCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCA
 TCACAAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCTCCATTCCACCAGGAAGCTGCAACGCGG
 25 TCGCAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCTT
 CGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCT
 GATTGCCCGGCATACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGG
 GTTGATGTTGCTTGAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTCGACATAGAGCTGGTTAC
 AACACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCTGACAGCCGCT
 30 GCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGACAGAGGGC
 TGGGGAAATGGATGTGGACTTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCG
 GGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTGAGTTTCATGGCTCCAGCACAGTGGGATGATCGT
 TAATGACACAGGACATGAAACTGATGAGAATAGAGCGAAAGTTGAGATAACGCCCAATTCACCGAGAGCCGAAGCCACC
 CTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCCTTGACTTTTCAGATTTGTATTACTTGACTATG
 35 AATAACAAGCACTGGTTGGTTTACAAGGAGTGGTTCCACGACATTCCATTACCTTGGCACGCTGGGGCAGACACCGGAAC
 TCCACACTGGAACAACAAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCGTGGTTCTAGGG
 AGTCAAGAAGGAGCAGTTACACGCGCCCTTGTGGAGCTCTGGAGGCTGAGATGGATGGTGAAAGGGGAAGGCTGTCTT
 CTGGCCACTTGAAATGTCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTGTGACTGCAGCGTTCA
 CATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGACAGGACAGATGGACCTTG
 40 CAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTCTGACCCCAAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCA
 CTGAAAGCACTGAGAACTCTAAGATGATGCTGGAACCTTGATCCACCATTTGGGGACTCTTACATTGTCATAGGAGTCGGG
 GAGAAGAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGAAAAAGCATTGGAAGCCACTGTGAGAGGTGCCA
 AGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTCATTGGGCAAGGGCAT
 CCATCAAATTTTTGGAGCAGCTTCAAATCATTGTTTGGAGGAATGTCTGGTTCTCACAAATCTCATTGGAACGTTGCTG
 45 ATGTGGTTGGGTCTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCC
 ACAGCCGCTCTGCTGATGTGGGGTGTCTCGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTTCGTCT
 ATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAAGCA
 AGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAACATCATGTGGAGATCAGTAGAAGGGGAG
 50 CTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTC
 CACAGAGATTGCCCGTGCCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTATTTCTGTCAGAGCAGC
 AAAGACAAATAACAGCTTTGTCTGGATGGTGACACACTGAAGGAATGCCACTCAAACATAGAGCATGGAACAGCTTTC
 TTGTGGAGGATCATGGGTTTCGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGAT
 CCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAGTGTCTAGGCTACTGGATTGAGAGTGAGAAGA
 ATGACACATGGAGGCTGAAGAGGGCCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGAC

AGATGGAATAGAAGAGAGTGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCT
 ACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAATTCGGTTTTGAGGAATGCCAGGCACTAAGGTCCA
 CGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTG
 CTGCAGGGAGTGCACAATGCCCCACTGTCTGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGG
 5 AAAGAACCAGAAAGCAACTTAGTAAGGTCAATGGTGAAGTGCAGGATCAACTGATCACATGGACCACTTCTCCCTTGGAGT
 GCTTGTGATCCTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATGGCA
 GTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGC
 GGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTATCTT
 10 TCATCTTCAGAGCTAATTGGACACCCCGTAAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTTGCAAACCTGCGATCTCCG
 CTTTGGAAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCA
 CTGATAACATCACCTTGGCAATCCTGGCTGCTGACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGGAGAGCAGGC
 CTTGCTACTTGCAGGGGGTATATGCTCCTCTCTGTAAGGGGAAAAGGCAGTGTGAAGAAGAACTTACATTTGTCATGGC
 CCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGG
 AGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGA
 15 GATGGCTGGGCCCATGGCCGCGGTCTGCTAATTGTGAGTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTG
 AAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCGATGTGGCGCTAGATG
 AGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGATGACCATC
 TGTGGCATGAACCAATAGCCATACCTTTGCAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTG
 CTCTATGGGATGTGCTGCTCCCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAG
 20 ACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCACAAAAGGA
 TCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGAGATGTCAAGCAGGATCTGGTGTACACTGTGGTC
 CATGGAAGCTAGATGCCGCTGGGATGGGCACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGA
 ACATCCAGACTCTGCCGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAAC
 TTCAGGATCTCCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGATCAAAAACGGGAGT
 25 TATGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCCTCGATGCTGAAGAAGA
 AGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATA
 AAAACAAGACTCCGTACTGTGATCTTAGCTCCAACCAGGGTTGTCGCTGCTGAAATGGAGGAGGCCCTTAGAGGGCTTCC
 AGTGCGTTATATGACAACAGCAGTCAATGTACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCAC
 TTCAGTCTACTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCAAGT
 30 ATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACCAG
 GAACCCGTGACGCATTTCCGGAAGTCCAACCTACCAATTATGGACACCGAAGTGAAGTCCAGAGAGAGCCTGGAGCTCA
 GGCTTTGATTGGGTGACGGATCATTCTGGAAAAACAGTTTGGTTTGTTCGAAGCGTGAGGAACGGCAATGAGATCGCAGC
 TTGTCTGACAAAAGGCTGGAAAAACGGGTGCATACAGCTCAGCAGAAAAGACTTTTGAACAGAGTTCCAGAAAAACAAACATC
 AAGAGTGGGACTTTGTCGTGACAACCTGACATTTAGAGATGGGCGCCAACCTTAAAGCTGACCGTGTATAGATTCCAGG
 35 AGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCACTTGGCTGGACCCATGCCTGTACACATGCCAGCGCTGC
 CCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGAC
 TGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCT
 CTATCGACCTGAGGCCGACAAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTG
 GAACTCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGTTTGCATCTGCCGGAATAACCTACACAGATAGAAG
 40 ATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAGACACGGAGA
 GAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTT
 GCCGCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATT
 CAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGCGGCCCAAT
 TGCCGGAGACCCTAGAGACCATAATGCTTTTGGGGTGTCTGGGAACAGTCTCGCTGGGAATCTTCTTCTGCTTGTGATGAGG
 45 AACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGAAGTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTG
 AGCCAGCCAGAATTGCATGTGTCTCATTGTTGTGTTCTATTGCTGGTGGTGTCTATACCTGAGCCAGAAAAGCAAAGAT
 CTCCCCAGGACAACCAATGGCAATCATCATGTTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGAT
 GGTTGGAGAGAAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGAGGGGGCAACCATAGGATTCTCAATGG
 ACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACCTTCAATACCCAGCCGTCCAACATGCAGT
 50 GACCACCTCATACAACAACTACTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTGTTTGGCATGGGCAAAGGGATGC
 CATTCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATAGTGG
 CCATCATTTTGTCTGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGTGCCAGAAAGAGA
 ACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCA
 AGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTCGCGGACCGCCTGGGGG

TGGGGGGAGGCTGGGGCTCTGATCACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCT
 TACAGCCACTTCACTGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTAATCTACACAGTAACAAGAAACGC
 TGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTC
 5 GGCCCTGGAGTTCTACTCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGCTCAAGGAC
 GGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAAGTGAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAG
 CCCTATGGAAAGGTCAATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTACTACGTCGCCACCATCCGCAAAGTTCAAGA
 AGTGAAAGGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGT
 CTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATC
 10 TAGTCCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCCTCTCCATGGTGGGGGATTGGCTTGAAAAAGACCAGGAGCC
 TTTTGTATAAAAGTGTTGTGCCATACACCAGCACTATGATGGAAACCTGGAGCGACTGCAGCGTAGGTATGGGGGAG
 GACTGGTCAGAGTGCCACTCTCCCGCAACTCTACACATGAGATGTAAGTGGTCTCTGGAGCGAAAAAGCAACACCATAAAA
 AGTGTGTCCACCACGAGCCAGCTCCTCTTGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGAGGAGGATGTGA
 ATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAAAGG
 ATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGA
 15 GGCCCCCACACAAGGGTCAGCGTCCTCTAATAAACGGGGTGTGAGGCTCCTGTCAAACCTGGGATGTGGTGACTG
 GAGTCACAGGAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGACACTAGGGT
 GCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAGAGCTAGGCAACACAAAC
 GGCCACGAGTCTGCACCAAAGAAGAGTTCATCAACAAGGTTCTGATGAATGCAGCATTAGGGGCAATATTTGAAGAGGA
 AAAAGAGTGGAAGACTGCAGTGGAAGCTGTGAACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCA
 20 CCTGAGAGGAGAGTGCCAGAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAGAAACAAGGGGAATTTGAAAGGC
 CAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTCTTGAACGAGG
 ATCACTGGATGGGGAGAGAGAAGTCAAGGAGGTGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATGTCCTAGAAG
 AGATGAGTCGTATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCTTAGCAGGTTTGATCT
 GGAGAATGAAGCTCTAATCACCAACCAAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATAC
 25 CAAAACAAAGTGGTAAAGGTCTTAGACCAGCTGAAAAAGGGAAAAACAGTTATGGACATTATTTGAGACAAGACCAAA
 GGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTGGAATATGGAGGCT
 GAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGA
 TGGGATAGGCTCAAACGAATGGCAGTCAGTGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCT
 CAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAACCCTCAACTGGATGGGACAACCTGGGAA
 30 GAAGTTCGTTTTGCTCCCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCAA
 GATGAACTGATTGGCCGGGGCCGCGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAAAATCAT
 ATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAG
 TTGACTGGGTTCCAAGTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGT
 GGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCC
 35 TATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGCTGAGAACATTA
 AAAACACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAAGTTTCGCTAC
 TTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTAAGCACCAATCTTAATGTTGTGAGGCTGCTAGTCAGCCACAGCTT
 GGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGG
 CACGGAAGAAGCCATGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGAT
 40 GGGAAAAAGAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAAGTGGAGATCAGCTGTGGATCTCCAGAAGAGG
 GACTAGTGGTTAGAGGA

SEQ ID NO: 5

KU509998.1 Zika virus strain Haiti/1225/2014, Haiti, complete genome

45 GTTGTTACTGTTGCTGACTCAGACTGCGACAGTTTCAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTGG
 ATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAACG
 CGGAGTAGCCCGTGTGAGCCCTTTGGGGGCTTGAAGAGGTGCCAGCCGACTTCTGCTGGGTGATGGGCCCATCAGG
 ATGGTCTTGGCAATTCTAGCCTTTTGAAGATTACGGAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTG
 GGGAAAAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGGA
 50 AGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGGAATTGTTGGCCTCTGCTGACCACAGCTATGGCAGCGGAGG
 TCACTAGACGTGGGAGTGCATACTATATGTAAGTGGACAGAAACGATGCTGGGGAGGCCATATCTTTTCAACCACATTG
 GGGATGAATAAGTGTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCT
 GGATGAGGGGGTGGAACCAGATGACGTGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGACGGAACCTGCCAT
 CACAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCTCCATTCCACTAGGAAGCTGCAACGCGGT

CGCAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCTTC
 GCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCT
 GATTGCCCCGGCATACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGG
 GTTGATGTTGCTTGAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGTTAC
 5 AACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCT
 GCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGACAGAGGC
 TGGGGAAATGGATGTGGACTTTTTGGCAAAGGGAGTCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCG
 GGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTGAGTTTATGGCTCCCAGCACAGTGGGATGATCGT
 10 TAATGACACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACC
 CTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGTATTACTTGACTATG
 AATAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCACGACATTCCATTACCTTGGCACGCTGGGGCAGACACCGGAAC
 TCCACACTGGAACAACAAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCCAACTGTCGTGGTTCTAGGG
 AGTCAAGAAGGAGCAGTTACACGCGCCCTTGTGAGGCTCTGGAGGCTGAGATGGATGGTGAAAGGGGAAGGCTGTCCT
 15 CTGGCCACTTGAAATGTCGCTGAAATGGATAAACTTAGATTGAAGGGCGTGTACTACTCTTGTGTACCGCAGCGTTCA
 CATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGACGGGACAGATGGACCTTG
 CAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCA
 CTGAAAGCACTGAGAACTCTAAGATGATGCTGGAACCTTGATCCACCATTGGGGACTTTACATTGTCATAGGAGTCGGG
 GAGAAGAAGATCACCCACACTGGCACAGGAGTGGCAGCACCATTTGAAAAAGCATTGAAGCCACTGTGAGAGGTGCCA
 20 AGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTATTGGGCAAGGGCAT
 CCATCAAATTTTTGGAGCAGCTTTCAAATCATTGTTGGAGGAATGTCCTGGTTCTCACAAATTCATTGGAACGTTGCTG
 ATGTGGTTGGGTCTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTATCC
 ACAGCCGTCTCTGCTGATGTGGGGTGTCTGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGCT
 ATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAAGCA
 25 AGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTCAAGAATGGAAAACATCATGTGGAGATCAGTAGAAGGGGAG
 CTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAACCCCATGTGGAGAGGTC
 CACAGAGATTGCCCGTGCCTGTGAACGAGCTGCCCCAGGCTGGAAGGCTTGGGGGAAATCGCACTTCGTAGAGCAGC
 AAAGACAAATAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACAGCTTTC
 TTGTGGAGGATCATGGGTTGCGGGTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGAT
 30 CCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAGTATCTAGGCTACTGGATTGAGAGTGAGAAGA
 ATGACACATGGAGGCTGAAGAGGGGCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCACACATTGTGGAC
 AGATGGAATAGAAGAGAGTGATCTGATCATACCAAGTCTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCT
 ACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTTGAGGAATGCCAGGCACTAAGGTCCA
 CGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTG
 35 CTGCAGGGAGTGACAATGCCCCACTGTGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCAGG
 AAAGAACCAGAAAGCAACTTAGTAAGGTCAATGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGGAGT
 GCTTGTGATTCTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATATAAGCACATCAATGGCA
 GTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGC
 GGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTATCTT
 40 TCATCTTCAGAGCTAATTGGACACCCCGTGAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTTGCAAACTGCGATCTCCG
 CTTTGGAAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCA
 CTGATAACATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCGGGGCACACTGCTTGTGGCGTGGAGAGCAGGC
 CTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAAGGCAGTGTGAAGAAGAAGTACCATTGTGATGGC
 CCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGGGCTGCTGTTGCTCACAAGGAGTGGGAAGCGG
 45 AGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGA
 GATGGCTGGGCCCATGGCCGCGGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTG
 AAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCGATGTGGCGCTAGATG
 AGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGATGACCATC
 TGTGGCATGAACCAATAGCCATACCTTTGCAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTG
 50 CTCTATGGGATGTGCTGCTCCCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAG
 ACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTACAAAAAGGA
 TCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGTACTACTGTGGTC
 CATGGAAGCTAGATGCCCGCTGGGACGGGCACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGA
 ACATCCAGACTCTGCCCGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAAC
 TTCAGGATCTCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCGTGATCAAAAATGGGAGT

TATGTTAGTGCCATCACCCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGCTGAAGAAGA
 AGCAGCTAACTGTCTTAGACTTGATCCTGGAGCTGGGAAAACAGGAGAGTCTTCTGAAATAGTCCGTGAAGCCATA
 AAAACAAGACTCCGTACTGTGATCTTAGCTCCAACCAGGGTTGTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCC
 5 AGTGCGTTATATGACAACAGCAGTCAATGTACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCAC
 TTCACGTCTACTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCAAGT
 ATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGGCGGCTGCCATCTTCATGACCGCCACGCCACCAG
 GAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACACCGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCA
 GGCTTTGATTGGGTGACGGATTATTCTGAAAAACAGTTTGGTTTGTTCGAAGCGTGAGGAACGGCAATGAGATCGCAGC
 10 TTGTCTGACAAAAGGCTGGAAAACGGGTCATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATC
 AAGAGTGGGACTTTGTCTGACAACTGACATTTAGAGATGGGCGCCAACCTTAAAGCTGACCGTGTATAGATTCCAGG
 AGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGACCCATGCCTGTCACACATGCCAGCGCTGC
 CCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGAC
 TGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCT
 15 CTATCGACCTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTG
 GAACTCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAGATAGAAG
 ATGGTGCTTTGATGGCAGCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAGACACGGAGA
 GAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTT
 GCCGCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCTC
 CAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCGGCCCAAT
 20 TGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAATCTTTTCTGTTGATGAGG
 AACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTG
 AGCCAGCCAGAATTGCATGTGTCTCATTGTTGTGTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGAT
 CTCCCCAGGACAACCAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGAT
 25 GGTTGGAGAGAAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATGGGATTCTCAATGG
 ACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACCTTTCATTACCCAGCCGTCCAACATGCAGT
 GACCACTTCATACAACAACTACTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGC
 CATTCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGTTGCTACTCACAATTAACGCCCTGACCCTAATAGTGG
 CCATCATTTTGTCTGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCCAGAAAGAGA
 ACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCA
 30 AGTGGAGAAAAAGATGGGACAGGTGCTACTCATGGCAGTAGCCGTCTCCAGCGCCATACTGTCGCGGACCGCCTGGGGG
 TGGGGGGAGGCTGGGGCCCTGATCACAGCCGCAACTTCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTC
 TACAGCCACTTCACTGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTAATCTACACAGTAACAAGAAACGC
 TGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTC
 35 GGCCCTGGAGTTCTACTCTACAAAAAGTCAGGCATACCGAGGTGTGCAGAGAAGAGGCCCGCCGCGCCCTCAAGGAC
 GGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAAGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAG
 CCCTATGGAAAGGTCAATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGA
 AGTGAAAGGATACAAAAAGGAGGCCCTGGTCATGAAGAACCCTGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGT
 CTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATC
 40 TAGTCCTGAAGTGGAAGAAGCAGGACGCTCAGAGTCTCTCCATGGTGGGGGATTGGCTTGAAAAAGACCAGGAGCC
 TTTTGTATAAAAGTGTTGTGCCATACACCAGCACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAG
 GACTGGTCAGAGTGCCACTCTCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAAGCAACACCATAAAA
 AGTGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCTAGGAGGCCAGTGAAATATGAGGAGGATGTGA
 ATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAAAGG
 ATCCGAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAAACCCATATAGGACATGGGCTTACCATGGAAGCTATGA
 45 GGCCCCACACAAGGGTCAGCGTCCTCTAATAAACGGGGTTGTGAGGCTCCTGTCAAACCCCTGGGATGTGGTGACTG
 GAGTCACAGGAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTAGGGT
 GCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAAGAGCTAGGCAAACACAAAC
 GGCCACGAGTCTGTACCAAGAAGAGTTCATCAACAAGGTTCTGATGCAATGCAGCATTAGGGGCAATATTTGAAGAGGA
 AAAAGAGTGGAAGACTGCAGTGGAAGCTGTGAACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGACCA
 50 CCTGAGAGGAGAGTGCCAGAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAGAAACAAGGGGAATTTGAAAGGC
 CAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTCTTGAACGAGG
 ATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATGCTCTAGAAG
 AGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCT
 GGAGAATGAAGCTCTAATCACCAACCAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATAC

CAAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTGAGACAAGACCAAA
 GGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTCGGAATATGGAGGCT
 GAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGA
 5 TGGGATAGGCTCAAACGAATGGCAGTCACTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGACATGCCCT
 CAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAACCCCTCAACTGGATGGGACAACCTGGGAA
 GAAGTTCCGTTTTGCTCCACCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCAA
 GATGAAGTATTGGCCGGGCGCGCTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAAAATCAT
 ATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAG
 10 TTGACTGGGTTCCAACCTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGT
 GGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCCAAGTTACGAAATGGACAGACATTCCC
 TATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGGCTGAGAACATTA
 AAAACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAAGTTCGCTAC
 TTGGGTGAAGAAGGGTCTACACCTGGAGTGTGTAAGCACCAATCTTAATGTTGTGAGGCCTGCTAGTCAGCCACAGCTT
 GGGGAAAAGCTGTGCAGCCTGTGACCCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGG
 15 CACGGAAGAAGCCATGCTGCCTGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGAT
 GGGAAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCCAGAAGAGG
 GACTAGTGGTTAGAGGAGA

SEQ ID NO: 6

KU527068.1 Zika virus strain Natal RGN, Brazil: Rio Grande do Norte, Natal, complete genome

AGTTGTTGATCTGTGTGAATCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGTTTTATTTT
 GGATTTGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAA
 CGCGGAGTAGCCCGTGTGAGCCCCCTTGGGGGCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTCTATGAGGTTTCAG
 25 GGATGGTCTTGGCAATTCTAGCCTTTTGAAGATTACCGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTTCAG
 TGGGGAAAAAGAGGCTATGGAATAATAAAGAAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAG
 GAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGGAATTGTTGGCCTCTGCTGACCACAGCTATGGCAGCGGA
 GGCTACTAGACGTGGGAGTGCATACTATATGTAAGTGGACAGAAACGATGCTGGGGAGGCCATATCTTTTCCAACCAT
 TGGGGATGAATAAGTGTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATG
 30 CTGGATGAGGGGTGGAACAGATGACGTCGATTGTTGGTGAACACGACGTCAACTTGGGTTGTGACGGAACCTGCC
 ATCAGAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCCTCCATTCCACTAGGAAGCTGCAAAACGCG
 GTCGCAAACTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCT
 TCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGC
 TGATTGCCCGGCATACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTG
 35 GGTTGATGTTGTCTTGAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGTTA
 CAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGC
 TGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAAGCTTGTAGTGAGAGG
 CTGGGGAAATGGATGTGGACTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACC
 GGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTGAGTTTATGGCTCCAGCACAGTGGGATGATCG
 40 TTAATGACACAGGACATGAAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTACCAAGAGCCGAAGCCAC
 CCTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGTATTACTTGACTAT
 GAATAACAAGCACTGGTTGGTCCACAAGGAGTGGTTCCACGACATTCCATTACCTTGGCAGCTGGGGCAGACACCGGAA
 CTCCACACTGGAACAACAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCCAACTGTCGTGGTTCTAGG
 GAGTCAAGAAGGAGCAGTTCACACGGCCCTTGTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTC
 45 CTCTGGCCACTTGAAATGTCGCCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTGTGTACCGCAGCGTT
 CACATTCACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGCAGGGACAGATGGACCT
 TGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTCTGACCCCAAGTTGGGAGGTTGATAACCGCTAACCCCGTAAT
 CACTGAAAGCACTGAGAACTCTAAGATGATGCTGGAACCTTATCCACCATTTGGGACTCTTACATTGTCATAGGAGTCG
 GGGAGAAGAAGATCACCCCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTTGAAGCCACTGTGAGAGGTG
 50 CCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTCATTGGGCAAGGG
 CATCCATCAAAATTTTGGAGCAGCTTTCAAATCATTGTTTGGAGGAATGTCCTGGTTCTCACAATCCTCATTGGAACGTTG
 CTGATGTGGTTGGGTCTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTGATCTTCTTA
 TCCACAGCCGTCTGCTGATGTGGGGTGTCTGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCCG
 TCTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAAG
 CAAGCCTGGGAAGATGGTATCTGCGGGATCTCCTGTGTTCAAGAATGGAGAACATCATGTGGAGATCAGTAGAAGGGG

AGCTCAACGCAATCTTGGAAGAGAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAACCCCATGTGGAGAGG
 TCCACAGAGATTGCCCCGTGCCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTGAGAGCA
 GCAAAGACAAATAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCACTCGAACATAGAGCATGGAACAGCT
 TTCTTGTGGAGGATCATGGGTTCCGGGTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGT
 5 GATCCAGCCGTTATTGGAACAGCTGTTAAGGGGAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATTGAGAGTGAGA
 AGAATGACACATGGAGGCTGAAGAGGGGCCATCTAATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTG
 GGCAGATGGAATAGAAGAGAGTGATCTGATCATTCCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGG
 GCTACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCGGGCGACTAAGGT
 10 CCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATG
 GTGCTGCAGGGAGTGACAATGCCCCACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCC
 AGGAAAGAACCAGAAAGCAACTTAGTAAGGTCAGTGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGG
 AGTGCTTGTGATTCTGCTCATGGTGACGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATG
 GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGCGCCACCTT
 CGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTA
 15 TCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTTTGCAAAGTGCATCT
 CCGCCTTGAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCAC
 GCACTGATAACATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCGGGCACACTGCTTGTGGCGTGGAGAGCA
 GGCCTTGTACTTGCAGGGGGTTTATGCTCCTCTCTGAAGGGAAAAGGCAGTGTGAAGAAGAACTTACCATTTGTCAT
 GGCCCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAG
 20 CGGAGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCAAGGCAGATAT
 AGAGATGGCTGGGCCCATGGCCGCGTCCGCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTAC
 ATTGAAAGAGCAGGTGACATCACATGGGAAAAGATGCGGAAGTCACTGGAACAGTCCCCGGCTCGATGTGGCGCTAG
 ATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGATGACC
 ATCTGTGGCATGAACCAATAGCCATACCCTTTCAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTG
 25 GTGCTCTATGGGATGTGCTGCTCCCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCG
 TAGACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCACAAAA
 GGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGTACTACTGTG
 GTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCAGCTCTTGCCGCTGCCCGCGGAGAGAGAGCGA
 GGAACATCCAGACTCTGCCCGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGG
 30 AACTTCAGGATCTCCAATCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGATCAAAAAATGGG
 AGTTATGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGCTGAAGA
 AGAAGCAGCTAACTGTCTTAGACTTGATCCTGGAGCTGGGAAAACCAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCC
 AAAAAACAAGACTCCGTAAGTGTGATCTTAGCTCCAACCAAGGTTGTGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCT
 TCCAGTGCGTTATATGACAACAGCAGTCAATGTCAACCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTT
 35 CACTTCAGTCTACTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCCACTTCACAGATCCCTCA
 AGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCAC
 CAGGAACCCGTGACGCATTTCCGGAAGTCCAACCTACCAATTATGGACACCGAAGTGAAGTCCCAGAGAGAGCCTGGAG
 CTCAGGCTTTGATTGGGTGACGGATCATTCTGGAACCAAGTGGTTGTTGTTCCAAGCGTGAGGAACGGCAATGAGATCG
 CAGCTTGTCTGACAAAGGCTGGAACCGGGTCATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAAACAA
 40 ACATCAAGAGTGGGACTTTGTCGTGACAAGTACATTTAGAGATGGGCGCCAACCTTAAAGCTGACCGTGTATAGATT
 CCAGGAGATGCCTAAAGCCGCTCATACTTGATGGCGAGAGAGTCAATTTGGCTGGACCATGCCTGTACACATGCCAGC
 GCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCA
 GAGACTGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGC
 CTCGCTCTATCGACCTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACC
 45 TTTGTGGAACATGAAAAGAGGAGATCTTCTGTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAGAT
 AGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGCGAGAGGTGTGGACCAGACAC
 GGAGAGAAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCAATCAAGG
 AGTTTGCCGCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGA
 GATTCCAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGCGGCG
 50 CCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGTTGCTGGGAACAGTCTCGCTGGGAATCTTTTTCGTTGAT
 GAGGAACAAGGGCATAGGGAAGATGGGCTTGGGAATGGTGACTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGA
 AATTGAGCCAGCCAGAATTGCATGTGTCTCATTGTTGTGTTCTATTGCTGGTGGTGTCTACCTGAGCCAGAAAAGCA
 AAGATCTCCCCAGGACAACCAAATGGCAATCATCATGTTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACT
 CGGATGGTTGGAGAGAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGAGCAACCATAGGATTCTC

AATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACTTTCATTACCCCAGCCGTCCAACA
 TGCAGTGACCACTTCATACAACAACTACTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTGTTTGGTATGGGCAAAG
 GGATGCCATTCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCTGACCCTAA
 TAGTGGCCATCATTTTGTCTGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCCAG
 5 AAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTG
 ACCCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGCAGTCTCCAGCGCCATACTGTGCGGGACCGC
 CTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGG
 AACTCCTCTACAGCCACTTCACTGTGTAACATTTTTAGGGGAAGTACTTGGCTGGAGCTTCTCTAATCTACATAGTAACAA
 10 GAAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAAC
 CAGATGTCGGCCCTGGAGTTCTACTCTACAAAAAGTCAGGCATACCGAGGTGTGCAGAGAAGAGGCCCGCCGCGCCC
 TCAAGGATGGTGTGGCAACGGGAGGCCATGCTGTGTCCGAGGAAGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGAT
 ACCTGCAGCCCTATGGAAAGGTCATTGATCTTGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAA
 GTTCAAGAAGTGAAAGGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCGTGTTGGTGCAAAGCTATGGTGGAAC
 ATAGTCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGA
 15 GTCATCATCTAGTCTGAAGTGAAGAAGCACGGACGCTCAGAGTCTCTCCATGGTGGGGGATTGGCTTAAAAAAGA
 CCAGGAGCCTTTGTATAAAAGTGTGTGCCATACACCAGCACTATGATGGAAACCCTGGAGCGACTGCAGCGTAGGTA
 TGGGGGAGGACTGGTCAGAGTGCCACTCTCCCGCAACTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAAC
 ACCATAAAAAGTGTGTCCACCACGAGCCAGTCTCTTGGGGCGCATGGACGGCCTAGGAGGCCAGTGAAATATGAGG
 AGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGC
 20 ATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATG
 GAAGCTATGAGGCCCCACACAAGGGTCAGCGTCTCTCTAATAAACGGGGTTGTCAGGCTCTGTCAAAACCCTGGGAT
 GTGGTGACTGGAGTCACAGGAATAGCCATGACCGACACCACCCGATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGG
 ACACTAGGGTGCCAGACCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGAAAGAGCTAGGC
 AAACACAAACGGCCACGAGTCTGTACCAAGAAGAGTTCATCAACAAGGTTCTAGCAATGCAGCATTAGGGGCAATATT
 25 TGAAGAGGAAAAAGAGTGAAGACTGCAGTGAAGCTGTGAACGATCCAAGGTTCTGGGCTCTAGTGGAACAAGGAAAG
 AGAGCACCACTGAGAGGAGAGTGCCAGAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAAGGGGAATT
 TGGAAAGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCTGAAGCCCTTGGATTCT
 TGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATG
 TCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAG
 30 GTTCGATCTGGAGAATGAAGCTCTAATCACCAACCAAATGGAGAAAGGGCATAGGGCCTTGGCATTGGCCATAATCAAGT
 ACACATACCAAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAAAACAGTTATGGACATTATTTTCGAGACAA
 GACCAAGGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTGGAATAT
 GGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAG
 CAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCA
 35 CATGCCCTCAGGTTCTTGAATGATATGGGAAAAAGTTAGGAAGGACACACAAGAGTGGAAACCCTCAACTGGATGGGACA
 ACTGGGAAGAAGTTCCGTTTTGCTCCACCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCC
 GCCACCAAGATGAAGTATTGGCCGGGCGCGCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGC
 AAAATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTTCATC
 TGTGCCAGTTGACTGGGTTCCAAGTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAAATGGATGACCACTGAAGAC
 40 ATGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACA
 GACATTCCCTATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGCTGA
 GAACATTAAAAACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAAG
 TTCGTAATTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTAAGCACCAATCTTAATGTTGTCAGGCCTGCTAGTCAGC
 CACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAAC
 45 GCCATGGCACGGAAGAAGCCATGCTGCCTGTGAGCCCCCAGAGGACACTGAGTCAAAAAACCCATGCGCTTGGAGGC
 GCAGGATGGGAAAAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCCA
 GAAGAGGGACTAGTGGTTAGAGGAGACCCCCGAAAAACGCAAAACAGCATATTGACGCTGGGAAAGACCAGAGACTC
 CATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAATAGCGGCGGCCGGTGTGGGAAATCCATGGGTCTT

50 SEQ ID NO: 7

KU681081.3 Zika virus isolate Zika virus/H.sapiens-tc/THA/2014/SV0127- 14, Thailand, complete genome
 AGTTGTTGATCTGTGTGAATCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTT
 GGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAA
 CGCGGAGTAGCCCGTGTGAGCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGGAAGTCTGCTGGGTGATGGGCCCATCA

GGATGGTCTTGGCGATTCTAGCCTTTTGGAGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTTCAG
TGGGAAAAAAGAGGCTATGGAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAG
GAAGGAGAAGAAGAGACGAGGCACAGATACTAGTGTGGAATTGTTGGCCTCTGCTGACCACAGCTATGGCAGCGGA
5 GGTCACTAGACGTGGGAGTGCATACTATATGTACTTGACAGAAGCGATGCTGGGGAGGCCATATCTTTTCCAACCACAC
TGGGGATGAATAAGTGTTATATACAGATCATGGATCTTGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATG
CTGGATGAGGGGGTAGAACCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCC
ATCACA AAAAAGGTGAAGCACGGAGATCCAGAAGAGCTGTGACGCTCCCTCCCTTCCACTAGGAAGCTGCAAAACGCG
10 GTCGCAGACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCT
TCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGC
TGATTGCCCCGGCATAACAGCATCAGGTGCATAGGAGTCAGTAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTG
GGTTGATGTTGTCTTGAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTCGACATAGAGCTGGTTA
CAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCGGACATGGCTTCGGACAGCCG
CTGCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAAGAACGTTAGTGACAGAG
15 GCTGGGGAAATGGATGTGGACTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGAC
CGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTCAGTTTCATGGCTCCAGCACAGTGGGATGATC
GTTAATGACACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCA
CCCTGGGGGGTTTGGAAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTTCAGATTGTATTACTTGACTA
TGAACAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCCACGACATTCCATTACCTTGGCACACTGGGGCAGACACCGGA
20 ACTCCACTGGAACAACAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCCAACTGTCGTGGTTCTAG
GGAGTCAAGAAGGAGCAGTTCACACGGCCCTTCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGT
CCTCTGGCCACTTGAAATGTCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGCATACTCCTTGTGTACCGCAGCGT
TCACATTACCAAGATCCCGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGAGGGACAGATGGACC
TTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTTGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAA
25 TCACTGAAGGCACTGAGAATCTAAGATGATGCTGGAACCTGATCCACCATTGGGGACTTTACATTGTCATAGGAGTCG
GGGAGAAGAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTTGGAAAAGCATTGGAAGCCACTGTGAGAGGTG
CCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGTTCTTAATCATTGGGCAAGGG
CATCCATCAAATTTTGGAGCAGCTTTCAAATCATTGTTTGGAGGAATGTCCTGGTTCTCACAATTTCTATTGGAACGTTG
CTGATGTGGTTGGGTCTGAATACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTTA
30 TCCACAGCCGTCTCCGCTGATGTGGGGTCTCGGTGGACTTCTCAAAGAAGGAAACGAGATGCGGTACAGGGGTGTTG
TCTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCTCGTAGATTGGCAGCAGTAGTCAAG
CAAGCCTGGGAAGATGGTATCTGTGGGATCTCCTCTGTTTCAAGAAATGGA AAAACATCATGTGGAGATCAGTAGAAGGGG
AGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGG
TCCACAGAGATTGCCCGTGCCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTGAGAGCA
35 GCAAAGACAAATAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACAGCTT
TCTTGTGGAGGATCATGGGTTTCGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTACTAGAGTGTG
ATCCAGCCGTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAGTATCTAGGCTACTGGATTGAGAGTGAGAA
GAACGACACATGGAGGCTGAGGAGGGCCACCTGATCGAGATGAAAACATGTGAATGGCCAAAAGTCCACACATTGTGG
ACAGATGGAATAGAAGAGAGTGATCTGATCATACCAAGTCTTTAGCTGGGCCACTCAGCCATCACAACACCAGAGAGG
40 GCTACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCAGGCACTAAGGT
CCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATG
GTGCTGCAGGGAGTGACAATGCCCCACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCC
AGGAAAGAACCAGAAAGTAAGTAAAGTCAATGGTGACTGCAGGATCAACTGATCAGATGATCACTTTTCCCTTGG
AGTGCTTGTGATTCTGCTCATGGTGACGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATG
45 GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGATCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTT
GCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGGTAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTAT
CTTTCATCTTCAGAGCTAATTGGACACCCGTGAAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTTGCAAACTGCGATCTC
CGCCTTGGAAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACG
50 CACTGACAATATCACTTGGCAATCCTGGCTGCTGACACCACTGGCCGGGGCACACTGCTTGCGGTGGAGAGCAG
GCCTTGCTACTTGCGGGGGGTTGATGCTCCTCTCTGAAGGGGAAAGGCAGTGTGAAGAAGAACTTACCATTTGTCATG
GCCCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGC
GGAGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATAT
AGAGATGGCTGGGCCCATGGCCGCGTCCGTCTGCTAATTGTGAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTAC
ATTGAAAGAGCAGGTGACATCATGGGAAAAAGATGCGGAAGTTACTGGAAACAGTCCCCGGCTCGATGTGGCACTAG
ATGAGAGTGGTGATTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAAGTGGTCTGATGACC

ATCTGTGGCATGAACCCAATAGCCATACCCTTTGCAGCTGGAGCGTGGTACGTATACGTGAAAACTGGAAAAAGGAGTG
 GTGCTCTATGGGATGTGCTGCTCCCAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCG
 TAGACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCATGTCACAAAAG
 5 GATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGTCTACTGTGG
 TCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAG
 GAACATCCAGACTCTGCCCAGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGACTATCCAGCAGGA
 ACTTCAGGATCTCCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTCTATGGCAATGGGGTCGTGATCAAGAATGGGA
 GTTATGTCAAGTCCATCACCAAGGGAGGGAGGAAGAGACTCCTGTTGAGTGCTCGAGCCTTCGATGCTGAAGAA
 10 GAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACCAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCA
 TAAAAACGAGACTCCGTACTGTGATCTTAGCTCCAACCAGGGTTGTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTT
 CCAGTGCGTTATATGACAACAGCAGTCAATGTCACCCATTCTGGGACAGAAATCGTTGACTTAATGTGCCATGCCACCTTC
 ACTTCACGTCTACTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCAA
 GTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCAGCTGCCATCTTCATGACCGCCACGCCACC
 AGGAACCCGTGACGCATTCCCGGACTCCAACCTACCAATTATGGACACCGAAGTGGAAGTCCCAGAGAGAGCCTGGAGC
 15 TCAGGCTTTGATTGGGTGACGGATCATTCTGAAAAACAGTTTGGTTTGTCCCAAGCGTGAGGAACGGCAATGAGATCGC
 AGCTTGTCTGACAAAGGCTGGAAAACGGGTCTACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAA
 CATCAAGAGTGGGACTTCGTGCGTGAACCTGACATTTAGAGATGGGCGCAACTTTAAAGCTGACCGTGCATAGATTC
 CAGGAGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGACCCATGCCTGTCACACATGCCAGCG
 CTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAACTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAG
 20 AGACTGATGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCT
 CGCTCTATCGACCTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTT
 TGTGGAACCTCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGAATAACCTACACAGATA
 GAAGATGGTGCTTTGATGGCATGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAGACACG
 25 GAGAGAAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGA
 GTTTGCCGCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACGGAGAG
 ATTCCAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGCGGCC
 CAATTGCCGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAATCTTTTTCGTTCTTGATG
 CGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAA
 TTGAGCCAGCCAGAATTGCATGCGTCCTATTGTTGTCTTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAA
 30 GATCCCCCAGGACAACCAAATGGCAATCATCATGCTAGCAGTAGGTCTTCTGGGCTTGATTACCGCAATGAACTCG
 GATGGTTGGAGAGAACAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATAGGATTCTCAA
 TGGACATTGACCTGCGGCCAGCCTCGGCCTGGGCCATCTATGCTGCCCTGACAACCTTCATTACCCAGCCGTCCAACATG
 CAGTGACCACTTCATACAACAACTACTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGG
 ATGCCATTCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATA
 35 GTGGCTATCATTTTGTCTGCTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCCAGAA
 GAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACTATTGAC
 CCCAAGTGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTGCGGGACCGCCT
 GGGGGTGGGGGAAGCTGGGGCCCTGATCACAGCTGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAA
 CTCCTCTACAGCCACTTCACTGTGCAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGA
 40 AACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCA
 GATGTCGGCCCTGGAGTTCTACTCCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGCGCCCTC
 AAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCGAGGAAGTGCAAGCTGAGATGGTTGGTGAGCGGGGATAC
 CTGCAGCCCTATGGAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGT
 TCAAGAAGTGAAAGGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCTGTTGGTGCAAAGCTATGGGTGGAACATA
 45 GTCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTC
 ATCATCTAGTCCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCCTCTCCATGGTGGGGGATTGGCTTAAAAAAGACCA
 GGAGCCTTTTGTGTAAGAGTGTGTGCCCATACACCAGCACTATGATGGAAACCCTGGAGCGACTGCAGCGTAGGTATGG
 GGGAGGACTGGTCAGAGTGCCACTCTCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACC
 ATAAAAAGTGTGTCCACCACGAGCCAGCTCCTTTGGGGCGCATGGACGGGGCCAGGAGGCCAGTGAAATATGAGGAG
 50 GATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCAT
 TGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATGGA
 AGCTATGAGGCCCTACACAAGGGTCAGCGTCCTCTCTAATAAACGGGGTTGTCAGGCTCCTGTCAAAACCCTGGGATGT
 GGTGACTGGAGTCACAGGAATAGCCATGACCGACACCACCCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGAC
 ACCAGGGTGCCAGACCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAGAGCTAGGCA

AACACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTCTGTAGCAATGCAGCATTAGGGGCAATATTT
 GAAGAGGAAAAAGAGTGGAAAGACCGCAGTGGAAGCTGTGAACGATCCAAGTTCTGGGCTCTAGTGGACAAGGAAAGA
 GAGCACCACCTGAGAGGAGAGTGCCAGAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTT
 5 GGAAAGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTCTT
 AAATGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATGT
 CCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAG
 GTTTGATCTGGAGAATGAAGCTTTAATCACCAACCAAATGGAGAAAGGGCACAGGGCCTTAGCATTGGCCATAATCAAGT
 ACACATACCAAAACAAAGTGGTAAAGGTCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTCAAGACAA
 10 GACCAAAGGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTGGGAATAT
 GGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAG
 CAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCA
 CATGCCCTCAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAACCCCTCAACTGGATGGGACA
 ACTGGGAAGAAGTTCCGTTTTGTTCCACCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCC
 15 GCCACCAAGATGAACTGATTGGCCGGGCCCCGTGTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGC
 AAAGTCATATGCGCAAATGTGGCAGCTCCTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATCTGTTCATC
 TGTGCCAGTTGACTGGGTTCCAAGTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGAC
 ATGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCCAAGTTACGAAATGGACA
 GACATTCCTATCTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGCTG
 AGAACATTAAAAACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAA
 20 GTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTATAAGCACCAATCTTAGTGTGTCAGGCCTGCTAGTCAG
 CCACAGCTTGGGGAAGCTGTGCAGCCTGTGACCCCCCAGGAGAGGCTGGGAAACCAAGCCCATAGTCAGGCCGAGAA
 CGCCATGGCACGGAAGAAGCCATGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGG
 CGCAGGATGGGAAAAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCC
 25 AGAAGAGGGACTAGTGGTTAGAGGAGACCCCCGAAAAACGAAAACAGCATATTGACGCTGGGAAAGACCAGAGACT
 CCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAATAGCGGCGGCCGGTGTGGGGAAATCCATGGGTCT

SEQ ID NO: 8

KU681082.3 Zika virus isolate Zika virus/H.sapiens-tc/PHL/2012/CPC-0740, Philippines, complete genome

AGTTGTTGATCTGTGTGAATCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGTTTTATTTT
 30 GGATTTGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAA
 CGCGGAGTAGCCCGTGTGAGCCCCCTTGGGGGCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGCCATGGGCCCATCA
 GGATGGTCTTGGCGATACTAGCCTTTTGTGATTACGGCAATCAAGCCATCACTGGGTCTCATATAGATGGGGTTCA
 GTGGGGAAAAAAGAGGCTATGGAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTA
 35 GGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGCGTCGGAATTGTTGGCCTCCTCTGACCACAGCCATGGCAGTAG
 AGGTCACTAGACGTGGGAGTGCATACTATGTACTTGGACAGAAGCGATGCTGGGGAGGCCATATCTTTTCAACCACA
 CTGGGGATGAATAAGTGTACATACAAATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTAT
 GTTGGATGAGGGGGTAGAACAGATGACGTCGATTGCTGGTGCAACACGACATCAACTTGGGTTGTGTATGGAACCTGC
 CACCACAAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCTCCATTCCACTAGGAAGCTGCAAACGC
 40 GGTGCGAGACCTGGTTGGAATCAAGAGAATACACAAAGCACCTGATTAGAGTTGAAAATTGGATATTAGGAACCTGG
 CTTGCGGTTAGCAGCAGCTGTCATCGCTTGGCTTTTGGGAAGTTCAACGAGCCAAAAAGTCATATATCTGGTCATGATACT
 GCTGATTGCCCCGCGATACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACT
 TGGGTTGATGTTGTCTTGAACATGGAGGTTGTGTTACCGTAATGGCACAGGACAAACCGACTGTCGACATAGAGCTGGT
 TACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCGGATATGGCTTCGGACAGCC
 45 GCTGCCCAACACAAGGTGAGGCCTACCTTGACAAGCAGTCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGACAGA
 GGCTGGGGAAATGGATGTGGACTTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGA
 CCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTGTCAGTTTCATGGCTCCAGCACAGTGGGATGAT
 CGTTAATGACACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCC
 ACCCTGGGGGGTTTTGGGAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTTCAGATTTGATTACCTGACT
 50 ATGAATAACAAGCACTGGTTGGTTCAAGGAGTGTTCCACGACATTCCATTACCTTGGCATGCTGGGGCAGACACTGG
 AACTCCACATTGGAACAACAAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCAAAAAGGCCAACTGTCGTGGTTCTA
 GGGAGTCAAGAAGGAGCAGTTCACACGGCCCTTGTGGAGCTCTGGAGGCTGAGATGGATGGAGCCAAGGGAAGGCTG
 TCCTCTGGCCACTTGAAATGTCGCCTGAAAATGGATAAATCTAGATTGAAGGGCGTGTCTACTCCTTGTGCACTGCAGCG
 TTCATTACCAAGATCCCGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACGTACGCAGGGACAGATGGAC
 CTTGCAAGGTTCCAGCTCAGATGGCGGTGGATATGCAAACTTGACCCAGTTGGGAGGTTGATAACCGCTAACCTGTA

ATCACTGAAAGCACCGAGAACTCTAAGATGATGCTGGAACCTTGATCCACCATTGGGGACTCTTACATTGTCATAGGAGTC
 GGGGAGAAGAAGATCACCCATCACTGGCACAGGAGTGGCAGCACCATTGAAAAAGCATTGAAGCCACTGTGAGAGGT
 GCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGGGGTGCTCTCAACTATTGGGCAAGG
 5 GCATCCATCAAAATTTTGGAGCAGCTTTCAAATCATTGTTGCGAGGAATGTCTGGTTCTCACAAATTCTCATTGGAACGTT
 GCTGGTGTGGTTGGGTCTGAATACAAAGAATGGATCTATTTCCCTTACGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTT
 ATCCACAGCCGTTTCTGCTGATGTGGGGTCTCGGTGGACTTCTCAAAGAAGGAAACGAGATGCGGTACAGGGGTGTTT
 GTCTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCTCGTAGATTGGCAGCAGCAGTCAA
 GCAAGCCTGGGAAGATGGGATCTGTGGGATCTCTGTCTCAAGAATGGAAAACATCATGTGGAGATCAGTAGAAGGG
 10 GAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGACGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAG
 GTCCACAGAGATTGCCCGTGCCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTACAGAGC
 AGCAAAGACAAATAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACAGC
 TTTCTTGTGGAGGATCATGGGTTTGGGGTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGT
 GATCCAGCCGTCATTGGAACAGCTGCTAAGGGAAAGGAGGCTGTGCACAGCGATCTAGGCTACTGGATTGAGAGTGAGA
 AGAACGACACATGGAGGCTGAAGAGGGCCACCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTG
 15 GACAGATGGAGTAGAAGAAAGTGATCTGATCATACCCAAGTCTTAGCTGGGCCACTCAGCCATCACAACACCAGAGAG
 GGCTACAGGACTCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAATTCGGTTTGAAGGAATGCCAGGCACTAAGG
 TCCACGTGGAGGAAACATGTGGGACAAGAGGACCATCCCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAAT
 GGTGCTGCAGGGAATGCACAATGCCCCACTGTCGTTCCGAGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCC
 CAGGAAAGAACCAGAAAGTAAGTCTAGTAAGGTCAATGGTACTGCAGGATCAACTGATCAGATGGATCACTTCTCTTCTG
 20 GAGTGCTTGTGATTTTCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATATAAGCACATCAAT
 GGCAGTGCTGGTAGCCATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTATGGGTGCCACCT
 TCGCGGAAATGAACACTGGAGGAGATGTAGCTCATTTGGCGCTGATAGCGGCATTCAAAGTCAGACCTGCGTTGCTGGTA
 TCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAGAGCATGCTGCTGGCCTTGGCCTCGTGTCTTCTGCAAACCTGCGATCT
 CCGCCTTGAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCAC
 25 GCACTGACAACATCACCTTGGAATCCTGGCTGCTCTGACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGGAGAGCA
 GGCCTTGTACTTGCAGGGGGGTTTCTGCTCTCTCTGAAGGGGAAAGGCAGTGTGAAGAAGAACCTACCATTGTGTCAT
 GGCCTTGGGACTAAGTCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAG
 CGGAGCTGGCCCCCTAGTGAAGTACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCGGATA
 TAGAGATGGCTGGGCCCATGGCCGCGGTGCTGCTAATTGTGAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTA
 30 CATTGAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAATCACTGGAAACAGTCCCCGGCTCGATGTGGCACTA
 GATGAGAGTGGTGATTTCTCCTAGTGGAGGATGATGGTCCACCATGAGAGAGATCATACTCAAAGTGGTCTGATGAC
 CATCTGCGGCATGAACCCAATAGCCATACCCTTTGAGCTGGAGCGTGGTACGTGTATGTGAAGACTGGAAAAAGGAGT
 GGTGCTCTATGGGATGTGCCTGCTCCCAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGACAGAGTAATGACTC
 GTAGACTGCTTGGTTCAACACAAGTTGGAGTGGGAGTCATGCAAGAGGGGGTCTTCCACACTATGTGGCACGTCACAAA
 35 AGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGTCTACTGT
 GGTCCGTGGAAGCTAGACGCCGCTGGGACGGGCACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCG
 AGGAACATCCAGACTCTGCCCGGAACATTTAAGACAAAGGATGGGGACATTGGAGCAGTTGCGTGGACTACCCAGCAG
 GAACCTCAGGATCTCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTCTATGGTAATGGGGTCGTGATAAAAAATGG
 GAGTTATGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGCTGAAG
 40 AAGAAGCAGCTAACTGTCTTAGACCTGCATCCTGGAGCCGGGAAAAACCAGGAGAGTTCTTCTGAAATAGTCCGTGAAGC
 CATAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACAGGGTCTGCTGCTGAAATGGAGGAAGCCCTTAGAGGGC
 TTCCAGTTCGTTATATGACAACAGCAGTCAATGTACCCATTCTGGGACAGAAATCGTTGACTTAATGTGCCATGCTACCTT
 CACTTCACGCCTACTACAACCAATCAGAGTCCCCAACTATAATTTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCA
 AGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCAC
 45 CAGGAACCCGTGACGCATTCCCGGACTCCAACCTACCAATTATGGACACCGAGGTGGAAGTCCAGAGAGAGCCTGGAG
 CACAGGCTTTGATTGGGTGACGGATCATTTCTGGGAAAAACAGTCTGGTTTGTTCGAAGCGTGAGGAACGGCAATGAGATC
 GCAGCTTGTCTGACAAAGGCTGGAAAACGGGTATACAGCTCAGCAGAAAGACTTTTGAAGACAGAGTTCCAGAAAACGA
 AAAATCAAGAGTGGGACTTCGTGCTGACAACCGACATTTAGAGATGGGCGCAACTTTAAAGCTGACCGTGTATAGAT
 50 TCCAGGAGATGCTTAAAGCCGGTCATACTTGATGGCGAGAGAGTCAATTTGGCTGGACCCATGCCTGTACACATGCCAG
 CGCTGCTCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAACTGGAGATGAGTATCTGTATGGAGGTGGGTGCGC
 AGAGACTGATGAAGATCACGCACACTGGCTTGAAGCAAGAATGCTTCTGACAACATTTACCTCAAGATGGCCTCATAG
 CTTGCTCTATCGACCTGAGGCCGACAAAGTAGCAGCTATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGAC
 CTTTGTGGAACATCATGAAAAGAGGAGATCTCCGGTTTGGTTGGCTATCAGGTTGCATCTGCCGGAATAACCTACACAG
 ATAGAAGATGGTGCTTTGATGGCATGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAGATA

CGGAGAGAAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTGAGATCATGCGGCCCTGAAGTCATTCAA
 GAGTTTGCCGCTGGGAAAAGAGGAGCGGCCTTTGGAGTGATAGAAGCCCTGGGAACACTGCCAGGACACATGACAGAG
 AGATTCCAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCGG
 5 CCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAATCTTTTCGTCTTGA
 TGCGGAACAAGGGCATGGGGAAGATGGGCTTTGGAATGGTGACTCTTGGGGCCAGCGCATGGCTTATGTGGCTCTCGGA
 AATTGAGCCAGCCAGAATTGCATGTGTCCTCATTGTCGTGTTCTATTGCTGGTGGTGTCTACACCTGAGCCAGAAAAGCA
 AAGATCTCCTCAGGACAACCAAATGGCAATCATCATCATGGTAGCAGTGGGTCTTCTGGGCTTGATTACCGCCAATGAACT
 CGGATGGTTGGAGAGAACAAAAAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGGCAACCACAGGATTCTC
 10 AATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCTATCTATGCTGCTCTGACAACTTTCATCACCCAGCCGTCCAACA
 TGCGGTGACCACTTCATACAACAACTACTCCTTAATGGCGATGGCCACGCAAGCTGGGGTGTGTTTGGTATGGGCAAAG
 GGATGCCATTCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATGGGTTGCTACTCACAATTAACACCTCTGACCCTAA
 TAGTGGCCATCATTTTGTCTGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGGGCTGCCAG
 AAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGAAGTGTGACTGACATTGACACAATGACAATTG
 ACCCCCAAGTGAAAAAAGATGGGGCAGGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTGCGGACCGC
 15 CTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACAGCTGCAACTTCCACCTTGTTGGGAAGGCTCTCCGAACAAGTACTGG
 AACTCCTCCACAGCCACTTCACTGTGTAACATTTTTAGGGGAAGTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAA
 GAAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACGGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCCTGAAC
 CAGATGTCGGCCCTGGAGTTCTACTCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGTGCCCT
 CAAGGACGGTGTGGCAACAGGAGGCCATGCTGTGTCCCAGGAAGTGCAAAGCTTAGATGGCTGGTGGAGAGAGGATA
 20 CCTGCAGCCCTATGGAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTACTATGCCGCCACCATCCGCAAAG
 TTCAGGAAGTGAAGGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCTGTTGGTGCAAAGCTATGGGTGGAACAT
 AGTCCGTCTTAAGAGTGGGGTGGACGTCTTTCACATGGCGGCTGAGCCGTGTGACACTTTGCTGTGTGATATAGGTGAGT
 CATCATCTAGTCTGAAGTGAAGAAGCACGGACGCTCAGAGTCTCTCCATGGTGGGGGATTGGCTTAAAAAAGACC
 AGGAGCCTTTTGTATAAAGTGTGTGCCATACACCAGCACTATGATGGAACCCTGGAGCGACTGCAGCGTAGGTATG
 25 GGGGAGGACTGGTCAGGGTGCCACTCTCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACAC
 CATAAAAAGTGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCAGGAGGCCAGTGAAATATGAGGAG
 GATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCAT
 TGAGAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATGGA
 AGCTATGAGGCCCTACACAAGGGTCAGCGTCTCTCTAATAAACGGGGTGTGACGGCTCTGTCAAAACCCTGGGATGT
 30 GGTGACTGGAGTCACAGGAATAGCCATGACTGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGAC
 ACTAGGGTGCCAGACCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTATGGAAGGAGCTAGGCAA
 ACACAAACGGCCACGAGTCTGTACCAAGAAGAGTTCATCAACAAGGTTCTGAGCAATGCAGCATTAGGGGCAATATTTG
 AAGAGGAAAAAGAGTGAAGACTGCAGTGGAAGCTGTGAATGATCCAAGGTTCTGGGCTCTAGTGGAACAAGGAAAGAG
 AGCATCACCTGAGAGGAGAGTGTGAGAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTG
 35 GAAAGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTCTAGAGTTCGAAGCCCTTGATTCTTG
 AATGAGGATCATTGGATGGGGAGAGAGAATTCAAGAGGTGGTGTGAAAGACTGGGATTACAAAGACTCGGATATGTC
 CTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGATACTGCTGGCTGGGACACCCGCATCAGCAGGT
 TTGATCTGGAGAATGAAGCTCTAATCACCAACCAAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTAC
 ACATACCAAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTCAAGACAAG
 40 ACCAAAGGGGGAGCGGACAAGTTGTCACTTACGCTCTTAATACATTACCAACCTGGTGGTGCAGCTCATTGGAATATG
 GAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGCCAGAGAAAAGTGACCAACTGGTTGCAAAGC
 AACGGATGGGATAGGCTCAAAGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAACCAATTGATGATAGGTTTGCAC
 ATGCCCTCAGGTTCTTGAATGATATGGGAAAAAGTTAGGAAGGACACACAAGAGTGGAAACCCTCAACTGGATGGGACAA
 CTGGGAAGAAGTTCCGTTTTGCTCCCACTTCAACAACTCCATCTTAAGGACGGGAGGTCCATTGTGGTTCCCTGCCG
 45 CCACCAAGATGAACTGATTGGCCGAGCCGCGTATCACCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCATGCA
 AAATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTCTCT
 GTGCCAGTTGATTGGGTTCCAACCTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAAATGGATGACCACTGAAGACA
 TGCTTGTGGTATGGAACAGAGTGTGGATTGAGGAAAACGACCACATGGAAGACAAGACCCCACTTACAAAATGGACAGA
 50 CATTCCCTATTTGGGAAAAAGAGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGTACTACCTGGGCTGAGA
 ACATCAAAAATACAGTCAACATGATGCGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAGGTT
 CGCTACTTGGGTGAAGAAGGGTCCACACCTGGAGTGCTGAAGCACAATCTTAGTGTTGTCAGGCTGCTAGTCAGCCA
 CAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCCAGGAGAAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGC
 CATGGCACGGAAGAAGCCATGCTGCCTGTGAGCCCCCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGAGGGCGC
 AGGATGGGAAAAAGAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCCAGA

AGAGGGACTAGTGGTTAGAGGAGACCCCCGAAAAACGCAAAACAGCATATTGACGCTGGGAAAGACCAGAGACTCCA
TGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAATAGCGGCGGCCGGTGTGGGGAATCCATGGGTCT

SEQ ID NO: 9

5 KU707826.1 Zika virus isolate SSABR1, Brazil, complete genome

GACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGTTTTATTTGGATTGGAAACGAGAGTTTCTGGTCAT
GAAAAACCCAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCTTT
GGGGGCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTTCATGGGCCATCAGGATGGTCTTGCGGATTCTAGCCTTTT
10 GAGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGAAAAAGAGGCTATGGAAATA
ATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGGAAGGAGAAGAAGAGACGAGGCGCA
GATACTAGTGTGGAATTGTTGGCCTCTGCTGACCACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTA
TATGTACTTGGACAGAAACGATGCTGGGGAGGCCATATCTTTCCAACCACATTGGGGATGAATAAGTGTATATACAGA
TCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGAACACGATGAC
15 GTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCAGAAAAAGGTGAAGCACGGAGAT
CTAGAAGAGCTGTGACGCTCCCTCCCTCCATTCCACTAGGAAGCTGCAAAACGCGTCGAAACCTGGTTGGAATCAAGAGAA
TACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTG
GCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATACAGCATCAGGT
GCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACCTGGGTTGATGTTGTCTTGAACATGGAGG
20 TTGTGTCACCGTAATGGCACAGGACAAACCGACTGTCGACATAGAGCTGGTTACAACAACAGTCAGCAACATGGCGGAG
GTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCTGCCAACACAAGGTGAAGCCTACCT
TGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAATGGATGTGGACTTTTT
GGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGAAGAGCATCCAGCCAGAGAATC
TGGAGTACCGGATAATGCTGTGAGTTCATGGCTCCAGCACAGTGGGATGATTGTTAATGACACAGGACATGAAACTGAT
25 GAGAATAGAGCGAAAGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACCCTGGGGGGTTTTGGAAGCCTAGGAC
TTGATTGTGAACCGAGGACAGGCCTTGACTTTTTCAGATTTGTATTACTTGACTATGAATAACAAGCACTGGTTGGTTCACA
AGGAGTGGTTCACGACATTCCATTACCTTGGCAGCTGGGGCAGACACCGGAACCTCCACTGGAACAACAAAGAACG
ACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAGTTACACG
GCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCCTTGCCCACTTGAAATGTCGCTGA
AAATGGATAAACTAGATTGAAGGGCGTGTCACTCCTTGTGTACTGCAGCGTTCACATTACCAAGATCCCGGCTGAAA
30 CACTGCACGGGACAGTCACAGTGGAGGTACGTACGAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGT
GGACATGCAAACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTAAGA
TGATGCTGGAACCTGATCCACCATTTGGGGACTCTTACATTGTATAGGAGTCCGGGAGAGAAGATCACCCACCACTGG
CACAGGAGTGGCAGCACCATTTGAAAAAGCATTTGAAGCCACTGTGAGAGGTGCCAAGAGAATGGCAGTCTTGGGAGAC
ACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTATTGGGCAAGGGCATCCATCAAATTTTTGGAGCAGCTTT
35 CAAATCATTTGTTGGAGGAATGTCCTGGTTCTCAGAAATCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAA
GAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCCACAGCCGTCTCTGCTGATGTGGG
GTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGTCTATAACGACGTTGAAGCCTGGAGG
GACAGGTACAAGTACCATCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCG
GGATCTCCTCTGTTTCAAGAATGAAAAACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAA
40 TGGAGTTCAACTGACGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTGTGA
ACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTGAGCAGCAGCAAGACAAATAACAGCTTTGTCGT
GGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACAGCTTTCTGTGGAGGATCATGGGTTCCGG
GTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTT
AAGGGAAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGG
45 GCCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGAATAGAAGAGAGTGATC
TGATCATACCAAGTCTTTAGCTGGGCCACTCAGCCATCAATAACAGAGAGGGCTACAGGACCCAAATGAAAGGGCCA
TGGCACAGTGAAGAGCTTGAATTCGTTTTGAGGAATGCCCAGGCACTAAGGTCCACGTGGAGGAAACATGTGGAACAA
GAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTGTGTCAGGGAGTGACAAATGCCCC
ACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAGAACCAGAAAAGCAACTTAGTA
50 AGGTCAATGGTGACTGCAGGATCAACTGATCAGATGGACCACTTCTCCCTTGGAGTGCTTGTGATTCTGCTCATGGTGCAG
GAAGGGCTGAAGAAGAGAATGACCACAAAGATCATATAAGCACATCAATGGCAGTGCTGGTAGCTATGATCCTGGGAG
GATTTTCAATGAGTGACCTGGCTAAGCTTGAATTTGATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTA
GCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCC
CGTGAAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTTGCAAACTGCGATCTCCGCTTGAAGGCGACCTGATGGTTCTC

ATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGATAACATCACCTTGGCAATCCTG
 GCTGCTCTGACACCACTGGCCCCGGGGCACACTGCTTGTGGCGTGGAGAGCAGGCCTTGCTACTTGCGGGGGGTTTATGCT
 CCTCTCTCTGAAGGGAAAAAGGCAGTGTGAAGAAGAACTTACCATTGTGTCATGGCCCTGGGACTAACCCTGTGAGGCTGG
 TCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCAC
 5 AGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTGCGCAAGGCAGATATAGAGATGGCTGGGCCATGGCCGCGGTG
 GGTCTGCTAATTGTGCTGATTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTGAAAGAGCAGGTGACATCACATGGG
 AAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCGATGTGGCGCTAGATGAGAGTGGTGATTCTCCCTGGTGGG
 GGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCCAATAGCCATAC
 10 CCTTTCAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCCTGCTCCCAA
 GGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTAGGTTCAACACAAGTTGG
 AGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTACAAAAGGATCCGCGCTGAGAAGCGGTGAAGG
 GAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGTACACTGTGGTCCATGGAAGCTAGATGCCGCTGG
 GACGGGCACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCCGAATAT
 TTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTCAGGATCTCCAATCTAGACAA
 15 GTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGATCAAAAATGGGAGTTATGTTAGTGCCATCACCAAGGG
 AGGAGGGAGGAAGAGACTCCTGTTGAGTGTCTCGAGCCTTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGC
 ATCCTGGAGCTGGGAAAACAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGATC
 TTAGCTCCAACAGGGTTGTCGCTGCTGAAATGGAGGAGGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGT
 CAATGTCACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACTTCACGTCTACTACAGCCAATCAGA
 20 GTCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCAAGTATAGCAGCAAGAGGATACATTTCA
 ACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACT
 CCAACTACCAATTATGGACACCGAAGTGGAAGTCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCA
 TTCTGGAAAAACAGTTTGGTTTGTCCAAAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAAGGCTGGAAAAAC
 GGGTCATACAGCTCAGCAGAAAAGACTTTTGAGACAGAGTTCCAGAAAAACAAACATCAAGAGTGGGACTTTGTCGTGAC
 25 AACTGACATTTAGAGATGGGCGCCAACCTTAAAGCTGACCGTGTGATAGATTCCAGGAGATGCCTAAAGCCGGTCATAC
 TTGATGGCGAGAGAGTCACTTCTGGCTGGACCATGCTGTGACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGG
 CAGGAATCCCAACAAACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGG
 CTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTGAGGCCGACAAA
 GTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGAGCAAGGAAGACCTTTGTGGAACCTATGAAAAGAGGAGAT
 30 CTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGAATAACCTACACAGATAGAAGATGGTGCTTTGATGGCACGACC
 AACACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAGACACGGAGAGAAAAAGTGTCAAACCGAGG
 TGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGGCGCTGGGAAAAGAGGAGCGG
 CTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAAGCCATTGACAACCTCGC
 TGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCGGCCCAATTGCCGAGACCTAGAGACCATT
 35 ATGCTTTTGGGGTTGCTGGGAACAGTCTCGTGGAATCTTCTCTGCTTGTGATGAGGAACAAGGGCATAGGGAAGATGG
 GCTTTGGAATGGTGACTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTC
 CTCATTGTTGTGTTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAACCAAATGGCA
 ATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGATGGTTGGAGAGAACAAGAGTGGA
 CCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCA
 40 GCTTGGGCCATCTATGCTGCCTTGACAACCTTTCATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAACACT
 CCTTAATGGCGATGGCCACGCAAGCTGGAGTGTGTTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTGGA
 GTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATAGTGCCATCATTTTGCTCGTGGCGCACT
 ACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCCAGAAGAGAACGGCAGCTGGCATCATGAAGAA
 CCCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCAAGTGGAGAAAAAGATGGGACAG
 45 GTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTGCGGACCGCCTGGGGGTGGGGGGAGGCTGGGGCCCTGA
 TCACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTACAGCCACTTCACTGTGTAACA
 TTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGGG
 GGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTCGGCCCTGGAGTTCTACTCCTACA
 AAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATG
 50 CTGTGTCCCGAGGAAGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCT
 TGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAGGATACACAAAAGG
 AGGCCCTGGTTCATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGTCTTAAGAGTGGGGTGGACGTC
 TTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATCTAGTCTGAAGTGAAGAAGC
 ACGGACGCTCAGAGTCTCTCATGGTGGGGGATTGGCTTGAAAAAGACCAGGAGCCTTTGTATAAAGGTGTTGTGCC

CATACACCAGCACTATGATGGAAACCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTC
 CCGCAACTCTACACATGAGATGTATTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAGTGTGTCCACCACGAGCCAGC
 TCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAATATGAGGAGGATGTGAATCTCGGCTCTGGCACGCGGGC
 TGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAA
 5 ACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGC
 GTCCTCTCTAATAAACGGGGTTGTCAAGGCTCTGTCAAAACCCTGGGATGTGGTGACTGGAGTCACAGGAATAGCCATGA
 CCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTAGGGTGCCAGACCCCAAGAAGGCAC
 TCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAAGAGCTAGGCAAACACAAACGGCCACGAGTCTGTACCAAAG
 AAGAGTTCATCAACAAGTTCTGTAGCAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACTGCAGT
 10 GGAAGCTGTGAACGATCCAAGTTCTGGGCTCTAGTGGATAAGGAAAAGAGAGACCACCTGAGAGGAGAGTGCCAGAG
 TTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGAAAAGGCCAAGGGCAGCCGCGCCATCTG
 GTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTCTTGAACGAGGATCACTGGATGGGGAGAGAG
 AACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATGTCCTAGAAGAGATGAGTCGTATACCAGGAG
 GAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACC
 15 AACCAATGGAAAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAACAAAGTGGTAAAGGTCC
 TTAGACCAGCTGAAAAAGGGAAAAAGTTATGGACATTATTTGAGACAAGACCAAGGGGGAGCGGACAAGTTGTCAC
 TTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTGGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAG
 ACTTGTGGCTGCTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGG
 CAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCTCAGGTTCTTGAATGATATGGGA
 20 AAAGTTAGGAAGGACACACAAGAGTGGAAACCCTCAACTGGATGGGACAACTGGGAAGAAGTTCCGTTTTGCTCCCACC
 ACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCAAGATGAACTGATTGGCCGGGCC
 CGCGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTGCCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCT
 TTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAAGTGGGAG
 AACTACCTGGTCAATCCATGGAAGGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGGATT
 25 GAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATCCCCTATTTGGGAAAAAGGGAAGACT
 TGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGCTGAGAACATTAACACAGTCAACATGGTGCAGC
 AGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACC
 TGGAGTGTGTAAGCACCAGTCTTAATGTTGTGAGGCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGA
 CCCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTGCCTGT
 30 GAGCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGATGGGAAAAGAAGGTGGCGACCTTC
 CCCACCCTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAG

SEQ ID NO: 10

KU744693.1 Zika virus isolate VE_Ganxian, China, complete genome

35 GTTGTACTGTTGCTGACTCAGACTGCGACAGTTTCAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTGG
 ATTTGGAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAACG
 CGGAGTAGCCCGTGTGAGCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTGATGGGCCCATCAGG
 ATGGTCTTGGCAATTCTAGCCTTTTGAAGATTACCGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTG
 GGGAAAAAGATGCTATGGAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGGA
 40 AGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGGAATTTGTTGGCTCCTGCTGACCACAGCTATGGCAGCGGAGG
 TCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACGATGCTGGGGAGGCCATATCTTTTCCAACCACATTG
 GGGATGAATAAGTGTTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCT
 GGATGAGGGGGTGGAACCAAGATGACGTCGATTGTTGGTGCAACACGACGTCACCTTGGGTTGTGTACGGAACCTGCCAT
 CACAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCTTCCATTCCACTAGGAAGCTGCAACGCGGT
 45 CGCAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCTTC
 GCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCT
 GATTGCCCCGGCATACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGG
 GTTGATGTTGCTTGAACATGGAGGTTGTGCACCGCAATGGCACAGGACAAACCGACTGTCGACATAGAGCTGGTTAC
 AACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCT
 50 GCCCAACACAAGGTGAAGCTACCTTGACAAGCAATCAGACACTCAATATGTTTGCAAAAGAAGCTTAGTGACAGAGGC
 TGGGGAAATGGATGTGGACTTTTGGCAAAGGGAGTCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCG
 GGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTGAGTTTATGGCTCCAGCACAGTGGGATGCTCGTT
 AATGACACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTACCAAGAGCCGAAGCCACCC
 TGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAAGTTTGTATTACTTGACTATGA

ATAACAAGCACTGGTTGGCTCACAAGGAGTGGTTCCACGACATTCCATTACCTTGGCACGCTGGGGCAGCCACCGGAACT
 CCACACTGGAACAACAAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACCTGTCGTGGTTCTAGGGA
 GTCAAGAAGGAGCAGTTCACACGGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCCTC
 TGGCCACTTGAAATGTCGCCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTGTTACCGCAGCGTTTCA
 5 ATTCACCAAGATCCCGGTGAAACAGTGGACGGGACAGTACAGTGGAGGGACAGTACGGAGGGACAGATGGACCTTG
 CAAGGTTCCAGCTCAGATGGCGGTGGACATGCAGACTCTGACCCCACTTGGGAGGTTGATAACCGCTAACCCGTAATCA
 CTGAAAGCACTGAGAACTCTAAGATGATGCTGGAACCTTGATCCACCATTTGGGGACTCTTACATTGTCATAGGAGTCGGG
 GAGAAGAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGAAAAAGCATTTGAAGCCACTGTGAGAGGTGCCA
 AGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTCATTGGGCAAGGGCAT
 10 CCATCAAATTATTGGAGCAGCTTTCAAATCATTGTTGGAGGAATGTCCTGGTTCTCACAAATTCTCATTGGGACGTTGCTG
 ATGTGGTTGGGTCTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCC
 ACAGCCGTCTCAGGTGGTGTGGGGTCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGTCT
 ATAACGATGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAAGCA
 AGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGAAAAACATCATGTGGAGATCAGTAGAAGGGGAG
 15 CTCAACGCAATCTGGAAGAGAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTC
 CACAGAGATTGCCCGTGCCTGTGAACGAGCTGCCCCAGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTAGAGCAGC
 AAAGACAAATAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACAGCTTTC
 TTGTGGAGGATCATGGGTTGCGGGTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGACTATTGGTTAGAGTGTGAT
 CCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGA
 20 ATGACACATGGTGGCTGAAGAGGGCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCACACATTGTGGAC
 AGATGGAATAGAAGAGAGTGATCTGATCATACCAAGTCTTAGCTGGGCCACTCAGCCATCACAATGCCAGAGAGGGCT
 ACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAATTCGGTTTGAGGAATGCCCAGGCACTAAGGTCCA
 CGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTG
 CTCCAGGGAGTGCACAATGCCCCACTGTCTTCCAGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCAGG
 25 AAAGAACCAGAAAGCAACTTAGTAAGGTCAATGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGGAGT
 GCTTGTGATTCTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATGGCA
 GTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGC
 GGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTATCTT
 TCATCTTCAGAGCTAATTGGACACCCCGTGAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTTGCAAACTGCGATCTCCG
 30 CTTGGAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCA
 CTGATAACATCACCTTAGCAATCCTGGCTGCTCTGACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGGAGAGCAGGC
 CTTGCTACTTGCGGGGGGTTTATGCTCCTCTCTGAAGGGAAAAAGGCAGTGTGAAGAAGAACTTACCATTGTGATGGC
 CCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGG
 AGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGA
 35 GATGGCTGGGCCCATGGCCGCGGTGCGTCTGCTAATTGTGAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTG
 AAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAACAGTCCCCGGCTCGATGTGGCGCTAGATG
 AGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGATGACCATC
 TGTGGCATGAACCAATAGCCATACCCCTTTCGAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTG
 CTCTATGGGATGTGCTGCTCCCAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGCAG
 40 ACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCACAAAAGGA
 TCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGAGATGTCAAGCAGGATCTGGTGTCTACTGTGGTC
 CATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCAGCTCTTGCCGTGCCCCCGGAGAGAGAGCGGAGGA
 ACATCCAGACTCTGCCGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCACTGGATTACCCAGCAGGAAC
 TTCAGGATCTCCAATCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCGTGATCAAAAATGGGAGT
 45 TATGTTAGTGCCATCACCAAGGGAGGAGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGCTGAAGAAGA
 AGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAAACCAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATA
 AAAACAAGACTCCGTACTGTGATCTTGGCTCCAACCAGGGTTGTCGCTGCTGAAATGGAGGAGGCCCTTAGAGGGCTTCC
 AGTGCGTTATATGACAACAGCAGTCAATGTACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCAC
 TTCACGTCTACTACAGCCAATTAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTACAGATCCCTCAAGT
 50 ATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACCAG
 GAACCCGTGACGCATTTCCGGACTCCAACACCAATTATGGACACCGAAGTGGAAGTCCAGAGAGAGCCTGGAGCTCA
 GGCTTTGATTGGGTGACGGAGTATTCTGGAAAAACAGTTTGGTTTGTCCACGCGTGAGGAACGGCAATGAGATCGCAG
 CTTGTCTGACAAAGGCTGGAAAAACGGGTCTACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCAGAAAAACAAACAT
 CAAGAGTGGGACTTTGTCGTGACAACCTGACATTTAGAGATGGGCGCCAACCTTAAAGCTGACCGTGTATAGATTCCAG

GAGATGCCTAAAGCCGGTCATACTGGTGGCGAGAGAGTCATTCTGGCTGGACCCATGCCTGTCACACATGCCAGCGCTG
 CCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGA
 CTGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGC
 TCTATCGACCTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGT
 5 GAACTCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAGATAGAA
 GATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAGACACGGAG
 AGAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAAGTCATTCAAGGAGTT
 TGCCGCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATT
 10 CCAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCGGCCCAA
 TTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAATCTTTTTCGTCTTGATGAGG
 AACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTG
 AGCCAGCCAGAATTGCATGTGTCTCATTGTTGTGTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGAT
 CTCCCCAGGACAACCAATGGCCATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGAT
 15 GGTTGGAGAGAAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATGGGATTCTCAATGG
 ACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATCCTGCCTTGACATCTTTCATTACCCAGCCGTCCAACATGCAGT
 GACCACTTCATAACAACACTACTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGC
 CATTCTACGCATGGGACTTTGGAGTCCGCTGCTAATGATAGGTTGCTACTCACAATTAACGCCCTGACCCTAATAGTGG
 CCATCATTTTGTCTGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCCAGAAGAGA
 20 ACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGAGGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCC
 AAGTGGAGAAAAAGATGGGACAGGTGCTACTCATGGCAGTAGCCGTCTCCAGCGCCATACTGTCGAGGACCGCTGGGG
 GTGGGGGGGAGGCTGGGGCCCTGATCACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTC
 TCTACAGCCACCTCACTGTGTAACATTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAAC
 GCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGAT
 25 GTCGGCCCTGGAGTTCTACTCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCCGCGCGCCCTCAAG
 GACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCAGGAAGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTG
 CAGCCCTATGGAAAGGTCACTGATCTTGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCA
 AGAAGTGAAAGGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAGT
 CCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCAT
 30 CATCTAGTCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCTCTCATGGTGGGGGATTGGCTGAAAAAAGACCAGG
 AGCCTTTTGTATAAAAGTGTTGTGCCCATACACCAGCACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGG
 GAGGACTGGTCAGAGTGCCACTCTCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATA
 AAAAGTGTGTCCACCACGAGCCAGCTCCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAAATATGAGGAGGAT
 GTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGA
 35 AAGGATCCGCGCTGAGAAAGCGGAAACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATGGAAGC
 TATGATGCCGCCACACAAGGGTCAGCGTCTCTCTAATAAACGGGGTGTGAGGCTCCTGTCAAAACCTGGGATGTGGT
 GACTGGAGTCACAGGAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACT
 AGGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAAGAGCTAGGCAAAC
 ACAAACGGCCACGAGTCTGTACCAAGAAGAGTTCATCAACAAGGTTCTAGCAATGCAGCATTAGGGGCAATATTTGAA
 GAGGAAAAAGAGTGGAAAGACTGCAGTGGAAGCTGTGAACGATCCAAGGTTCTGGGCTCTAGTGGAACAAGGAAAGAGAG
 40 CACCACCTGAGAGGAGAGTGCCAGAGTTGTGTGTACATCACAATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGA
 AAGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTCTTGAA
 CGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATGTCCT
 AGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTT
 GATCTGGAGAATGAAGCTAATCACCAACCAATGGAGAAAAGGCGACAGGGCCTTGGCATTGGCCATAATCAAGTACA
 45 CATACCAAAACAAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTTCGAGACAAGA
 CCAAAGGGGGAGCGGACAAGTTGTCACTTACGCTCTCAACACATTTACCAACCTAGTGGTGCAACTCATTGGAATATGG
 AGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAGCA
 ACGGATGGGATAGGCTCAAACGAATGGCGGTGAGTGAGATGATTGCGTTGTGAAACCAATTGATGATAGGTTTGCACA
 50 TGCCCTCAGGTTCTTGAATGATATGGGAAAAAGTTAGGAAGGACACACAAGAGTGGAAACCTCAACTGGATGGGACAAC
 TGGAAGAAGTTCCCTTCTGCTCCACCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGC
 CACCAAGATGAAGTATTGGCCGGGCGCGTCTCTCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAA
 AATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTTCATCTG
 TGCCAGTTGACTGGGTTCCAAGTGGGAGAACTACCTGGTCAATCCATGGAAAAGGAGAAATGGATGACCACTGAAGACAT
 GCTTGTGGCGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTCACGAAATGGACAGA

CATTCCCTATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGCTGAGA
ACATTAACAAACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAAGTT
CGCTACTTGGGTGAAGAAAGGTCTACACCTGGAGTGCTGAAGCACCAATCTTAATGTTGTCAGGCCTGCTAGTCAGCCA
CAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGC
5 CATGGCACGGAAGAAGCCATGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGAGGGCGC
AGGATGGGAAAAGAAGGTGGCGACCTTCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCCAGA
AGAGGGACTAGTGGTTAGAGGAGA

SEQ ID NO: 11

10 LC002520.1 Zika virus genomic RNA, strain: MR766-NIID, Uganda, complete genome

AGTTGTTGATCTGTGTGAGTCAGACTGCGACAGTTCGAGTCTGAAGCGAGAGCTAACACAGTATCAACAGGTTTAATTT
GGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAGAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAA
ACGCGGAGTAGCCCGTGTAAACCCCTTGGGAGGTTTGAAGAGGTTGCCAGCCGGACTTCTGCTGGGTCATGGACCCATCA
GAATGGTTTTGGCGATACTAGCCTTTTTGAGATTTACAGCAATCAAGCCATCACTGGGCCTTATCAACAGATGGGGTTCCG
15 TGGGGAAAAAAGAGGCTATGGAAATAATAAAGAAAGTTCAAGAAAGATCTTGCTGCCATGTTGAGAATAATCAATGCTAG
GAAAGAGAGGAAGAGACGTGGCGCAGACACCAGCATCGGAATCATTGGCCTCTGCTGACTACAGCCATGGCAGCAGA
GATCACTAGACGCGGGAGTGCATACTACATGTACTTGGATAGGAGCGATGCCGGGAAGGCCATTTGTTTTGCTACCACAT
TGGGAGTGAACAAGTGCCACGTACAGATCATGGACCTCGGGCACATGTGTGACGCCACCATGAGTTATGAGTGCCCTATG
CTGGATGAGGGAGTGGAACCAGATGATGTCGATTGCTGGTGCAACACGACATCAACTTGGGTTGTGTACGGAACCTGTC
20 ATCACAAAAAAGGTGAGGCACGGCGATCTAGAAGAGCCGTGACGCTCCCTTCTCACTCTACAAGGAAGTTGCAACGCG
GTCGCAGACCTGGTTAGAATCAAGAGAATACACGAAGCACTTGATCAAGGTTGAAAAGTGGATATTCAGGAACCCCGGG
TTTGCCTAGTGCCGTTGCCATTGCTTGGCTTTTGGGAAGCTCGACGAGCCAAAAAGTCATATACTTGGTCATGATACTG
CTGATTGCCCCGGCATAACAGTATCAGGTGCATTGGAGTCAGCAATAGAGACTTCGTGGAGGGCATGTCAGGTGGGACCT
GGGTTGATGTTGCTTGAACATGGAGGCTGCGTTACCGTGATGGCACAGGACAAGCCAACAGTTGACATAGAGTTGGT
25 CACGACGACGGTTAGTAACATGGCCGAGGTAAGATCCTATTGCTACGAGGCATCGATATCGGACATGGCTTCGGACAGTC
GTTGCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAAGAACATTAGTGGACAGA
GGTTGGGGAAACGTTTGTGGACTTTTTGGCAAAGGGAGCTTGGTGACATGTGCAAGTTTACGTGTTCTAAGAAGATGA
CCGGGAAGAGCATTCAACCGGAAAAATCTGGAGTATCGGATAATGCTATCAGTGCATGGCTCCAGCATAGCGGGATGAC
TGTCATGATATAGGATATGAAACTGACGAAAAATAGAGCGAAAAGTCGAGGTTACGCCTAATTACCAAGAGCGGAAGCA
30 ACCTTGGGAGGCTTTGGAAGCTTAGGACTTGACTGTGAACCAAGGACAGGCCTTGACTTTTCAGATCTGTATTACCTGACC
ATGAACAATAAGCATTGGTTGGTGACAAAGAGTGGTTTCATGACATCCCATTGCCTTGGCATGCTGGGGCAGACACTGG
AACTCCACACTGGAACAACAAAGAGGCATTGGTAGAATTCAAGGATGCCACGCCAAGAGGCCAAACCGTCGTCGTTCTG
GGGAGCCAGGAAGGAGCCGTTACACGGCTCTCGCTGGAGCTCTAGAGGCTGAGATGGATGGTGCAAAGGGAAAGCTG
TTCTCTGGCCATTTGAAATGCCGCCTAAAAATGGACAAGCTTAGATTGAAGGGCGTGTCATATTCCTGTGCACTGCGGCA
35 TTCACATTACCAAGGTCCCAGCTGAAACACTGCATGGAACAGTCACAGTGGAGGTGCAGTATGCAGGGACAGATGGAC
CCTGCAAGATCCAGTCCAGATGGCGGTGGACATGCAGACCCTGACCCCAAGTTGGAAGGCTGATAACCGCCAACCCCGTG
ATTACTGAAAGCACTGAGAACTCAAAGATGATGTTGGAGCTTGACCCACCATTGTTGGGATTCTTACATTGTATAGGAGTT
GGGGACAAGAAAAATCACCCACCACTGGCATAGGAGTGGTAGCACCATCGGAAAAGGCATTTGAGGCCACTGTGAGAGGC
GCCAAGAGAATGGCAGTCCTGGGGGATACAGCCTGGGACTTCGGATCAGTCGGGGGTGTGTTCAACTCACTGGGTAAGG
40 GCATTCACCAGATTTTTGGAGCAGCCTTCAAATCACTGTTTGGAGGAATGTCCTGTTCTCACAGATCCTCATAGGCACGC
TGCTAGTGTGGTTAGTTTGAACACAAAGAATGGATCTATCTCCCTCACATGCTTGGCCCTGGGGGGAGTGATGATCTTCC
TCTCCACGGCTGTTTCTGCTGACGTGGGGTGCTCAGTGGACTTCTCAAAAAGGAAACGAGATGTGGCACGGGGGATTTC
ATCTATAATGATGTTGAAGCCTGGAGGGACCGGTACAAGTACCATCCTGACTCCCCCGCAGATTGGCAGCAGCAGTCAA
GCAGGCCTGGGAAGAGGGGATCTGTGGGATCTCATCCGTTTCAAGAATGGAAAACATCATGTGGAATCAGTAGAAGGG
45 GAGCTCAATGCTATCCTAGAGGAGAATGGAGTTCAACTGACAGTTGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAG
GTCCACAAAGATTGCCAGTGCTGTGAATGAGCTGCCCCATGGCTGGAAAGCCTGGGGGAAATCGTATTTTGTAGGGCG
GCAAAGACCAACAACAGTTTTGTTGTCGACGGTGACACACTGAAGGAATGTCGCTTGAAGCAGAGCATGGAATAGTTT
TCTTGTGGAGGATCACGGGTTTGGAGTCTTCCACACCAAGTGTCTGGCTTAAGGTCAGAGAAGATTACTCATTAGAATGTG
ACCCAGCCGTCATAGGAACAGCTGTTAAGGGAAGGGAGGCCGCGCACAGTGATCTGGGCTATTGGATTGAAAGTGAAAA
50 GAATGACACATGGAGGCTGAAGAGGGCCACCTGATTGAGATGAAAACATGTGAATGGCCAAAGTCTCACACATTGTGG
ACAGATGGAGTAGAAGAAAGTGATCTTATCATACCAAGTCTTTAGCTGGTCCACTCAGCCACCACAACACCAGAGAGGG
TTACAGAACCAAGTGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATCCGTTTGAAGGAATGTCCAGGCACCAAGGTT
TACGTGGAGGAGACATGCGGAAGTGAAGGACCATCTCTGAGATCAACTACTGCAAGTGGAAGGGTCATTGAGGAATGGT
GCTGTAGGGAATGCACAATGCCCCCACTATCGTTTCGAGCAAAAGACGGCTGCTGGTATGGAATGGAGATAAGGCCAG

GAAAGAACCAGAGAGCAACTTAGTGAGGTCAATGGTGACAGCGGGGTCAACCGATCATATGGACCACTTCTCTTGGAG
 GTGCTTGTGATTCTACTCATGGTGCAGGAGGGGTTGAAGAAGAGAATGACCACAAAGATCATCATGAGCACATCAATGG
 CAGTGCTGGTAGTCATGATCTTGGGAGGATTTTCAATGAGTGACCTGGCCAAGCTTGTGATCCTGATGGGTGCTACTTTCC
 CAGAAATGAACACTGGAGGAGATGTAGCTCACTTGGCATTGGTAGCGGCATTTAAAGTCAGACCAGCCTTGCTGGTCTCC
 5 TTCATTTTCAGAGCCAATTGGACACCCCGTGAGAGCATGCTGCTAGCCCTGGCTTCGTGCTTCTGCAAACTGCGATCTCT
 GCTCTTGAAGGTGACTTGATGGTCCTCATTAAATGGATTTGCTTTGGCCTGGTTGGCAATTCGAGCAATGGCCGTGCCACGC
 ACTGACAACATCGCTCTACCAATCTTGGCTGCTCTAACACCACTAGCTCGAGGCACACTGCTCGTGGCATGGAGAGCGGG
 CCTGGCTACTTGTGGAGGGATCATGCTCCTCTCCCTGAAAGGGAAAGGTAGTGTGAAGAAGAACCTGCCATTTGTCATGG
 10 CCCTGGGATTGACAGCTGTGAGGGTAGTAGACCCTATTAATGTGGTAGGACTACTGTTACTCACAAGGAGTGGGAAGCG
 GAGCTGGCCCCCTAGTGAAGTTCTCACAGCCGTTGGCCTGATATGTGCACTGGCCGGAGGGGTTTGCCAAGGCAGACATTG
 AGATGGCTGGACCCATGGCTGCAGTAGGCTTGCTAATTGTGAGCTATGTGGTCTCGGGAAGAGTGTGGACATGTACATT
 GAAAGAGCAGGTGACATCACATGGGAAAAGGACGCGGAAGTCACTGGAAACAGTCCTCGGCTTGACGTGGCACTGGAT
 GAGAGTGGTGATTTCTCTTGGTAGAGGAAGATGGTCCACCCATGAGAGAGATCATACTTAAGGTGGTCTGATGGCCAT
 CTGTGGCATGAACCAATAGCTATACCTTTTGTGTCAGGAGCGTGGTATGTGTATGTGAAGACTGGGAAAAGGAGTGGC
 15 GCCCTCTGGGACGTGCTGCTCCCAAAGAAGTGAAGAAAAGGAGAGACCACAGATGGAGTGTACAGAGTGTGACTCGCA
 GACTGCTAGGTTCAACACAGGTTGGAGTGGGAGTCATGCAAGAGGGAGTCTTCCACACCATGTGGCACGTTACAAAAGG
 AGCCGCACTGAGGAGCGGTGAGGGAAGACTTGATCCATACTGGGGGGATGTCAAGCAGGACTTGGTGTCTACTGTGG
 GCCTTGGAAGTTGGATGCAGCTTGGGATGGACTCAGCGAGGTACAGCTTTTGGCCGTACCTCCCGGAGAGAGGGGCCAGA
 AACATTGAGACCTGCCTGGAATATTCAAGACAAAGGACGGGGACATCGGAGCAGTTGCTCTGGACTACCTGCAGGGA
 20 CCTCAGGATCTCCGATCTAGACAAATGTGGAAGAGTGATAGGACTCTATGGCAATGGGGTTGTGATCAAGAAATGGAAG
 CTATGTTAGTGCTATAACCCAGGGAAAGAGGGAGGAGAGACTCCGTTGAATGTTTCGAACCTCGATGCTGAAGAAG
 AAGCAGCTAACTGTCTTGGATCTGCATCCAGGAGCCGGAACCAAGGAGAGTTCTTCTGAAATAGTCGTGAAGCCAT
 AAAAAAGAGACTCCGGACAGTGATCTTGGCACCACTAGGGTTGTGCTGCTGAGATGGAGGAGGCCTTGAGAGGACTT
 CCGGTGCGTTACATGACAACAGCAGTCAACGTACCCATTCTGGGACAGAAATCGTTGATTTGATGTGCCATGCCACTTTC
 25 ACTTCACGCTTACTACAACCCATCAGAGTCCCTAATTACAATCTCTACATCATGGATGAAGCCCACTTCACAGACCCCTCAA
 GTATAGCTGCAAGAGGATATATATCAACAAGGGTTGAAATGGGCGAGGCGGCTGCCATTTTTATGACTGCCACACCACCA
 GGAACCCGTGATGCGTTTCTGACTCTAACTACCAATCATGGACACAGAAGTGAAGTCCCAGAGAGAGCCTGGAGCTC
 AGGCTTTGATTGGGTGACAGACCATTCTGGGAAAACAGTTTGTTGCTTCCAAGCGTGAGAAACGGAAATGAAATCGCA
 30 GCCTGTCTGACAAAGGCTGGAAAGCGGGTCATACAGCTCAGCAGGAAGACTTTTGAGACAGAATTCAGAAAACAAAAA
 ATCAAGAGTGGGACTTTGTGATAACAACCTGACATCTCAGAGATGGGCGCCAACCTCAAGGCTGACCGGGTCATAGACTCT
 AGGAGATGCCTAAACAGTCATACTTGATGGTGAGAGAGTCATCTTGGCTGGGCCATGCCTGTACGCATGCTAGTGC
 TGCTCAGAGGAGAGGACGTATAGGCAGGAACCTAACAACCTGGAGATGAGTACATGTATGGAGGTGGGTGTGCAGA
 GACTGATGAAGGCCATGCACACTGGCTTGAAGCAAGAATGCTTCTTGACAACATCTACCTCCAGGATGGCCTCATAGCCTC
 35 GCTCTATCGGCTGAGGCCGATAAGGTAGCCGCCATTGAGGGAGAGTTTAAAGCTGAGGACAGAGCAAAGGAAGACCTTC
 GTGGAACCTCATGAAGAGAGGAGACCTTCCCGTCTGGCTAGCCTATCAGGTTGCATCTGCCGGAATAACTTACACAGACAG
 AAGATGGTGCTTTGATGGCACAACCAACAACACCATAATGGAAGACAGCGTACCAGCAGAGGTGTGGACAAAGTATGGA
 GAGAAGAGAGTGCTCAAACCGAGATGGATGGATGCTAGGGTCTGTTAGACCATGCGGCCCTGAAGTCGTTCAAAGAAT
 TCGCCGCTGGAAGGAGAGGAGCGGCTTTGGGAGTAATGGAGGCCCTGGGAACACTGCCAGGACACATGACAGAGAGGT
 TTCAGGAAGCCATTGACAACCTCGCCGTGCTCATGCGAGCAGAGACTGGAAGCAGGCCTTATAAGGCAGCGGCAGCCCA
 40 ACTGCCGAGACCCATAGAGACCATTATGCTCTTAGGTTTGTGTTGGAACAGTTTCACTGGGGATCTTCTCGTCTTGATGCG
 GAATAAGGGCATCGGGAAGATGGGCTTTGGAATGGTAACCTTGGGGCCAGTGCATGGCTCATGTGGCTTTGCGAAATT
 GAACCAGCCAGAATTGCATGTGTCTCATTGTTGTGTTTTATTACTGGTGGTGTCTATACCCGAGCCAGAGAAGCAAAGA
 TCTCCCAAGATAACCAGATGGCAATTATCATCATGGTGGCAGTGGGCTTCTAGGTTTGATAACTGCAAACGAACTTGA
 45 TGGCTGGAAAGAACAAAAAATGACATAGCTCATCTAATGGGAAGGAGAGAGAAAGGAGCAACCATGGGATTCTCAATG
 GACATTGATCTGCGGCCAGCCTCCGCCTGGGCTATCTATGCCGATTGACAACCTCATCACCCAGCTGTCCAACATGCG
 GTAACCACTTCATACAACAACTACTCCTTAATGGCGATGGCCACACAAGCTGGAGTGCTGTTTGGCATGGGCAAAGGGAT
 GCCATTTTATGCATGGGACCTTGGAGTCCCGCTGCTAATGATGGGTTGCTATTCACAATTAACACCCCTGACTCTGATAGT
 AGCTATCATTCTGCTTGTGGCGCACTACATGTACTTGATCCCAGGCCTACAAGCGGCAGCAGCGCGTGTGCCAGAAAA
 50 GGACAGCAGCTGGCATCATGAAGAATCCCGTTGTGGATGGAATAGTGGTAACCTGACATTGACACAATGACAATAGACCC
 CCAGGTGGAGAAGAAGATGGGACAAGTGTTACTCATAGCAGTAGCCATCTCCAGTGCTGTGCTGCTGCGGACCGCCTGG
 GGATGGGGGGAGGCTGGAGCTCTGATCACAGCAGCGACCTCCACCTTGTGGGAAGGCTCTCCAAACAAATACTGGAAC
 CCTCTACAGCCACCTCACTGTGCAACATCTTCAAGGAAAGCTATCTGGCAGGAGCTTCCCTTATCTATACAGTGACGAGAA
 ACGCTGGCCTGGTTAAGAGACGTGGAGGTGGGACGGGAGAGACTCTGGGAGAGAAGTGGAAAGCTCGTCTGAATCAGA
 TGTCGGCCCTGGAGTTCTACTCTATAAAAAAGTCAGGTATCACTGAAGTGTGTAGAGAGGAGGCTCGCCGTGCCCTCAAG

GATGGAGTGGCCACAGGAGGACATGCCGTATCCCGGGGAAGTGCAAAGCTCAGATGGTTGGTGGAGAGAGGATATCTG
 CAGCCCTATGGGAAGGTTGTTGACCTCGGATGTGGCAGAGGGGGCTGGAGCTATTATGCCGCCACCATCCGCAAAGTGC
 AGGAGGTGAGAGGATACACAAAGGGAGGTCCCGGTCTATGAAGAACCCATGCTGGTGCAAAGCTATGGGTGGAACATAG
 5 TCGTCTCAAGAGTGGAGTGGACGTCTTCCACATGGCGGCTGAGCCGTGTGACACTCTGCTGTGTGACATAGGTGAGTCA
 TCATCTAGTCTGAAGTGAAGAGACACGAACACTCAGAGTGCTCTCTATGGTGGGGGACTGGCTTGAAAAAGACCAG
 GGGCCTTCTGTATAAAGGTGCTGTGCCATACACCAGCACTATGATGGAAACCATGGAGCGACTGCAACGTAGGCATGG
 GGGAGGATTAGTCAGAGTGCCATTGTCTCGCAACTCCACACATGAGATGTACTGGGTCTCTGGGGCAAAGAGCAACATCA
 TAAAAAGTGTGTCCACCACAAGTCAGCTCCTCCTGGGACGCATGGATGGCCCCAGGAGGCCAGTGAAATATGAGGAGGA
 10 TGTGAACCTCGGCTCGGGTACACGAGCTGTGGCAAGCTGTGCTGAGGCTCCTAACATGAAAATCATCGGCAGGCGCATTG
 AGAGAATCCGCAATGAACATGCAGAAACATGGTTTCTTGATGAAAACCACCCATACAGGACATGGGCCTACCATGGGAGC
 TACGAAGCCCCACGCAAGGATCAGCGTCTTCCCTCGTGAACGGGGTTGTTAGACTCCTGTCAAAGCCTTGGGACGTGGT
 GACTGGAGTTACAGGAATAGCCATGACTGACACCACCCATACGGCCAACAAAGAGTCTTCAAAGAAAAAGTGGACACC
 AGGGTGCCAGATCCCCAAGAAGGCACTCGCCAGGTAATGAACATAGTCTTCTTCTGGCTGTGGAAGGAGCTGGGGAAAC
 GCAAGCGGCCACGCGTCTGCACCAAAGAAGAGTTTATCAACAAGGTGCGCAGCAATGCAGCACTGGGAGCAATATTTGA
 15 AGAGGAAAAAGAATGGAAGACGGCTGTGGAAGCTGTGAATGATCCAAGTTTTGGGCCCTAGTGGATAGGGAGAGAGA
 ACACCACCTGAGAGGAGAGTGTACAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAGCAAGGAGAGTTCGG
 GAAAGCAAAGGTAGCCGCGCCATCTGGTACATGTGGTTGGGAGCCAGATTCTTGGAGTTTGAAGCCCTTGGATTCTTGA
 ACGAGGACCATTGGATGGGAAGAGAAAACTCAGGAGGTGGAGTCGAAGGGTTAGGATTGCAAAGACTTGATACATTC
 TAGAAGAAATGAATCGGGCACCAGGAGGAAAGATGTACGCAGATGACACTGCTGGCTGGGACACCCGCATTAGTAAGTT
 20 TGATCTGGAGAATGAAGCTCTGATTACCAACCAATGGAGGAAGGGCACAGAACTCTGGCGTTGGCCGTGATTAAATAC
 ACATACCAAAACAAAGTGGTGAAGGTTCTCAGACCAGCTGAAGGAGGAAAAACAGTTATGGACATCATTTCAAGACAAG
 ACCAGAGAGGGAGTGGACAAGTTGTCACTTATGCTCTCAACACATTCACCAACTTGGTGGTGCAGCTTATCCGGAACATG
 GAAGCTGAGGAAGTGTTAGAGATGCAAGACTTATGGTTGTTGAGGAAGCCAGAGAAAGTGACCAGATGGTTGCAGAGC
 AATGGATGGGATAGACTCAAACGAATGGCGGTCAGTGGAGATGACTGCGTTGTGAAGCCAATCGATGATAGGTTTGCAC
 25 ATGCCCTCAGTTCTTGAATGACATGGGAAAAAGTTAGGAAAGACACACAGGAGTGGAAACCCTCGACTGGATGGAGCAA
 TTGGGAAGAAGTCCCGTTCTGCTCCCACTTCAACAAGCTGTACCTCAAGGATGGGAGATCCATTGTGGTCCCTTGCCG
 CCACCAAGATGAACTGATTGGCCGAGCTCGCGTCTACCAGGGGCAGGATGGAGCATCCGGGAGACTGCTGTCTTGCA
 AAATCATATGCGCAGATGTGGCAGCTCCTTTATTTCCACAGAAGAGACCTTCGACTGATGGCTAATGCCATTTGCTCGCT
 GTGCCAGTTGACTGGGTACCAACTGGGAGAACCACCTGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAGGACA
 30 TGCTCATGGTGTGGAATAGAGTGTGGATTGAGGAGAACGACCATATGGAGGACAAGACTCCTGTAACAAAATGGACAGA
 CATTCCCTATCTAGGAAAAAGGGAGGACTTATGGTGTGGATCCCTTATAGGGCACAGACCCCGCACCCTTGGGCTGAAA
 ACATCAAAGACACAGTCAACATGGTGGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTATCTATCCACCCAAGTC
 CGCTACTTGGGTGAGGAAGGGTCCACACCCGGAGTGTTGTAAGCACCAATTTAGTGTTGTCAGGCCTGCTAGTCAGCCA
 CAGTTTGGGGAAAGCTGTGCAGCTGTAACCCCCCAGGAGAAGCTGGGAAACCAAGCTCATAGTCAGGCCGAGAACGC
 35 CATGGCACGGAAGAAGCCATGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAAAGCGC
 AGGATGGGAAAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGACTAGCTGTGAATCTCCAGC
 AGAGGGACTAGTGGTTAGAGGAGACCCCCGAAAAACGCAAAACAGCATATTGACGCTGGGAAAGACCAGAGACTCCA
 TGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAACAGCGGCGCCGGTGTGGGGAATCCATGGTTTCT

40 SEQ ID NO: 12

AY632535.2 NC_012532.1 Zika virus strain MR 766, Uganda, complete genome
 AGTTGTTGATCTGTGTGAGTCAGACTGCGACAGTTCGAGTCTGAAGCGAGAGCTAACAACAGTATCAACAGGTTTAATTT
 GGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCCAAAGAAGAAATCCGGAGGATCCGGATTGTCAATATGCTAAA
 ACGCGGAGTAGCCCGTGTAAACCCCTTGGGAGGTTTGAAGAGGTTGCCAGCCGACTTCTGCTGGGTATGGACCCATCA
 45 GAATGGTTTTGGCGATACTAGCCTTTTTGAGATTTACAGCAATCAAGCCATCACTGGGCCTTATCAACAGATGGGGTTCCG
 TGGGGAAAAAGAGGCTATGGAAATAATAAAGAAAGTTCAAGAAAGATCTTGCTGCCATGTTGAGAATAATCAATGCTAG
 GAAAGAGAGGAAGAGACGTGGCGCAGACACCAGCATCGGAATCATTGGCCTCCTGCTGACTACAGCCATGGCAGCAGA
 GATCACTAGACGCGGGAGTGCATACTACATGTACTTGATAGGAGCGATGCCGGGAAGGCCATTTGTTTTGCTACCAT
 TGGGAGTGAACAAGTGCCACGTACAGATCATGGACCTCGGGCAGATGTGTGACGCCACCATGAGTTATGAGTGCCCTATG
 50 CTGGATGAGGGAGTGAACACAGATGATGTCGATTGCTGGTGCAACACGACATCAACTTGGGTTGTGTACGGAACCTGTC
 ATCACAAAAAAGGTGAGGCACGGCGATCTAGAAGAGCCGTGACGCTCCCTTCTCACTCTACAAGGAAGTTGCAAAACGCG
 GTCGCAGACCTGGTTAGAATCAAGAGAATACACGAAGCACTTGATCAAGGTTGAAAAGTGGATATTGAGGAACCCCGGG
 TTTGCGCTAGTGGCCGTTGCCATTGCTGGCTTTTGGGAAGCTCGACGAGCCAAAAAGTCATATACTTGGTCATGATACTG
 CTGATTGCCCCGGCATACAGTATCAGGTGCATTGGAGTCAGCAATAGAGACTTCGTGGAGGGCATGTCAGGTGGGACCT

GGGTTGATGTTGTCTTGGAACATGGAGGCTGCGTTACCGTGATGGCACAGGACAAGCCAACAGTCGACATAGAGTTGGT
 CACGACGACGGTTAGTAACATGGCCGAGGTAAGATCCTATTGCTACGAGGCATCGATATCGGACATGGCTTCGGACAGTC
 GTTGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACATTAGTGGACAGA
 5 GGTGGGGGAAACGGTTGTGGACTTTTTGGCAAAGGGAGCTTGGTGACATGTGCAAGTTTACGTGTTCTAAGAAGATGA
 CCGGGAAGAGCATTCAACCGGAAAAATCTGGAGTATCGGATAATGCTATCAGTGATGGCTCCAGCATAGCGGGATGAT
 TGGATATGAAACTGACGAAGATAGAGCGAAAGTCGAGGTTACGCCTAATTACCAAGAGCGGAAGCAACCTTGGGAGGC
 TTTGGAAGCTTAGGACTTGACTGTGAACCAAGGACAGGCCTTGACTTTTCAGATCTGTATTACCTGACCATGAACAATAAG
 CATTGGTTGGTGACAAAGAGTGGTTTCATGACATCCATTGCCTTGGCATGCTGGGGCAGACACCGGAACTCCACACTG
 10 GAACAACAAAGAGGCATTGGTAGAATTCAAGGATGCCACGCCAAGAGGCAAAACCGTCGTCGTTCTGGGGAGCCAGGAA
 GGAGCCGTTACACGGCTCTCGCTGGAGCTCTAGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTTCTCTGGCCATT
 TGAAATGCCGCCTAAAAATGGACAAGCTTAGATTGAAGGGCGTGTATATTCCTTGTGCACTGCGGCATTACATTCACCA
 AGGTCCCAGCTGAAACACTGCATGGAACAGTCACAGTGGAGGTGAGTATGCAGGGACAGATGGACCCTGCAAGATCCC
 AGTCCAGATGGCGGTGGACATGCAGACCCTGACCCAGTTGGAAGGCTGATAACCGCCAACCCCGTGATTACTGAAAGC
 ACTGAGAACTCAAAGATGATGTTGGAGCTTGACCCACCATTTGGGGATTCTTACATTGTCATAGGAGTTGGGGACAAGAA
 15 AATCACCCACCACTGGCATAGGAGTGGTAGCACCATCGGAAAGGCATTTGAGGCCACTGTGAGAGGCGCCAAGAGAATG
 GCAGTCTGGGGGATACAGCCTGGGACTTCGGATCAGTCGGGGGTGTGTTCAACTCACTGGGTAAGGGCATTACCAGA
 TTTTGGAGCAGCCTTCAAATCACTGTTTGGAGGAATGTCTGGTTCTCACAGATCCTCATAGGCACGCTGCTAGTGTGGT
 TAGGTTTGAACACAAAGAATGGATCTATCTCCCTCACATGCTTGGCCCTGGGGGGAGTGATGATCTTCTCTCCACGGCTG
 TTTCTGCTGACGTGGGGTGCTCAGTGGACTTCTCAAAAAGGAAACGAGATGTGGCACGGGGGATTTCATCTATAATGAT
 20 GTTGAAGCCTGGAGGGACCGGTACAAGTACCATCCTGACTCCCCCGCAGATTGGCAGCAGCAGTCAAGCAGGCCTGGG
 AAGAGGGGATCTGTGGGATCTCATCCGTTTCAAGAATGGAACATCATGTGGAAATCAGTAGAAGGGGAGCTCAATGC
 TATCCTAGAGGAGAATGGAGTTCAACTGACAGTTGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAAAGAT
 TGCCAGTGCCTGTGAATGAGCTGCCCCATGGCTGGAAGCCTGGGGGAAATCGATTTTGTAGGGCGGCAAGACCAA
 CAACAGTTTTGTTGTCGACGGTGACACACTGAAGGAATGTCCGCTTGAGCACAGAGCATGGAATAGTTTTCTTGTGGAGG
 25 ATCAGGGTTTGGAGTCTTCCACACCACTGTCTGGCTTAAGGTCAGAGAAGATTACTCATTAGAATGTGACCCAGCCGTCA
 TAGGAACAGCTGTTAAGGGAAGGGAGGCCGCGCACAGTGTCTGGGCTATTGGATTGAAAGTGAAAAGAATGACACAT
 GGAGGCTGAAGAGGGCCACCTGATTGAGATGAAAACATGTGAATGGCCAAAGTCTCACACATTGTGGACAGATGGAGT
 AGAAGAAAGTGATCTTATCATACCAAGTCTTTAGCTGGTCCACTCAGCCACCACAACACCAGAGAGGGTTACAGAACCC
 AAGTGAAAGGGCCATGGCACAGTGAAGAGCTTGAATCCGTTTGAGGAATGTCCAGGCACCAAGGTTTACGTGGAGG
 30 AGACATGCGAACTAGAGGACCATCTCTGAGATCAACTACTGCAAGTGGAAGGGTCATTGAGGAATGGTGCTGTAGGGA
 ATGCACAATGCCCCCACTATCGTTTCGAGCAAAAGACGGCTGCTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACCA
 GAGAGCAACTTAGTGAGGTCAATGGTGACAGCGGGGTCAACCGATCATATGGACCACTTCTCTTGGAGTGCTTGTGAT
 TCTACTCATGGTGACAGGAGGGGTTGAAGAAGAGAATGACCACAAAGATCATCATGAGCACATCAATGGCAGTGCTGGTA
 GTCATGATCTTGGGAGGATTTTCAATGAGTGACCTGGCCAAGCTTGATGCTGATGGGTGCTACTTTCGCAGAAATGAA
 35 CACTGGAGGAGATGTAGCTCACTTGGCATTGGTAGCGGCATTTAAAGTCAGACCAGCCTTGCTGGTCTCCTTCATTTTCAG
 AGCCAATTGGACACCCCGTGAGAGCATGCTGCTAGCCCTGGCTTCTGTCTTCTGCAAACTGCGATCTCTGCTCTTGAAGG
 TGACTTGATGGTCTCATTAAATGGATTGCTTTGGCCTGGTTGGCAATTCGAGCAATGGCCGTGCCACGCACTGACAACAT
 CGCTCTACCAATCTTGGCTGCTCTAACACCACTAGCTCGAGGCACACTGCTCGTGGCATGGAGAGCGGGCCTGGCTACTT
 GTGGAGGGATCATGCTCCTCTCCCTGAAAGGGAAAGGTAGTGTGAAGAAGAACCTGCCATTTGTATGGCCCTGGGATT
 40 GACAGCTGTGAGGGTAGTAGACCTATTAATGTGGTAGGACTACTGTTACTACAAGGAGTGGGAAGCGGAGCTGGCCC
 CTAAGTGAAGTTCTCACAGCCGTTGGCCTGATATGTGCACTGGCCGAGGGTTTGCCAAGGCAGACATTGAGATGGCTG
 GACCCATGGCTGCAGTAGGCTTGCTAATTGTGAGTATGTGGTCTCGGGAAAGAGTGTGGACATGTACATTGAAAGAGCA
 GGTGACATCACATGGGAAAAGGACGCGGAAGTCACTGGAACAGTCCTCGGCTTGACGTGGCACTGGATGAGAGTGGT
 GACTTCTCCTTGGTAGAGGAAGATGGTCCACCCATGAGAGAGATCATACTCAAGGTGGTCTGATGGCCATCTGTGGCAT
 45 GAACCAATAGCTATACCTTTTGTGTCAGGAGCGTGGTATGTGTATGTGAAGACTGGGAAAAGGAGTGGCGCCCTCTGG
 GACGTGCCTGCTCCCAAAGAGTGAAGAAAGGAGAGACCACAGATGGAGTGTACAGAGTGTGACTCGCAGACTGCTA
 GGTTCAACACAGTTGGAGTGGGAGTCATGCAAGAGGGAGTCTTCCACACCATGTGGCACGTTACAAAAGGAGCCGCAC
 TGAGGAGCGGTGAGGGAAGACTTGATCCATACTGGGGGGATGTCAAGCAGGACTTGGTGTCTACTGTGGCCTTGAA
 GTTGGATGCAGCTTGGATGGACTCAGCGAGGTACAGCTTTTGCCGTACCTCCCGGAGAGAGGGCCAGAAACATTAG
 50 ACCCTGCCTGGAATATTCAAGACAAAGGACGGGGACATCGGAGCAGTTGCTCTGGACTACCCTGCAGGGACCTCAGGAT
 CTCCGATCCTAGACAAATGTGGAAGAGTGATAGGACTCTATGGCAATGGGGTTGTGATCAAGAATGGAAGCTATGTTAGT
 GCTATAACCCAGGGAAAGAGGGAGGAGGAGACTCCGTTGAATGTTTCGAACCCTCGATGCTGAAGAAGAAGCAGCTA
 ACTGTCTTGATCTGCATCCAGGAGCCGAAAAACAGGAGAGTTCCTTCTGAAATAGTCCGTGAAGCCATAAAAAAGAG
 ACTCCGGACAGTGATCTTGGCACCAACTAGGGTTGTGCTGCTGAGATGGAGGAGGCCTTGAGAGGACTTCCGGTGCGT

TACATGACAACAGCAGTCAACGTACCCATTCTGGGACAGAAATCGTTGATTTGATGTGCCATGCCACTTTCACCTTCACGC
TTACTACAACCCATCAGAGTCCCTAATTACAATCTCAACATCATGGATGAAGCCCACTTCACAGACCCCTCAAGTATAGCTG
CAAGAGGATACATATCAACAAGGGTTGAAATGGGCGAGGCGGCTGCCATTTTTATGACTGCCACACCACAGGAACCCGT
5 GATGCGTTTTCTGACTCTAACTACCAATCATGGACACAGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGA
TTGGGTGACAGACCATTCTGGGAAAACAGTTTGGTTCGTTCCAAGCGTGAGAAACGGAATGAAATCGCAGCCTGTCTGA
CAAAGGCTGGAAAGCGGGTCATACAGCTCAGCAGGAAGACTTTTGAGACAGAATTTAGAAAAACAAAAATCAAGAGTG
GGACTTTGTCTATAACAACGACATCTCAGAGATGGGCGCAACTTCAAGGCTGACCGGGTCATAGACTCTAGGAGATGCC
10 TAAACACAGTCATACTTGATGGTGAGAGAGTCATCTTGGCTGGGCCCATGCCTGTCACGCATGCTAGTGCTGCTCAGAGG
AGAGGACGTATAGGCAGGAACCTAACAAACCTGGAGATGAGTACATGTATGGAGGTGGGTGTGCAGAGACTGATGAA
GGCCATGCACACTGGCTTGAAGCAAGAATGCTTCTGACAACATCTACCTCCAGGATGGCCTCATAGCCTCGCTCTATCGG
CCTGAGGCCGATAAGGTAGCCGCCATTGAGGGAGAGTTTAAAGCTGAGGACAGAGCAAAGGAAGACCTTCGTGGAACCTC
ATGAAGAGAGGAGACCTTCCCCTGCTAGCCTATCAGGTTGCATCTGCCGAATAACTTACACAGACAGAAGATGGTG
CTTTGATGGCACAACCAACAACACCATAATGGAAGACAGTGACCAGCAGAGGTTTGGACAAAGTATGGAGAGAAGAGA
15 GTGCTCAAACCGAGATGGATGGATGCTAGGGTCTGTTGACACCATGCGGCCCTGAAGTCGTTCAAAGAATTCGCCGCTGG
AAAAAGAGGAGCGGCTTTGGGAGTAATGGAGGCCCTGGGAACACTGCCAGGACACATGACAGAGAGGTTTCAGGAAGC
CATTGACAACCTCGCCGTGCTCATGCGAGCAGAGACTGGAAGCAGGCCTTATAAGGCAGCGGCAGCCCAACTGCCGGAG
ACCCTAGAGACCATTATGCTCTTAGGTTTCTGTTGGAACAGTTTCACTGGGGATCTTCTCGTCTTGATGCGGAATAAGGGC
ATCGGGAAGATGGGCTTTGGAATGGTAACCTTGGGGCCAGTGCATGGCTCATGTGGCTTCGGAAATTGAACCAGCCA
GAATTGCATGTGCTCTATTGTTGTGTTTTATTACTGGTGGTGCTCATACCCGAGCCAGAGAAGCAAAGATCTCCCAAG
20 ATAACCAGATGGCAATTATCATCATGGTGGCAGTGGGCTTCTAGGTTTGATAACTGCAAACGAACTTGGATGGCTGGAA
AGAACAAAAATGACATAGCTCATCTAATGGGAAGGAGAGAAGAAGGAGCAACCATGGGATTCTCAATGGACATTGATC
TGCGGCCAGCCTCCGCTGGGCTATCTATGCCGATTGACAACCTCATACCCAGCTGTCCAACATGCGGTAACCACTT
CATACAACAACACTACTCCTAATGGCGATGGCCACACAAGCTGGAGTGCTGTTGGCATGGGCAAAGGGATGCCATTTATG
CATGGGGACCTTGGAGTCCCGCTGCTAATGATGGGTTGCTATTACAATTAACACCCCTGACTCTGATAGTAGCTATCATT
25 CTGCTTGTGGCGCACTACATGTACTTGATCCAGGCCTACAAGCGGCAGCAGCGCTGCTGCCAGAAAAAGGACAGCAG
CTGGCATCATGAAGAATCCCGTTGTGGATGGAATAGTGGTAACTGACATTGACACAATGACAATAGACCCCAAGGTGGA
GAAGAAGATGGGACAAGTGTTACTCATAGCAGTAGCCATCTCCAGTGCTGTGCTGCTGCGGACCGCCTGGGGATGGGGG
GAGGCTGGAGCTCTGATCAGCAGCAGCAGCTCCACCTTGTGGGAAGGCTCTCCAAACAAATACTGGAACCTCTACAGC
CACCTCACTGTGCAACATCTTCAGAGGAAGCTATCTGGCAGGAGCTTCCCTTATCTATACAGTGACGAGAAAACGCTGGCCT
30 GGTTAAGAGACGTGGAGGTGGGACGGGAGAGACTCTGGGAGAGAAGTGGAAGCTCGTCTGAATCAGATGTCGGCCCT
GGAGTTTACTCTTATAAAAAGTCAGGTATCACTGAAGTGTGTAGAGAGGAGGCTCGCCGTGCCCTCAAGGATGGAGTG
GCCACAGGAGGACATGCCGTATCCCGGGGAAGTGCAAAGATCAGATGGTTGGAGGAGAGAGGATATCTGCAGCCCTAT
GGGAAGGTTGTTGACCTCGGATGTGGCAGAGGGGGCTGGAGCTATTATGCCGCCACCATCCGCAAAGTGACAGGAGGTG
AGAGGATACACAAAGGGAGGTCCCGGTATGAAGAACCCATGCTGGTGCAAAGCTATGGGTGGAACATAGTTCGTCTCA
35 AGAGTGAGTGAGTGGACGTCTTCCACATGGCGGCTGAGCCGTGTGACACTCTGCTGTGTGACATAGGTGAGTCATCATCTAGT
CCTGAAGTGGAAGAGACACGAACACTCAGAGTGCTCTCTATGGTGGGGGACTGGCTTGAAAAAAGACCAGGGGCCCTTCT
GTATAAAGGTGCTGTGCCATACACCAGCACTATGATGGAAGCATGGAGCGACTGCAACGTAGGCATGGGGGAGGATT
AGTCAGAGTGCCATTGTGTGCAACTCCACACATGAGATGTACTGGGTCTCTGGGGCAAAGAGCAACATCATAAAAAGTG
TGTCCACCACAAGTCAGCTCCTCCTGGGACGCATGGATGGCCCCAGGAGGCCAGTGAAATATGAGGAGGATGTGAACCT
40 CGGCTCGGGTACACGAGCTGTGGCAAGCTGTGCTGAGGCTCCTAACATGAAATCATCGGCAGGCGCATTGAGAGAATC
CGCAATGAACATGCAGAAACATGGTTTCTTGATGAAAACCAACCATACAGGACATGGGCCTACCATGGGAGCTACGAAGC
CCCCACGCAAGGATCAGCGTCTTCCCTCGTGAACGGGGTTGTTAGACTCCTGTCAAAGCCTTGGGACGTGGTGACTGGAG
TTACAGGAATAGCCATGACTGACACCACACCATAACGGCCAACAAAGAGTCTTCAAAGAAAAAGTGGAACACCAGGGTGCC
AGATCCCCAAGAAGGCACTCGCCAGGTAATGAACATAGTCTTCTTGGCTGTGGAAGGAGCTGGGGAACGCAAGCGG
45 CCACGCGTCTGCACCAAGAAGAGTTTATCAACAAGGTGCGCAGCAATGCAGCACTGGGAGCAATATTTGAAGAGGAAA
AAGAATGGAAGACGGCTGTGGAAGCTGTGAATGATCCAAGTTTTGGGCCCTAGTGGATAGGGAGAGAGAACACCACC
TGAGAGGAGAGTGTACAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAGCAAGGAGAGTTTCGGGAAAGCA
AAAGGTAGCCGCGCCATCTGGTACATGTGTTGGGAGCCAGATTCTTGGAGTTTGAAGCCCTTGGATTCTTGAACGAGGA
50 CCATTGGATGGGAAGAGAAAACTCAGGAGGTGGAGTGAAGGGTTAGGATTGCAAAGACTTGGATACATTCTAGAAGA
AATGAATCGGGCACCAGGAGGAAAGATGTACGCAGATGACACTGCTGGCTGGGACACCCGCATTAGTAAGTTTGATCTG
GAGAATGAAGCTCTGATTACCAACCAATGGAGGAAGGGCACAGAACTCTGGCGTTGGCCGTGATTAAATACACATACC
AAAACAAAGTGGTGAAGTTCTCAGACCAGCTGAAGGAGGAAAAACAGTTATGGACATCATTTCAAGACAAGACCAGAG
AGGGAGTGGACAAGTTGTCATTATGCTCTCAACACATTACCAACTTGGTGGTGCAGCTTATCCGGAACATGGAAGCTG
AGGAAGTGTTAGAGATGCAAGACTTATGGTTGTTGAGGAAGCCAGAGAAAAGTGACCAGATGGTTGCAGAGCAATGGAT

GGGATAGACTCAAACGAATGGCGGTCTAGTGGAGATGACTGCGTTGTGAAGCCAATCGATGATAGGTTTGACATGCCCT
 CAGGTTCTTGAATGACATGGGAAAAGTTAGGAAAGACACACAGGAGTGGAACCCCTCGACTGGATGGAGCAATTGGGA
 AGAAGTCCCCTTCTGCTCCCACCACTTCAACAAGCTGTACCTCAAGGATGGGAGATCCATTGTGGTCCCTTGCCGCCACCA
 AGATGAACTGATTGGCCGAGCTCGCGTCTCACCAGGGGAGGATGGAGCATCCGGGAGACTGCCTGTCTTGCAAAATCA
 5 TATGCGCAGATGTGGCAGCTCCTTTATTTCCACAGAAGAGACCTTCGACTGATGGCTAATGCCATTTGCTCGGCTGTGCCA
 GTTACTGGGTACCAACTGGGAGAACCACCTGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAGGACATGCTCA
 TGGTGTGGAATAGAGTGTGGATTGAGGAGAACGACCATATGGAGGACAAGACTCCTGTAACAAAATGGACAGACATTCC
 CTATCTAGGAAAAAGGGAGGACTTATGGTGTGGATCCCTTATAGGGCACAGACCCCGACCACTTGGGCTGAAAAATCA
 10 AAGACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTATCTATCCACCCAAGTCCGCTAC
 TTGGGTGAGGAAGGGTCCACACCCGAGTGTTGTAAGCACCAATTTAGTGTGTGTCAGGCCTGCTAGTCAGCCACAGTTT
 GGGGAAAGCTGTGCAGCCTGTAACCCCCCAGGAGAAGCTGGGAAACCAAGCTCATAGTCAGGCCGAGAACGCCATGG
 CACGGAAGAAGCCATGCTGCCTGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAAGCGCAGGAT
 GGGGAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGACTAGCTGTGAATCTCCAGCAGAGG
 15 GACTAGTGGTTAGAGGAGACCCCCGAAAACGAAAACAGCATATTGACGTGGGAAAGACCAGAGACTCCATGAGTTT
 CCACCACGCTGGCCGCCAGGCACAGATCGCCGAATTCGGCGGCCGGTGTGGGGAAATCCATGGTTTCT

SEQ ID NO: 13

KJ776791.1, Zika virus strain H/PF/2013 polyprotein gene, complete cds

AGTATCAACAGGTTTTATTTTGGATTTGGAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAAGAAATCCGGAGGATTC
 20 CGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTGAGCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGACTTCT
 GCTGGGTCTATGGGCCATCAGGATGGTCTTGGCGATTCTAGCCTTTTGTGATTACGGCAATCAAGCCATCACTGGGTCT
 CATCAATAGATGGGGTTCAGTGGGGAAAAAAGAGGCTATGGAATAATAAAGAAGTTCAAGAAAGATCTGGTGCCATG
 CTGAGAATAATCAATGCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGCGAATTGTTGGCCTCTGCTGA
 25 CCACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACGACGCTGGGGAGGC
 CATATCTTTTCAACCACATTGGGGATGAATAAGTGTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCAT
 GAGCTATGAATGCCCTATGCTGGATGAGGGGTGGAACCAGATGACGTCGATTGTTGGTGAACACGACGTCAACTTGG
 GTTGTGTACGGAACCTGCCATCAGAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCTCCATTCCAC
 TAGGAAGCTGCAAACGCGGTGCGAAACCTGGTTGGAATCAAGAGAATACAGAAAGCACTTGATTAGAGTCGAAAATTGG
 30 ATATTCAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCAT
 ATACTTGGTCATGATACTGCTGATTGCCCCGGCATAACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAG
 GTATGTCAGGTGGGACTTGGGTTGATGTTGTCTTGAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACT
 GTCGACATAGAGCTGGTTACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCGG
 ACATGGCTTCGGACAGCCGCTGCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAA
 35 AGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTG
 CATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTCAGTTCATGGCTCC
 CAGCACAGTGGGATGATCGTTAATGACACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATT
 CACCAAGAGCCGAAGCCACCTGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACGAGGACAGGCCTTGACTTTTCA
 GATTTGTATTACTTGACTATGAATAACAAGCACTGGTTGGTTACAAGGAGTGGTTCCACGACATTCCATTACCTTGGCAC
 40 GCTGGGGCAGACACCGGAACCTCCACTGGAACAACAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGG
 CAAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAGTTACACCGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATG
 GTGCAAAGGGAAGGCTGTCCTCTGGCCACTTGAAATGTCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTACATC
 TCCTTGTGTACCGCAGCGTTACATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTA
 CGCAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACCTTGACCCAGTTGGGAGGTTG
 45 ATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTTAAGATGATGCTGGAACCTGATCCACCATTGAAAAAGCATTG
 AAGCCACTGTGAGAGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCT
 CAACTCATTGGGCAAGGGCATCCATCAAATTTTGGAGCAGCTTCAAATCATTGTTTGGAGGAATGTCCTGGTTCTCACA
 AATTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGG
 50 GGGAGTGTTGATCTTCTATCCACAGCTGTCTGCTGATGTGGGTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGAT
 GCGGTACAGGGGTGTTCTGTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGA
 TTGGCAGCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGTGGGATCTCCTCTGTTTCAAGAATGGAAAACATCATGTG
 GAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAA
 AACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGCCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAAT
 CGTACTTCGTAGAGCAGCAAAGACAAATAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACAT

AGAGCATGGAACAGCTTTCTTGTGGAGGATCATGGGTTCGGGGTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGA
 TTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAGTGTCTAGGCTACT
 GGATTGAGAGTGAGAAGAATGACACATGGAGGGCTGAAGAGGGCCCATCTGATCGAGATGAAAAATGTGAATGGCCAA
 5 AGTCCCACACATTGTGGACAGATGGAATAGAAGAGAGTGTCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCAT
 CACAATACCAGAGAGGGGCTACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAAT
 GCCCAGGCACTAAGGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAG
 GGTGATCGAGGAATGGTGTGTCAGGGAGTGCACAATGCCCCCACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGA
 ATGGAGATAAGGCCCAGGAAAGAACCAGAAAGTAACCTAGTAAGGTCAATGGTGACTGCAGGATCAACTGATCACATGG
 10 ATCACTTCTCCCTTGGAGTGTCTGTGATTCTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATC
 ATAAGCACATCGATGGCAGTGTCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTT
 GATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGA
 CCAGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCCCGTAAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTT
 TGCAAACGCGATCTCCGCTTGAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAG
 15 CGATGGTTGTTCCACGCACTGATAACATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCGGGGCACACTGCTTG
 TGGCGTGGAGAGCAGGCCTTGTACTTTCGCGGGGGTTTATGCTCCTCTCTGAAGGGAAAAGGCAGTGTGAAGAAGAA
 CTTACCATTGTGTATGGCCCTGGGACTAACCGCTGTGAGGCTGGTGCACCCCATCAACGTGGTGGGACTGCTGTTGCTCAC
 AAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTC
 GCCAAGGCAGATATAGAGATGGCTGGGCCCATGGCCGCGGTGCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGA
 GTGTGGACATGTACATTGAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCT
 20 CGATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAG
 GTGGTCTGATGACCATCTGTGGCATGAACCAATAGCCATACCCTTTCAGCTGGAGCGTGGTACGTATACGTGAAGAC
 TGGAAAAAGGAGTGGTGTCTATGGGATGTGCTGCTCCCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTA
 CAGAGTAATGACTCGTAGACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGT
 GGCACGTCAAAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATC
 25 TGGTGTCACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCAGCTCTTGGCCGTGCCCCC
 CGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCCGAATATTTAAGACAAAAGGATGGGGACATTGGAGCGGTTGCGCT
 GGATTACCCAGCAGGAACCTCAGGATCTCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTC
 GTGATCAAAAATGGGAGTTATGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGC
 30 CTTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGATCCTGGAGCTGGGAAAACCAGGAGAGTTCTTCTGAA
 ATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACCAGGGTTGTCGCTGCTGAAATGGAGGA
 AGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGTCAATGTCACCCACTCTGGAACAGAAATCGTCGACTTAAT
 GTGCCATGCCACCTTCACTTCACGTCTACTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCAC
 TTCACAGATCCCTCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCAT
 35 GACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACACCGAAGTGGAAGTCCAG
 AGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGAAAAACAGTTTGTTTTGTTTCAAGCGTGAGGAAC
 GGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGGAACCGGGTCATACAGCTCAGCAGAAAGACTTTTGAGACAGAGT
 TCCAGAAAACAAAACATCAAGAGTGGGACTTTGTCTGTGACAACCTGACATTTTCAAGAGATGGGCGCAACTTTAAAGCTGAC
 CGTGTCTAGATTCCAGGAGATGCCTAAAGCCGGTCATCTTATGATGGCGAGAGAGTCACTTGGCTGGACCATGCCTGT
 CACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTATGGA
 40 GGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGA
 TGGCCTCATAGCCTCGCTCTATCGACCTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAG
 CAAAGGAAGACCTTTGTGGAACCTCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAAT
 AACCTACACAGATAGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTG
 TGGACCAGACCGGAGAGAAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGA
 45 AGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACA
 CATGACAGAGAGATTCCAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAA
 GCCGCGGCGGCCCAATTGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAATCTT
 TTTCTGTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTTGGGGCCAGCGCATGGCTCATG
 50 TGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCTCATTGTTGTGTTCTATTGCTGGTGGTGCTCATACCTGAG
 CCAGAAAAGCAAAGATCTCCCAGGACAACCAATGGCAATCATCATGAGTGGTAGCAGTAGGTCTTCTGGGCTTGATTAC
 CGCCAATGAACCTCGATGGTTGGAGAGAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAAC
 CATAGGATTCTAATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACCTTTCATTACCCCA
 GCCGTCCAACATGCAGTGACCACTTCATACAACAACCTACTCCTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTGGT
 ATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACC

CCTGACCCTAATAGTGGCCATCATTTTTGCTCGTGGCGCACTACATGTA CTTGATCCCAGGGCTGCAGGCAGCAGCTGCGC
 GTGCTGCCCAGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGA CTGACATTGACAC
 AATGACAATTGACCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGT
 5 CGCGGACCGCTGGGGGTGGGGGGAGGCTGGGGCCCTGATCAGCGGCAACTTCCACTTTGTGGGAAGGCTCTCCGA
 ACAAGTACTGGAACCTCTACAGCCACTTCACTGTGTAACTTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTA
 CACAGTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGG
 CCCGCTTGAACCAGATGTCGGCCCTGGAGTTCTACTCTACAAAAAGTCAGGCATACCGAGGTGTGCAGAGAAGAGGCC
 CGCCGCGCCCTCAAGGACGCTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAAGTGCAAAGCTGAGATGGTTGGTG
 10 GAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCA
 CCATCCGCAAAGTTCAAGAAGTGAAAGGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCTGTTGGTGCAAAGCTA
 TGGGTGGAACATAGTCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTG
 ACATAGGTGAGTCATCTAGTCTGAAAGTGAAGAAGCACGGACGCTCAGAGTCCTCTCCATGGTGGGGGATTGGCTT
 GAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTGTGCCCATACACCAGCACTATGATGGAAACCCTGGAGCGACTGCA
 GCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCG
 15 AAAAGCAACACCATAAAAAAGTGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCAGGAGGCCAGTGA
 AATATGAGGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCAT
 TGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCAACCATATAGGACATGG
 GCTTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGCGTCCTCTAATAAACGGGGTTGTCAGGCTCCTGTCAAA
 ACCCTGGGATGTGGTGACTGGAGTCACAGGAATAGCCATGACCACACCACACCGTATGGTCAGCAAAGAGTTTTCAAG
 20 GAAAAAGTGACACTAGGGTGCCAGACCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGA
 AAGAGCTAGGCAAACACAACGGCCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGTTCGTAGCAATGCAGCATT
 AGGGGCAATATTTGAAGAGGAAAAAGAGTGAAGACTGCAGTGGAAGCTGTGAACGATCCAAGGTTCTGGGCTCTAGT
 GGACAAGGAAAGAGAGCACCACCTGAGAGGAGAGTGCCAGAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGA
 AACAAGGGGAATTTGAAAGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGA
 25 AGCCCTTGGATTCTTGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACA
 AAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGAC
 ACCCGCATCAGCAGTTTGATCTGGAGAATGAAGCTTAATCACCACCAAATGGAGAAAGGGCACAGGGCCTTGGCAT
 TGGCCATAATCAAGTACACATACCAAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGA
 CATTATTTGAGACAAGACCAAAGGGGGAGCGGACAAGTTGCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGC
 30 AACTCATTCGGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAAAGTGAC
 CAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGAGATGATTGCGTTGTGAAGCCAATT
 GATGATAGGTTTGACATGCCCTCAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAACCCCT
 CAACTGGATGGGACAACCTGGGAAGAAGTTCCGTTTTGCTCCCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCC
 ATTGTGGTTCCCTGCCGCCACCAAGATGAACTGATTGGCCGGGGCCGCGTCTCTCCAGGGGCGGGATGGAGCATCCGGG
 35 AGACTGCTTGCCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCA
 ATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAAGTGGGAGAACTACCTGGTCAATCCATGGAAGGGGAGAATGG
 ATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCCA
 GTTACGAAATGGACAGACATTCCCTATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGC
 GCACCACCTGGGCTGAGAACATTAAAAACACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATGGA
 40 CTACCTATCCACCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTAAAGACCAATCTTAGTGTTGTC
 AGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAGAAGCTGGGAAACCAAGCCTA
 TAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTGCCTGTGAGCCCCTCAGAGGACACTGAGTCAAAAAACC
 CCACGCGCTTGGAGGCGCAGGATGGGAAAAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGAT
 45 CAGCTGTGGATCTCAGAAGAGGGGACTAGTGGTTAGAGGAG

In some embodiments, the Zika virus has a RNA genome corresponding to the DNA
 sequence provided by the nucleic acid sequence of any one of SEQ ID NOs: 2-13 or 72. In
 some embodiments, the Zika virus has a variant genome that is at least 80%, 81%, 82%, 83%,
 50 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%,
 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to any one of SEQ ID NOs: 2-13 or 72.

Provided below are amino acid sequences of the E-proteins of Zika strains that may be used in the methods, compositions, and/or vaccines described herein.

- 5 SEQ ID NO: 14
isol-ARB15076.AHF49784.1.Central_African_Republic/291-788 Flavivirus envelope glycoprotein E.
IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D E N R A K V E V T
10 P N S P R A E A T L G G F G S L G L D C E P R T G L D F S D L Y L T M N N K H W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F K D A H A K
R Q T V V L G S Q E G A V H T A L A G A L E A E M D G A K G R L F S G H L K C R L K M D K L R L K G V S Y S L C T A A F T F T K V P A E T L H G T V T V E V Q Y A G
T D G P C K V P A Q M A V D M Q T L T P V G R L I T A N P V I T E S T E N S K M M L E L D P P F G D S Y I V I G V G D K K I T H H W H R S G S I G K A F E A T V R G
A K R M A V L G D T A W D F G S V G G V F N S L G K G I H Q I F G A A F K S L F G G M S W F S Q I L I G T L L V W L G L N T K N G S I S L T C L A L G G V M I F L S T A
V S A
- 15 SEQ ID NO: 15
isol-IbH_30656.AEN75265.1.Nigeria/291-788 Flavivirus envelope glycoprotein E.
IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D E N R A K V E V T
20 P N S P R A E A T L G G F G S L G L D C E P R T G L D F S D L Y L T M N N K H W L V H K E W F H D I P L P W H S G A D T E T P H W N N K E A L V E F K D A H A K
R Q T V V L G S Q E G A V H T A L A G A L E A E M D G A K G R L S S G H L K C R L K M D K L R L K G V S Y S L C T A A F T F T K V P A E T L H G T V T V E V Q Y A G
R D G P C K V P A Q M A V D M Q T L T P V G R L I T A N P V I T E S T E N S K M M L E L D P P F G D S Y I V I G V G D K K I T H H W H R S G S I I G K A F E A T V R G
A K R M A V L G D T A W D F G S V G G V F N S L G K G I H Q I F G A A F K S L F G G M S W F S Q I L I G T L L V W L G L N T K N G S I S L T C L A L G G V M I F L S T A
V S A
- 25 SEQ ID NO: 16
ArB1362.AHL43500.1.-/291-794 Flavivirus envelope glycoprotein E.
IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D X X X X X X N R
30 A E V E V T P N S P R A E A T L G G F G S L G L D C E P R T G L D F S D L Y L T M N N K H W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F
K D A H A K R Q T V V L G S Q E G A V H T A L A G A L E A E M D G A K G R L F S G H L K C R L K M D K L R L K G V S Y S L C T A A F T F T K V P A E T L H G T V T V
E V Q Y A G T D G P C K V P A Q M A V D M Q T L T P V G R L I T A N P V I T E S T E N S K M M L E L D P P F G D S Y I V I G V G D K K I T H H W H R S G S T I G K A F
E A T V R G A K R M A V L G D T A W D F G S V G G V F N S L G K G I H Q I F G A A F K S L F G G M S W F S Q I L I G T L L V W L G L N T K N G S I S L T C L A L G G V
M I F L S T A V S A
- 35 SEQ ID NO: 17
ArD128000.AHL43502.1.-/291-794 Flavivirus envelope glycoprotein E.
IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M X X X X X G H E T D E N
40 R A K V E V T P N S P R A E A T L G G F G S L G L D C E P R T G L D F S D L Y L T M N N K H R L V R K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F
K D A H A K R Q T V V L G S Q E G A V H T A L A G A L E A E M D G A K G R L F S G H L K C R L K M D K L R L K G V S Y S L C T A A F T F T K V P A E T L H G T V T V
E V Q Y A G T D G P C K V P A Q M A V D M Q T L T P V G R L I T A N P V I T E S T E N S K M M L E L D P P F G D S Y I V I G V G D K K I T H H W L K K G S S I G K A F
E A T V R G A K R M A V L G D T A W D F G S V G G V F N S L G K G V H Q I F G A A F K S L F G G M S W F S Q I L I G T L L V W L G L N T K N G S I S L T C L A L G G
V M I F L S T A V S A
- 45 SEQ ID NO: 18
ArD158095.AHL43505.1.-/291-794 Flavivirus envelope glycoprotein E.
IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D I G H E T D E N R
50 A K V E V T P N S P R A E A T L G G F G S L G L D C E P R T G L D F S D L Y L T M N N K H W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F
K D A H A K R Q T V V L G S Q E G A V H T A L A G A L E A E M D G A K G R L F S G H L K C R L K M D K L R L K G V S Y S L C T A A F T F T K V P A E T L H G T V T V
E V Q Y A G T D G P C K V P A Q M A V D M Q T L T P V G R L I T A N P V I T E S T E N S K M M L E L D P P F G D S Y I V I G V G D K K I T H H W H R S G S T I G K A F

EATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
MIFLSTAVSA

SEQ ID NO: 19

5 ArD158084.AHL43504.1.-/291-794 Flavivirus envelope glycoprotein E.
IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D I G H E T D E N R
AKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLT MNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
10 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGR LFSGHLKCR LKMDKRLKGVSYSLCTAAFTFTKVP AETLHGT VTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGDKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
MIFLSTAVSA

SEQ ID NO: 20

15 isol-ARB13565.AHF49783.1.Central_African_Republic/291-794 Flavivirus envelope glycoprotein E.
IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D I G H E T D E N R
AKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLT MNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGR LFSGHLKCR LKMDKRLKGVSYSLCTAAFTFTKVP AETLHGT VTV
20 EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGDKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGVHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGG
VMIFLSTAVSA

SEQ ID NO: 21

25 isol-ARB7701.AHF49785.1.Central_African_Republic/291-794 Flavivirus envelope glycoprotein E.
IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D I G H E T D E N R
AKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLT MNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGR LFSGHLKCR LKMDKRLKGVSYSLCTAAFTFTKVP AETLHGT VTV
30 EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGDKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGVHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGG
VMIFLSTAVSA

SEQ ID NO: 22

35 isol-ArD_41519.AEN75266.1.Senegal/291-794 Flavivirus envelope glycoprotein E.
IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLT MNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVE
FKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGR LFSGHLKCR LKMDKRLKGVSYSLCTAAFTFTKVP AETLHGT VTV
40 VEVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGDKKITHHWHRS GSTIGKA
FEATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGG
VMIFLSTAVSA

SEQ ID NO: 23

45 MR766-NIID.BAP47441.1.Uganda/291-794 Flavivirus envelope glycoprotein E.
IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M T V N D I G Y E T D E N R
AKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYYLT MNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGR LFSGHLKCR LKMDKRLKGVSYSLCTAAFTFTKVP AETLHGT VTV
50 EVQYAGTDGPCKIPVQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGDKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
MIFLSTAVSA

SEQ ID NO: 24

LC002520.1/326-829 Zika virus genomic RNA, strain: MR766-NIID, Uganda, Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSGMTVNDIGYETDENR
AKVEVTPNSPRAEATLGGFGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
5 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGKGLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVAETLHGTVT
EVQYAGTDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGDKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
MIFLSTAVSA

10 SEQ ID NO: 25

isol-MR_766.AEN75263.1.Uganda/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTG YETDENR
AKVEVTPNSPRAEATLGGFGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
15 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGKGLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVAETLHGTVT
EVQYAGTDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGDKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
MIFLSTAVSA

20 SEQ ID NO: 26

ArD7117.AHL43501.1.-/291-794 Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDIGHETDENR
AKVEVTPNSPRAEATLGGFGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
25 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGKGLFSGHLKCRKMDKRLKGVSYSLCTAVCTAAKVAETLHGTVT
VEVQYAGTDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGDKKITHHWHRSGSTIGKAF
FEATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGG
VMIFLSTAVSA

30 SEQ ID NO: 27

AY632535.2/326-825 NC_012532.1 Zika virus strain MR 766, Uganda, Flavivirus envelope glycoprotein E.

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIGYETDEDRAKVE
VTPNSPRAEATLGGFGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAH
35 AKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGKGLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVAETLHGTVTVEVQY
AGTDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGDKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
MIFLSTAVSA

40 SEQ ID NO: 28

MR_766.AAV34151.1.Uganda/291-790 Flavivirus envelope glycoprotein E. |Q32ZE1|Q32ZE1_9FL

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIGYETDEDRAKVE
VTPNSPRAEATLGGFGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAH
45 AKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGKGLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVAETLHGTVTVEVQY
AGTDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGDKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGVFNSLKGKIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
MIFLSTAVSA

50 SEQ ID NO: 29

MR_766.YP_009227198.1.Uganda/1-500 envelope protein E [Zika virus]

IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGS�VTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIGYETDEDRAKVE
VTPNSPRAEATLGGFGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAH

AKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRFLSGHLKCRLLKMDKRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQY
AGTDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGDKITHHWHRSGSTIGKAFEATV
RGAKRMAVLGDTAWDFGSGVGFNSLKGKIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLTCALGGVMIFL
STAVSA

5

SEQ ID NO: 30

KU681081.3/308-811 Zika virus isolate Zika virus/H.sapiens-tc/THA/2014/SV0127- 14, Thailand, Flavivirus
envelope glycoprotein E.

10

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
R A K V E I T P N S P R A E A T L G G F G S L G L D C E P R T G L D F S D L Y L T M N N K H W L V H K E W F H D I P L P W H T G A D T G T P H W N N K E A L V E F
K D A H A K R Q T V V V L G S Q E G A V H T A L A G A L E A E M D G A K G R L S S G H L K C R L K M D K L R L K G V S Y S L C T A A F T F T K I P A E T L H G T V T V
E V Q Y A G T D G P C K V P A Q M A V D M Q T L T P V G R L I T A N P V I T E G T E N S K M M L E L D P P F G D S Y I V I G V G E K K I T H H W H R S G S T I G K A F
E A T V R G A K R M A V L G D T A W D F G S V G G V L N S L G K G I H Q I F G A A F K S L F G G M S W F S Q I L I G T L L M W L G L N T K N G S I S L M C L A L G G
V L I F L S T A V S A

15

SEQ ID NO: 31

isol-Zika_virus% H.sapiens-tc% THA% 2014% SV0127- _14.AMD61710.1.Thailand/291-794 Flavivirus envelope
glycoprotein E.

20

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
R A K V E I T P N S P R A E A T L G G F G S L G L D C E P R T G L D F S D L Y L T M N N K H W L V H K E W F H D I P L P W H T G A D T G T P H W N N K E A L V E F
K D A H A K R Q T V V V L G S Q E G A V H T A L A G A L E A E M D G A K G R L S S G H L K C R L K M D K L R L K G V S Y S L C T A A F T F T K I P A E T L H G T V T V
E V Q Y A G T D G P C K V P A Q M A V D M Q T L T P V G R L I T A N P V I T E G T E N S K M M L E L D P P F G D S Y I V I G V G E K K I T H H W H R S G S T I G K A F
E A T V R G A K R M A V L G D T A W D F G S V G G V L N S L G K G I H Q I F G A A F K S L F G G M S W F S Q I L I G T L L M W L G L N T K N G S I S L M C L A L G G
V L I F L S T A V S A

25

SEQ ID NO: 32

CK-ISL_2014.AIC06934.1.Cook_Islands/1-504 Flavivirus envelope glycoprotein E. (Fragment) OS=Zika virus
GN=E PE=4 SV=1

30

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
R A K V E I T P N S P R A E A T L G G F G S L G L D C E P R T G L D F S D L Y L T M N N K H W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F
K D A H A K R Q T V V V L G S Q E G A V H T A L A G A L E A E M D G A K G R L S S G H L K C R L K M D K L R L K G V S Y S L C T A A F T F T K I P A E T L H G T V T V
E V Q Y A G T D G P C K V P A Q M A V D M Q T L T P V G R L I T A N P V I T E T E N S K M M L E L D P P F G D S Y I V I G V G E K K I T H H W H R S G S T I G K A F
E A T V R G A K R M A V L G D T A W D F G S V G G A L N S L G K G I H Q I F G A A F K S L F G G M S W F S Q I L I G T L L M W L G L N T K N G S I S L M C L A L G G
V L I F L S T A V S A

35

SEQ ID NO: 33

Natal_RGN.AMB18850.1.Brazil:_Rio_Grande_do_Norte,_Natal/291-794 Flavivirus envelope glycoprotein E.]

40

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
R A K V E I T P N S P R A E A T L G G F G S L G L D C E P R T G L D F S D L Y L T M N N K H W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F
K D A H A K R Q T V V V L G S Q E G A V H T A L A G A L E A E M D G A K G R L S S G H L K C R L K M D K L R L K G V S Y S L C T A A F T F T K I P A E T L H G T V T V
E V Q Y A G T D G P C K V P A Q M A V D M Q T L T P V G R L I T A N P V I T E T E N S K M M L E L D P P F G D S Y I V I G V G E K K I T H H W H R S G S T I G K A F
E A T V R G A K R M A V L G D T A W D F G S V G G A L N S L G K G I H Q I F G A A F K S L F G G M S W F S Q I L I G T L L M W L G L N T K N G S I S L M C L A L G G
V L I F L S T A V S A

45

SEQ ID NO: 34

isol-Si323.AMC37200.1.Colombia/1-504 Flavivirus envelope glycoprotein E.

50

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
R A K V E I T P N S P R A E A T L G G F G S L G L D C E P R T G L D F S D L Y L T M N N K H W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F
K D A H A K R Q T V V V L G S Q E G A V H T A L A G A L E A E M D G A K G R L S S G H L K C R L K M D K L R L K G V S Y S L C T A A F T F T K I P A E T L H G T V T V

EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

5 SEQ ID NO: 35

KU707826.1/317-820 Zika virus isolate SSABR1, Brazil, Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
10 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAETLHGTVT
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

15 SEQ ID NO: 36

KU509998.1/326-829 Zika virus strain Haiti/1225/2014, Haiti, Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
20 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAETLHGTVT
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

25 SEQ ID NO: 37

isol-GDZ16001.AML82110.1.China/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
30 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAETLHGTVT
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

35 SEQ ID NO: 38

BeH819015.AMA12085.1.Brazil/291-794 Flavivirus envelope glycoprotein E.]

IRCI GVS NRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
40 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAETLHGTVT
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

45 SEQ ID NO: 39

MRS_OPY_Martinique_PaRi_2015.AMC33116.1.Martinique/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
50 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAETLHGTVT
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 40

KU501215.1/308-811 Zika virus strain PRVABC59, Puerto Rico, Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
5 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQT VVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKRLKGVSYSLCTAAFTFTKIPAE TLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PF GDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFG SVGGALNSLKG I HQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 41

Haiti%1225%2014.AMB37295.1.Haiti/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
15 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQT VVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKRLKGVSYSLCTAAFTFTKIPAE TLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PF GDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFG SVGGALNSLKG I HQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 42

KU527068.1/308-811 Zika virus strain Natal RGN, Brazil: Rio Grande do Norte, Natal, Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
25 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQT VVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKRLKGVSYSLCTAAFTFTKIPAE TLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PF GDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFG SVGGALNSLKG I HQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
30 VLIFLSTAVSA

SEQ ID NO: 43

isol-Z1106027.ALX35662.1.Suriname/5-508 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
35 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQT VVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKRLKGVSYSLCTAAFTFTKIPAE TLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PF GDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFG SVGGALNSLKG I HQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
40 VLIFLSTAVSA

SEQ ID NO: 44

isol-FLR.AMM39804.1.Colombia:_Barranquilla/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
45 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQT VVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKRLKGVSYSLCTAAFTFTKIPAE TLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PF GDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFG SVGGALNSLKG I HQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
50 VLIFLSTAVSA

SEQ ID NO: 45

PLCal_ZV_isol-From_Vero_E6_cells.AHL37808.1.Canada/254-757 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAETLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGEKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFG SVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 46

BeH818995.AMA12084.1.Brazil/291-794 Flavivirus envelope glycoprotein E. [Zika virus].

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAETLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGEKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFG SVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 47

H/PF/2013.AHZ13508.1.French_Polynesia/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAETLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGEKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFG SVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 48

PRVABC59.AMC13911.1.Puerto_Rico/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAETLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGEKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFG SVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 49

KU321639.1/326-829 Zika virus strain ZikaSPH2015, Brazil, Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAETLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGEKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFG SVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 50

ZikaSPH2015.ALU33341.1.Brazil/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD RGWGNGCGLFGKGS LVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAETLHGTVTV

EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

5 SEQ ID NO: 51

103344.AMC13912.1.Guatemala/291-794 polyprotein [Zika virus]. 103344.AMC13912.1.Guatemala Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEIRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
10 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTDTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

15 SEQ ID NO: 52

isol-Brazil-ZKV2015.AMD16557.1.Brazil/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
20 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGTQEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTDTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

25 SEQ ID NO: 53

KU497555.1/308-811 Zika virus isolate Brazil-ZKV2015, Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
30 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGTQEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTDTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

35 SEQ ID NO: 54

isol-ZJ03.AMM39806.1.China/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
40 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTDTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGARRMAVLGDTAWDFGSGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

45 SEQ ID NO: 55

isol-FSS13025.AFD30972.1.Cambodia/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
50 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKRLRLKGVSYSLCTAAFTFTKIPAETLHGTDTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 56

isol-Z1106032.ALX35660.1.Suriname/291-794 Flavivirus envelope glycoprotein E. [Zika virus]

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGA GRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAETLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGEKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLN AKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 57

isol-Z1106033.ALX35659.1.Suriname/291-794 Flavivirus envelope glycoprotein E. [Zika virus]

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGA GRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAETLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGEKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLN AKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 58

isol-BeH828305.AMK49165.1.Brazil/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGA GRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAETLHGTVTV
EVQYAGTDGPCKVPAQMAVDTQT LTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGEKKITHHWHRS GSTIGKA FE
ATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLN TKNGSISLMCLALGGV
LIFLSTAVSA

SEQ ID NO: 59

isol-GD01.AMK79468.1.China/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N G T G H E T D E N
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGA GRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAETLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGEKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLN TKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 60

isol-Z1106031.ALX35661.1.Suriname/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGA GRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIPAETLHGTVTV
EVQYAGTDGPCKVLAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGEKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLN TKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 61

ACD75819.1.Micronesia/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPAVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R GWNGCGLFGKGS LVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQT VVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIP AETLHGT VTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
LIFLSTAVSA

SEQ ID NO: 62

KU681082.3/308-811 Zika virus isolate Zika virus/H.sapiens-tc/PHL/2012/CPC-0740, Philippines, Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R GWNGCGLFGKGS LVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQT VVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIP AETLHGT VTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
LIFLSTAVSA

SEQ ID NO: 63

isol-Zika_virus% H.sapiens-tc% PHL% 2012% CPC-0740.AMD61711.1.Philippines/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R GWNGCGLFGKGS LVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQT VVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIP AETLHGT VTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
LIFLSTAVSA

SEQ ID NO: 64

isol-BeH823339.AMK49164.2.Brazil/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVSTTVSNMAEVRSYCYEATISDIASDSRCPTQGEAYLD
KQSDTQYVCKRTLVD R GWNGCGLFGKGS LVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDENR
AKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFK
DAHAKRQTAVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIP AETLHGT VTV
VQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGEKKITHHWHRSGSTIGKAFE
ATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGV
LIFLSTAVSA

SEQ ID NO: 65

isol-P6-740.AEN75264.1.Malaysia/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R GWNGCGLFGKGS LVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDXGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLT MN NKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQT VVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCR LKMDKLR LKGVSYS LCTAAFTFTKIP AETLHGT VTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDP PFGDSYIVIGVGD K KITHHWXRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGA AFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
LIFLSTAVSA

SEQ ID NO: 66

KU744693.1/326-829 Zika virus isolate VE_Ganxian, China, Flavivirus envelope glycoprotein E.

IRCI GVS NRDFVEGMSGGTWVDVVLEHGGCVTMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R GWNGCGLFGKGS LVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDEN

RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHWLAHKEWFHDIPLPWHAGAATGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKRLKGVSYSLCTAAFTFTKIPAETVDGTVTV
EGQYGGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIIGAFAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSG

SEQ ID NO: 67

isol-VE_Ganxian.AMK79469.1.China/291-794 Flavivirus envelope glycoprotein E.

IRCIQVSNRDFVEGMSGGTWVDVLEHGGCVTAMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGIFGKGSVTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSGLMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHWLAHKEWFHDIPLPWHAGAATGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKRLKMDKRLKGVSYSLCTAAFTFTKIPAETVDGTVTV
EGQYGGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGALNSLGKGIHQIIGAFAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSG

SEQ ID NO: 68

ArD157995.AHL43503.1.-/291-794 Flavivirus envelope glycoprotein E.

ISCIGVSNRDLVEGMSGGTWVDVLEHGGCVTEMAQDKPTVDIELVTMTVSNMAEVRSYCYEASISDMASASRCPTQGEPSL
DKQSDTQSVCKRTLGDGRWGNGCGIFGKGSVTCCKFTCKKMPGKSIQPENLEYRIMLPVHGSQHSGLMIVNDIGHETDENR
AKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHWLVHKEWFHDIPLPWHAGADTTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSFGHLKRLKMDKRLKGVSYSLCTAAFTFTKIPAETLHGTDTV
EVQSAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGDKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAFAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
MIFLSTAVSA

SEQ ID NO: 69

MR_766.ABI54475.1.Uganda/291-788 Flavivirus envelope glycoprotein E.

IRCIQVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGIFGKGSVTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSGLMIVNDENRAKVEVT
PNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHWLVHKEWFHDIPLPWHAGADTTPHWNNKEALVEFKDAHAK
RQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSFGHLKRLKMDKRLKGVSYSLCTAAFTFTKIPAETLHGTDTVVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGDKKITHHWHRSGSTIGKAFAEATVRG
AKRMAVLGDTAWDFGSGGVFNSLGKGIHQIFGAFAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGVMIFLSTA
VSA

SEQ ID NO: 70

5'-(dIdC)₁₃-3'

dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC

SEQ ID NO: 71

KLK peptide

KLKLLLLKLK

SEQ ID NO: 72

ZIKV Sequence H/PF/2013 as sequenced

CAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTTGGATTTGGAAACGAGAGTT
TCTGGTCATGAAAAACCCAAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAACGCGGAGTAGCCCGTGTG
AGCCCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTATGGGCCATCAGGATGGTCTTGCGATTCT
AGCCTTTTGAAGATTACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAAAAAAGAGGCTA
TGGAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGGAAGGAGAAGAAGAGAC
GAGGCGCAGATACTAGTGTGCGAATTGTTGGCCTCCTGCTGACCACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAG
TGCATACTATATGACTTGGACAGAAACGACGCTGGGGAGGCCATATCTTTCCAACCACATTGGGGATGAATAAGTGTT
ATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGGAA

CCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACTGCCATCACAAAAAGGTGAAGC
 ACGGAGATCTAGAAGAGCTGTGACGCTCCCCTCCCATTCCACTAGGAAGCTGCAAACGCGGTGCGAAACCTGGTTGGAAT
 CAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAAATTGGATATTAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCC
 5 ATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCGGCATACAGC
 ATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGTCTTGGAAC
 ATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGTTACAACAACAGTCAGCAACAT
 GCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCGGACATGGCTTCGGACAGCCGCTGCCAACACAAGGTGAA
 GCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTG
 10 GACTTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCC
 AGAGAATCTGGAGTACCGGATAATGCTGTCAGTTCATGGCTCCAGCACAGTGGGATGATCGTTAATGACACAGGACATG
 AAATGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACCCTGGGGGTTTTGGAAG
 CCTAGGACTTGATTGTGAACCGAGGACAGGCCCTTGACTTTTTCAGATTTGTATTACTTGACTATGAATAACAAGCACTGGTT
 GGTTTACAAGGAGTGGTTCCACGACATTCCATTACCTTGGCACGCTGGGGCAGACACCGGAACTCCACTGGAACAACA
 15 AAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAG
 TTCACACGGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCCTCTGCCACTTGAAATG
 TCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTACTACTCTTGTGTACCGCAGCGTTACATTACCAAGATCCC
 GGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGAGGGACAGATGGACCTTGCAAGGTTCCAGCTCAG
 ATGGCGGTGGACATGCAAACTTGACCCAGTTGGGAGGTTGATAACCGCTAACCCGTAATCACTGAAAGCACTGAGAA
 CTCTAAGATGATGCTGGAACCTTGATCCACCATTGGGGACTTTACATTGTCATAGGAGTCGGGGAGAAGAAGATCACCC
 20 ACCACTGGCACAGGAGTGGCAGCACCATTGAAAAGCATTGGAAGCCACTGTGAGAGGTGCAAGAGAATGGCAGTCTT
 GGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTCATTGGGCAAGGGCATCCATAAATTTTGGAG
 CAGCTTCAAATCATTGTTTGGAGGAATGTCCTGGTTCTCACAATTTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGA
 ACACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTATCCACAGCTGTCTCTGCTGA
 TGTGGGGTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGCTATAACGACGTTGAAGCC
 25 TGGAGGGACAGGTACAAGTACCATCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAAGCAAGCCTGGGAAGATGGTA
 TCTGTGGGATCTCTCTGTTTCAAGAATGGAAAACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAA
 GAGAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCGTGC
 CTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTGAGAGCAGCAAAGACAAATAACAGCTT
 TGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAACATAGAGCATGGAACAGCTTTCTTGTGGAGGATCATGGGT
 30 TCGGGGTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAG
 CTGTTAAGGGAAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGA
 AGAGGGCCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCACACATTGTGGACAGATGGAATAGAAGAGAG
 TGATCTGATCATAACCAAGTCTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTACAGGACCCAAATGAAAG
 GGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAAGGAATGCCAGGCACTAAGGTCCACGTGGAGGAAACATGTGG
 35 AACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGACAAAT
 GCCCCACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCAGGAAAGAACAGAAAGTAAC
 TTAGTAAGGTCAATGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGGAGTGCTTGTGATTCTGCTCATG
 GTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCGATGGCAGTGCTGGTAGCTATGATCC
 TGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGTATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGA
 40 GATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGG
 ACACCCCGTGAAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTTTCAAAGTGCAGTCTCCGCTTGGAAAGGCGACCTGATG
 GTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGATAACATCACCTTGCCA
 ATCCTGGCTGCTCTGACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGGAGAGCAGGCCTTGCTACTTGCGGGGGGTT
 TATGCTCCTCTCTGAAAGGGAAAAGGCAAGTGTGAAGAAGAACTTACCATTGTGATGGCCCTGGGACTAACCGCTGTGA
 45 GGCTGGTCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGT
 ACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCCATGGCC
 GCGGTGCTGCTGCTAATTGTGAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTGAAAGAGCAGGTGACATCAC
 ATGGGAAAAAGATGCGGAAGTCACTGGAACAGTCCCCGGCTCGATGTGGCGCTAGATGAGAGTGGTGATTCTCCCTG
 50 GTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCAATAGC
 CATACCTTTGACAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGCTCTATGGGATGTGCTGCTC
 CCAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTAGGTTCAACACAAGT
 TGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTACAAAAGGATCCGCGCTGAGAAGCGGTGAA
 GGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGTACTGTGGTCCATGGAAGCTAGATGCCGCT
 GGGACGGGCACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTTGCCCCGAA

TATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTCAGGATCTCCAATCCTAGAC
AAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCGTGATCAAAAATGGGAGTTATGTTAGTGCCATCACCCAAG
GGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTCGAGCCTTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTT
5 GCATCCTGGAGCTGGGAAAACAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTAAGTGTGA
TCTTAGCTCCAACCAGGGTTGTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCA
GTCAATGTCACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACTTCACGTCTACTACAGCCAATCA
GAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCAAGTATAGCAGCAAGAGGATACATTT
CAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGA
10 CTCCAACCTACCAATTATGGACACCGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATC
ATTCTGGAAAAACAGTTTGGTTTGTCCAAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGGAAA
ACGGGTGATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATCAAGAGTGGGACTTTGTCGTG
ACAACTGACATTTAGAGATGGGCGCCAACCTTAAAGCTGACCGTGTATAGATTCCAGGAGATGCCTAAAGCCGGTCAT
ACTTGATGGCGAGAGAGTCACTTCTGGCTGGACCATGCTGTACACATGCCAGCGCTGCCAGAGGAGGGGGGCGCATA
15 GGCAGGAATCCCAACAACTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACT
GGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTGAGGCCGACA
AAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTGTGGAACCTATGAAAAGAGGAG
ATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGAATAACCTACACAGATAGAAGATGGTGTCTTGATGGCACGA
CCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGCTCAAACCGA
GGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGGCGTGGGAAAAGAGGAGC
20 GGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAAGCCATTGACAACCTC
GCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCGGCCCAATTGCCGGAGACCCTAGAGACCA
TTATGCTTTTGGGGTGTGGAACAGTCTCGTGGAATCTTTTCGTCTTGATGAGGAACAAGGGCATAGGGAAGATG
GGCTTTGGAATGGTGACTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGT
25 CCTCATTGTTGTCTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAACCAAATGGC
AATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGATGGTTGGAGAGAACAAGAGTG
ACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTC
AGCTTGGGCCATCTATGCTGCCTTGACAACCTTTATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAACTAC
TCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTGTTTGGTATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTGG
30 AGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACCCCTGACCCTAATAGTGGCCATCATTTTGTCTGTGGCGCAC
TACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCCAGAAAGAGAACGGCAGCTGGCATCATGAAGA
ACCCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGGACA
GGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTCGCGGACCGCCTGGGGGTGGGGGGAGGCTGGGGCCCTG
ATCACAGCGGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTACAGCCACTTCACTGTGTAAC
35 ATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGAAAACGCTGGCTTGGTCAAGAGACGTGG
GGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTCGGCCCTGGAGTTCTACTCTAC
AAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGGCCCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCAT
GCTGTGTCCCGAGGAAGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAGGTCATTGATC
TTGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGGATACACAAAAGG
AGGCCCTGGTCATGAAGAACCCATGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGTCTTAAGAGTGGGGTGGACGTC
40 TTTTCATATGGCGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATCTAGTCTGAAGTGGAGAAGC
ACGGACGCTCAGAGTCTCTCCATGGTGGGGGATTGGCTTGAAAAAAGACCAGGAGCCTTTTGTATAAAAGTGTGTGCC
CATACACCAGCACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTC
CCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAGTGTGTCCACCACGAGCCAGC
45 TCCTCTTGGGGCGCATGGACGGGCCCAGGAGGCCAGTGAAATATGAGGAGGATGTGAATCTCGGCTCTGGCACGCGGG
CTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAAAGGATCCGCAGTGAGCACGCGGA
AACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAG
CGTCTCTCTAATAAACGGGGTTGTGAGGCTCCTGTCAAAACCCTGGGATGTGGTGACTGGAGTCACAGGAATAGCCATG
ACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTAGGGTGCCAGACCCCAAGAAGGCA
CTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAGAGCTAGGCAAACACAAACGGCCACGAGTCTGTACCAA
50 GAAGAGTTCATCAACAAGGTTCTGATCAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAGACTGCAG
TGGAAGCTGTGAACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCACCTGAGAGGAGAGTGCCAGA
GTTGTGTGTACAACATGATGGGAAAAAGAGAAAAGAAACAAGGGGAATTTGAAAGGCCAAGGGCAGCCGCGCCATCT
GGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGATTCTTGAACGAGGATCACTGGATGGGGAGAGA
GAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGA

GGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCA
CCAACCAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAACAAAGTGGTAAAGGT
CCTTAGACCAAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTTCGAGACAAGACCAAAAGGGGGAGCGGACAAGTTGTC
5 ACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTGGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAA
GACTTGTGGCTGCTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATG
GCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGACATGCCCTCAGGTTCTTGAATGATATGGG
AAAAGTTAGGAAGGACACACAAGAGTGGAACCCCTCAACTGGATGGGACAACCTGGGAAGAAAGTTCCGTTTTGCTCCAC
CACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTCCCTGCCGCCACCAAGATGAACTGATTGGCCGGGC
10 CCGCGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCTAGCAAAATCATATGCGCAAATGTGGCAGCTC
CTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAGTTGACTGGGTTCCAAGTGGG
AGAACTACCTGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGGA
TTGAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCCTATTTGGGAAAAAGGGAAGA
CTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGCTGAGAACATTAACACAGTCAACATGGTGC
15 GCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACA
CCTGGAGTGCTGTAAGCACCAATCTTAGTGTGTCAGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGT
GACCCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTGCCT
GTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGAGGGCGCAGGATGGGAAAAGAAGGTGGCGACCT
TCCCCACCCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAGACCC
20 CCCGAAAACGCAAAACAGCATATTGACGCTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGC
ACAGATCGCCGAATAGCGGCGGCCGGTGTGGGG

SEQ ID NO: 73

AH213508.1, Zika virus polyprotein from Polynesian outbreak (H/PF/2013)

MKNPKKKS GGFRI VNM LKRG VARS PFGL KRLPAG LLLGHGPI RMVLAILA FLRFTA IKPSLGLINRWG SVGKKEAMEI IKFKK
25 DLAAMLRIINARKEKKRRGADTSVIGV LLLTTAMAAEVTRGSAYMYLDRNDAGEAISFPTTLGMNKC YIQIMDLGHMCD
TMSYEC PMLDEGV EPDDVDCWCNTTSTWVVYGTCHHKKGEARRSRRAVTLPSHSTRKLQTRSQTWLESREYTKHLIRVENWI
FRNPGFALAAAAIAWLLGSSTSQKV IYLMILLIAPAYSIRCI GVS NRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIEL
VTTT VSNMAEVRSYCYEASISDMASDSRCPTQGEAYLDKQSDTQYVCKRTLVD RGWNGCGLFGKGS LVTCAKFACSKKMTG
30 KSIQPENLEYRIMLSVHGSQHS GMIVNDTGHE TDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFS DLYLTMNNKH
WL VHKEWFHDIPLPHWAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLK
CRLKMDKLR LKGVSYSLCTAAFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKM
MLELDP PFGDSYIVIGVGEKKITHWHRS GSTIGKA FEATVRGAKRMAVLGDTAWDFG SVGGALNSLGKGIHQIFGA AFKSLF
35 GGMSWF SQILIGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTAVSADVGCSVDFS KKETRCGTGVFVYNDVEAWRD RYKYHP
DSPRRLAAAVKQAWEDGICGISSVRMENIMWRSVEGELNAILENGVQLTVVVG SVKNPMWRGPQRLPVPVNLPHGWK
AWGKSYFVRAAKTNNSFVVDGDTLKECPLKHRAWNSFLVEDHGFV FHTSVWLKVREDYSLECDPAVIGTAVKGKEAVHSDL
40 GYWIESEKNDTWRLKRAHLIEMKTCEWPKSHTLWTDGIEESDLIPKSLAGPLSHHNTREGYRTQMKGPWHSEELEIRFECEPG
TKVHVEETCGTRGPSLRSTTASGRVIEEWCCRECTMPPLSFRAKDG CWYGM EIRPRKEPESNLVRSMTAGSTDHMDHFS LG
VLVILLMVQEGLKKRMTTKIIISTMAVLVAMILGGFSMSDLAKLAILMGATFAEMNTGGDVAHLALIAAFKVRPALLVSIFRA
NWTPRESM LALASCLLQTAISALEGDLMLVINGFALAWLAIRAMVVPRTDNITLAILAALTPLARGTLLVAWRAGLATCGGFM
45 LLSLKGGKSVKKNLPFVMALGLTAVRLVD PINVVG LLLLTRSGKRSWPPSEVLTAVGLICALAGGF AKADIEMAGPMAAVGLLIV
SYVVS GKSVD MYIERAGDITWEKDAEVTGNSPRLDVALDES GDFSLVEDDGPPMREIILKVVLMTICGMNPIAIPFAAGAWVYV
VKTGKRSGALWDVPAPKEVKKGETTDGVYRVMTRRLGSTQVGVGVMMQEGVFHTMWHVTKGSALRSGEGRDPYWG DVK
QDLVSYCGPWKLDAAWDGHSEVQLLAVPPGERARNIQTLP GIFTKDGDIGAVALDYPAGTSGSPILDKCGRVIGLYGNGVVIK
50 NGSYVSAITQGRREEETPVECFEPSMLKKKQLTVLDLHPGAGKTRRVLP EIVREAIKTRLRTVILAPTRVVAEME EALRGLPVRY
MTTAVNVTHSGTEIVDLMCHATFTSRLQPIRVPNYNLYIMDEAHFTDPSSIAARGYISTRVEMGEAAAFMTATPPGTRDAFP
DSNSPIMDTEVEVPERAWSSGFDWVTDHSGKT VWFVPSVRNGNEIAACLT KAGKRVIQLSRKTFETEFQKTKHQEWD FVVT
DISEMGANFKADRVIDSRCLKP VILDGERVILAGPMPVTHASAAQRRGRIGRNPKNPGDEYLYGGGCAETDEDHAWLEAR
MLLDNIYLDGLIASLYRPEADKVA AIEGEFKL RTEQRKTFVELMKRGLPVW LAYQVASAGITYTDRRWCFDGTNTTIMEDS
VPAEVWTRHGEKRV LKPRWMDARVCS DHAALKSFKEFAAGKRGAAFGVMEALGTLPGHMTERFQE AIDNLAVLMRAETGS
RYPKAAAAQLPETLETIMLLGLLGT VSLGIFVLMRNKGIGKMGFGMVTLGASAWLMWLSEIEPARIACVLIVFLLVLIPEPE
KQRSPQDNQMAIIMVAVGLLGLITANELGWLERTKSDLSHLMGRREEGATIGFSMDIDL RPASAWAIYAALTTFITPAVQHAV
TTSYNNYSLMAMATQAGVLFGMGKMPFYAWDFGVPLLMIGCYSQLTPLTLIVAIILLVAHYMYLIPGLQAAAAARAAQKRTAA
GIMKNPVVDGIVVTDIDTMTIDPQVEKKMGQVLLIAVAVSSA ILSRTAWGWGEAGALITAATSTLWEGSPNKYWNSSATSLC
NIFRGSYLAGASLIYVTRNAGLVKRRGGGTGETLGEKWKARLNQMSALEFY SYKKSGITEVCREEARALKDGVATGGHAVSR

5 GSAKLRLWVERGYLQPYGKVIDLGCGRGGWSYAAATIRKVQEVKGYTKGGPGHEEPMLVQSYGWNIVRLKSGVDVFHMAAE
PCDTLLCDIGESSSSPEVEEARTLRVLSMVGDWLEKRPAGFCIKVLCPYTSTMMETLERLQRRYGGGLVRVPLSRNSTHEMYWV
SGAKSNTIKSVSTTSQLLLGRMDGPRRPVKYEEDVNLGSGTRAVVSCAEAPNMKIIGNRIERIRSEHAETWFFDENHPYRTWAY
HGSYEAPTQGSASSLINGVVRLLSKPWDVVTGVTGIAMTDTTPYQQRVFKEKVDTRVPDPQEGTRQVMSMVSSWLWKELG
10 KHKRPRVCTKEEFINKVRSNAALGAIFEEKEWKTAVEAVNDPRFWALVDKEREHHLRGECQSCVYNMMGKREKKQGEFGKA
KGSRAIWYMWLGARFLEFEALGFLNEDHWMGRENSGGGVEGLGLQRLGYVLEEMSRIPEGGRMYADDTAGWDTRISRFDLE
NEALITNQMEKGHRALALAIKYTYQNKVVKVLPAEKGKTVMDIISRQDQRGSGQVVTYALNTFTNLVVQLIRNMEAEEVLEM
QDLWLLRRSEKVTNWLQSNGWDRLKRMVSGDDCVVKPIDDRFAHALRFLNDMGKVRKDTQEWKPSTGWDNWEEVPFC
SHHFNKLHLKDGRSIVVPCRHQDELIGRARVSPGAGWSIRETACLAKSYAQMWQLLYFHRRDLRLMANAICSSVPVDWVPTG
15 RTTWSIHGKGEWMTTEDMLVVWNRVWIEENDHMEDKTPVTKWTDIPYLGKREDLWCGSLIGHRPRTTWAENIKNTVNMV
RRIIGDEEKYMDYLSTQVRYLGEEGSTPGVL

15 SEQ ID NO: 74
9320_Zika_PF_1F
ttaggatccGTTGTTGATCTGTGTGAAT

20 SEQ ID NO: 75
9321_Zika_PF_1R
taactcgagCGTACACAACCCAAGTT

SEQ ID NO: 76
9322_Zika_PF_2F
ttaggatccTCACTAGACGTGGGAGTG

25 SEQ ID NO: 77
9323_Zika_PF_2R
taactcgagAAGCCATGTCYGATATTGAT

30 SEQ ID NO: 78
9324_Zika_PF_3F
ttaggatccGCATACAGCATCAGGTG

35 SEQ ID NO: 79
9325_Zika_PF_3R
taactcgagTGTGGAGTTCCGGTGTCT

40 SEQ ID NO: 80
9326_Zika_PF_4F
ttaggatccGAATAGAGCGAARGTTGAGATA

SEQ ID NO: 81
9327_Zika_PF_4R
taactcgAGTGGTGGGTGATCTTCTCT

45 SEQ ID NO: 82
9328_Zika_PF_5F
ttaggatccCAGTCACAGTGGAGGTACAGTAC

50 SEQ ID NO: 83
9329_Zika_PF_5R
taactcgagCRCAGATACCATCTTCCC

SEQ ID NO: 84
9330_Zika_PF_6F

ttaggatCCCTTATGTGCTTGGCCTTAG

SEQ ID NO: 85
9331_Zika_PF_6R
5 taactcgagTCTTCAGCCTCCATGTG

SEQ ID NO: 86
9332_Zika_PF_7F
10 ttaggatccAATGCCCCACTCAAACATAGA

SEQ ID NO: 87
9333_Zika_PF_7R
taactcgagTCATTCTCTTCTTCAGCCCTT

15 SEQ ID NO: 88
9334_Zika_PF_8F
ttaggatccAAGGGTGATCGAGGAAT

SEQ ID NO: 89
20 9335_Zika_PF_8R
taactcgagTTCCTTCAGAGAGAGGAGC

SEQ ID NO: 90
9336_Zika_PF_9F
25 ttaggatccTCTTTGCAAAGTGCATC

SEQ ID NO: 91
9337_Zika_PF_9R
30 taactcgagTCCAGCTGCAAAGGGTAT

SEQ ID NO: 92
9338_Zika_PF_10F
ttaggatccGTGTGGACATGTACATTGA

35 SEQ ID NO: 93
9339_Zika_PF_10R
taactcgagCCCATTGCCATAAAGTC

SEQ ID NO: 94
40 9340_Zika_PF_11F
ttaggatccTCATACTGTGGTCCATGGA

SEQ ID NO: 95
9341_Zika_PF_11R
45 taactcgagGCCCATCTCAACCCTTG

SEQ ID NO: 96
9342_Zika_PF_12F
50 ttaggatccTAGAGGGCTTCCAGTGC

SEQ ID NO: 97
9343_Zika_PF_12R
taactcgAGATACTCATCTCCAGGTTTGTG

SEQ ID NO: 98
9344_Zika_PF_13F
ttaggatccGAAAACAAAACATCAAGAGTG

5 SEQ ID NO: 99
9345_Zika_PF_13R
taactcgagGAATCTCTCTGTCATGTGTCCT

10 SEQ ID NO: 100
9346_Zika_PF_14F
ttaggatccTTGATGGCACGACCAAC

15 SEQ ID NO: 101
9347_Zika_PF_14R
ttaggatccGTTGTTGATCTGTGTGAAT

20 SEQ ID NO: 102
9348_Zika_PF_15F
taactcgagCAGGTCAATGTCCATTG

SEQ ID NO: 103
9349_Zika_PF_15R
ttaggatccTGTGTGTTCTATTGCTGGT

25 SEQ ID NO: 104
9350_Zika_PF_16F
taactcgaGTGATCAGRGCCCCAGC

30 SEQ ID NO: 105
9351_Zika_PF_16R
ttaggatccTGCTGCCCAGAAGAGAA

35 SEQ ID NO: 106
9352_Zika_PF_17F
taactcgaGCACCAACAYGGGTCTT

40 SEQ ID NO: 107
9353_Zika_PF_17R
ttaggatccCTCAAGGACGGTGTGGC

SEQ ID NO: 108
9354_Zika_PF_18F
taactcgagCAATGATCTTCATGTTGGG

45 SEQ ID NO: 109
9355_Zika_PF_18R
ttaggatccTATGGGGGAGGACTGGT

50 SEQ ID NO: 110
9356_Zika_PF_19F
taactcGAGCCCAGAACCTTGGATC

SEQ ID NO: 111
9357_Zika_PF_19R

ttaggatcCAGACCCCAAGAAGGC

SEQ ID NO: 112

9358_Zika_PF_20F

5 taactcgagCCCCTTTGGTCTTGTCT

SEQ ID NO: 113

9359_Zika_PF_20R

10 ttaggatccAGGAAGGATGTATGCAGATG

SEQ ID NO: 114

9360_Zika_PF_21F

taactcgagACATTTGCGCATATGATTTTG

SEQ ID NO: 115

9361_Zika_PF_21R

15 ttaggatccAGGAAGGACACACAAGAGT

SEQ ID NO: 116

9362_Zika_PF_22F

20 taactcgagACAGGCTGCACAGCTTT

SEQ ID NO: 117

9363_Zika_PF_22R

25 ttaggatccTCTCTCATAGGGCACAGAC

In some embodiments, the Zika virus has polyprotein, including an envelope (E) protein, with an amino acid sequence provided by any one of SEQ ID NOs: 14-69 or 72. In some embodiments, the polyprotein or E protein sequence is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to any one of SEQ ID NOs: 2-69 or 72.

The terms "identical" or percent "identity" in the context of two or more nucleic acids or amino acid sequences refer to two or more sequences or subsequences that are the same. Two sequences are "substantially identical" if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (*e.g.*, at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity) over a specified region or over the entire sequence, when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Optionally, the identity exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length. In some embodiments, the identity exists over the length of a protein, such as the E protein.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. Methods of alignment of sequences for comparison are well known in the art. See, *e.g.*, by the local homology algorithm of Smith and Waterman (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch, J. Mol. Biol. 48:443, 1970, by the search for similarity method of Pearson and Lipman. Proc. Natl. Acad. Sci. USA 85:2444, 1988, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, Jalview and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), by multi sequence alignment implementation using *e.g.* CLUSTALW (Larkin et al., (2007). Bioinformatics, 23, 2947-2948.) or MAFFT (Katoh & Toh 2008 Briefings in Bioinformatics 9:286-298), or by manual alignment and visual inspection (see. *e.g.*, Brent et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (Ringbom ed., 2003)). Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402, 1997 and Altschul et al., J. Mol. Biol. 215:403-410, 1990, respectively.

EXAMPLES

Example 1: Production of a Zika drug substance suitable for application as a vaccine in humans and animals

Materials and Methods:

For the production of ZikaV the JEV process platform (Srivastava et al., Vaccine 19 (2001) 4557-4565; US 6,309,650B1) was used as a basis. Small changes of certain process steps were adapted to ZikaV properties and to improve purity. A short summary of the process steps is outlined below (see also Figure 9A and B). Briefly, the unexpected and novel purification properties of protamine sulphate (PS) were evaluated in purification processes for Zika Virus. As shown in Figure 10, non-infectious virus particle aggregates, HCP and other LMW impurities were removed by PS precipitation as shown by removal of aggregate shoulder in SEC-HPLC and no loss of infectious virus titer by PS treatment. Further optimization of the Zika purification protocol is provided below.

Upstream:

- Roller Bottle based Vero cell expansion (25x850cm² CellBind):

- 5% CO₂, 35°C, MEM+2mM L-Glutamine + 10% FBS
- Infection with ZikaV research Master Seed Bank (rMSB) at MOI 0.01
- Virus Production without serum
- 5% CO₂, 35°C, MEM+2mM L-Glutamine
- 5 • Multiple harvests (days 2, 3, 5 and 7) with re-feed
- Sterile filtration of harvests and storage at 2-8°C until further processing

Downstream:

- Pooling of harvests and concentration by ultrafiltration (100kDa)
- Stabilization of concentrated harvest (Tris/10% sucrose) for storage if required (-80°C)
- 10 • Removal of hcDNA by Protamine Sulphate (2 mg/mL)
- Sucrose Gradient Purification (optimized three layered gradient)
- Formaldehyde Inactivation (0.02%, 22°C, 10 days), neutralization with Na-metabisulfite
- Dilution to DS antigen target content and formulation with Aluminium hydroxide (0.5mg Al/mL)

15

Zika Virus Strain H/PF/2013 was originally isolated from a 51-year-old woman (accession number KJ776791.1, also SEQ ID NO: 13 herein) from French Polynesia. A sample was obtained from the European Virus Archive (EVA; Ref-SKU: 001v-EVA1545). Based on this material, a research master seed bank (rMSB) was prepared on Vero cells as the cell substrate and the genomic sequence was checked by sequencing. Because the genomic sequence at the 5' and 3' flanking sequences of Zika virus strain H/PF/2013 was unknown, primers for sequencing were designed in those regions based on other Zika virus strains whereas the internal primers were designed from the published sequence (SEQ ID NOs: 74 to 117, see also Table A). The sequence obtained from the rMSB by use of these primers is provided by SEQ ID NO: 72. There was 100% overlap of the sequence with the published sequence of Zika Virus Strain H/PF/2013 (SEQ ID NO: 13). However, we sequenced additional regions 5' (an additional 40 bp) and 3' (an additional 160 bp) represented in SEQ ID NO: 72. In a preferred embodiment, the Zika virus of the invention comprises SEQ ID NO: 72. The genomic RNA is somewhat longer than the sequence according to SEQ ID NO: 72 (perhaps an additional 200 bp). Additionally, a Zika virus adapted to a host cell such as e.g. Vero cells may be expected to contain one or more mutations. For these reasons, the Zika virus of the current invention comprises the sequence of SEQ ID NO: 72 or, preferably, a sequence with at least 95%, 96%, 97%, 98%, or at least 99% sequence identity to the sequence provided by SEQ ID NO: 72. Furthermore, because the viral genome is likely to contain even further flanking regions to SEQ ID NO: 72; in one embodiment, the Zika virus of the invention contains the sequence of SEQ ID NO: 72 and optionally further comprises extensions at the 5' and/or 3' ends of at least 10, at least 20, at least 30, at least 40, at least 50, at least

35

60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120 or at least 130 nucleotides. In a preferred embodiment, the Zika virus comprises at least the coding sequence for the entire polyprotein of Zika Virus Strain H/PF/2013 of the invention i.e. the amino acid sequence of SEQ ID NO: 73 or a polyprotein with at least 95%, 96%, 97%, 98%, or at least 99% sequence identity to the sequence provided by SEQ ID NO: 73. Furthermore, the Zika virus comprises at least the coding sequence for the E-protein of Zika Virus Strain H/PF/2013 of the invention SEQ ID NO: 47 or an E-protein thereof with at least 95%, 96%, 97%, 98%, or at least 99% sequence identity to the sequence provided by SEQ ID NO: 47.

Virus growth on Vero Cells

Vero cells were grown in Eagle's minimal essential medium (EMEM) containing 10% fetal bovine serum (FBS). Roller bottle cultures of Vero cell monolayers were infected with Zika Virus Strain H/PF/2013 at a multiplicity of infection (moi) of 0.01 plaque forming units (pfu) per cell. After 2 hours of virus adsorption, the cultures were washed 3 times with PBS and fed with EMEM without FBS and incubated at +35°C with 5% CO₂. Infected Vero cell cultures were incubated until the virus titer reaches a desired level.

The culture medium was harvested at days 2, 3, 5 and 7 and were pooled from those harvest days and then centrifuged in a standard centrifuge. The supernatants were then filtered. Virus culture supernatants were concentrated by TFF ultrafiltration to remove cell culture media components and to reduce batch volume.

Evaluation of harvest Procedure

The current JEV harvest process has scheduled harvests on days 3, 5, 7 and 9 post infection. To mimic the JEV process roller bottles were infected with ZIKV bank P4-FBS at an MOI of 0.01 in infection medium (MEM with 2% FBS + 2mM L-glutamine) for 2 hours. After removing the inoculum the cells were washed twice with PBS and 200 mL production medium (MEM+ 2mM L-glutamine) was added.

After taking a sample on day 2 the first virus harvest was conducted on day 3 after infection. At this point significantly higher CPE could be observed compared to cells where virus was removed on day 2. Plaque assay analysis showed that the viral titers on day 2 were in the same range as for the standard harvesting schedule. However, starting with the day 3 harvest, the observed titers were significantly lower correlating with the increased CPE observed compared to the standard harvest schedule. On day 5 post infection no more living cells could be observed at all and the experiment was terminated with a final day 5 harvest.

Table 3: The calculated titers per plaque assay are summarized in the list below.

	Log 10 PFU/mL
sample day2	7.02
harvest day 3	6.66
harvest day 5	6.26

This finding led to an optimized harvest schedule to better control of CPE and allow additional harvest day 5 and 7, see Figure 15. For both harvest days the optimized ZikaV protocol yield significant higher virus titers compared to the modified protocol showing that the time of the first harvest is crucial for production yields. Additionally first harvesting at day 3 results in maximum 2 harvest points whereas first harvesting at day 2 allows for 4 harvest points further increasing the yield gain.

Downstream Purification of Zika virus

The purification process was carried out at room temperature (18-22°C) unless stated otherwise. Virus purification started with concentration of filtered combined harvest using 100 kDa cut-off TFF ultrafiltration modules to remove cell culture media components and reduce batch volume. After concentration, the pooled filtered harvest material was adjusted to a final concentration of 25 mM Tris pH 7.5 and 10% sucrose (w/w) using stock solution of both components (see Figure 11 for SEC-HPLC of different harvests prior to PS treatment). This allowed for freezing the concentrated harvest at <-65°C if required.

Host cell DNA and protein reduction as well reduction of non-infectious virus aggregates in the concentrated material was achieved by precipitation with protamine sulphate (2 mg/mL) followed by sucrose density centrifugation (2-8°C) as final polishing step (see Figure 20 for SEC-HPLC of different harvests post PS treatment). The purification process was designed to be completed within 2 working days with SGC starting on end of day 1 followed by fractionation and SDS-PAGE analysis on day 2. The sucrose gradient fractions were stored at 2-8 °C during the SDS-PAGE analysis (Silver staining) to identify the pure fractions containing ZikaV (see Figure 21). After pooling the relevant fractions, the pool was diluted and inactivated by Formalin. After pooling the relevant fractions of sucrose gradient centrifugation, the pool was diluted 1:3 in PBS and inactivated by Formalin (0.02% v/v, 200ppm). Fractions were subjected to analysis by SDS-PAGE.

Effect of PS treatment on virus recovery

Samples of individual 30x concentrated harvests days 2, 3, 5 and 7 were analysed before (Figure 11) and after PS (Figure 12) treatment by SEC-HPLC and plaque assay. SEC-HPLC was used for determination of relative total ZikaV content (active + inactive) expressed as peak area, whereas the rel. ZikaV peak purity is given as relative content of virus monomer population to total virus peak.

Plaque assay states the content of total active virus particles in each sample. Experimental results are summarized in Table 4. The virus peak recovery by SEC-HPLC was only between 12 to 36% with peak purity after PS treatment in the range of >90% (no virus aggregates detected). The recovery of active virus particles by plaque assay was all > 100% (130-700%, range within the variability of the assay) showing that no active virus particles were lost during PS treatment. These results show that during PS treatment only non-infective (immature and/or aggregated virus) particles were removed.

Table 4: ZikaV recovery by SEC-HPLC and plaque assay before and after PS treatment.

SEC-HPLC

	Peak area mAU*min			
Harvest day	30x conc	30x + PS	SEC Recovery (%)	rel. virus monomer content after PS (%)
Day 2	101.36	18.63	18	89%
Day 3	144.51	17.48	12	90%
Day 5	19.97	5.92	30	96%
Day 7	68.80	24.43	36	99%

Plaque Assay

	PFU/mL		
Harvest day	30x conc	30x + PS	Plaque Recovery (%)
Day 2	3E+08	5E+08	179
Day 3	2E+08	4E+08	193
Day 5	1E+08	9E+08	700
Day 7	3E+08	4E+08	132

Sucrose gradient centrifugation

The PS treated harvest was split in two parts and loaded on two centrifuge bottles. Sucrose density gradient centrifugation (SGC) was used for final concentration and polishing of the ZikaV material. The ZikaV PS treated concentrated harvest was loaded on top of a solution consisting of three layers of sucrose with different densities. The three sucrose layers were selected based on a preliminary study which showed the formation of a linear sucrose gradient and complete separation of the virus particles from residual contaminants as demonstrated for ChikV (Fig. 15D). The optimal volumes of

the sucrose solutions were determined empirically. The volumes of individual layers for a centrifugation in 100 mL bottle scale are shown in Table 5.

Table 5: Individual layers/volumes for a centrifugation in bottle.

Solution	Volume (mL)
PS treated harvest in 10% sucrose (L)	40
15% sucrose (J)	15
35% sucrose (I)	15
50% sucrose (H)	20
Total volume	90

5

The sucrose gradient bottles were prepared by stratifying the individual sucrose layers. A plastic tube was attached to peristaltic pump tubing. The plastic tube was mounted on a laboratory stand using a clamp and placed into the centrifuge bottle. The nozzle of the plastic tube was touching the bottom of the bottle. Using a peristaltic pump the ZikaV material and the sucrose solutions were pumped into the cylinder. A measuring cylinder was used as feed vessel. The first solution pumped was the ZikaV material as it represented the solution of lowest density (10 % sucrose (w/w)). After the ZikaV material the sucrose solutions were pumped in ascending order starting with the 15 % (w/w) solution J, followed by 35 % sucrose solution I and finishing with the highest density sucrose solution H (50 % (w/w)). The described setup is shown in Figure 14. After all sucrose solutions were transferred the plastic tubing was carefully removed in order not to disturb the layers.

15

Prior to centrifugation the centrifuge was pre-cooled to 4°C. The prepared SG bottles were carefully transferred into the pre-cooled rotor. (Note: Sudden movement of the bottles during transfer to the rotor must be avoided in order not to disturb the sucrose layers.) The bottles were centrifuged at ~11.000 RCF max at 4 °C for at least 20 hours, no brake/deceleration activated. In case a different centrifuge system with a different rotor is used the necessary speed and centrifugation times need to be calculated based on the k-factor in order to achieve comparable centrifugation efficiency.

20

Harvesting of the sucrose gradient was done manually using a peristaltic pump. A plastic tube attached to peristaltic pump tubing was used for harvesting the sucrose gradient. The bottle containing the gradient was mounted onto a laboratory stand in a tilted position (~12°) using a clamp. The plastic tubing was then placed into the bottle touching the bottom edge of the bottle and was fastened in

25

position using a clamp. This resulted in a small gap of 1-2 mm between the tubing inlet and the bottom of the bottle (see Figure 14).

Using a peristaltic pump set to a flow rate of 30 mL per minute the gradient was harvested and manually split into 2 mL fractions. A total number of 32 fractions per bottle were harvested (~ 64 mL) and the remaining volume was discarded. The fractions were immediately tested by SDS-PAGE / silver stain to identify the virus containing fractions with sufficient high purity. Representative SDS-PAGE is shown in Figure 14. Fraction 10-14 were pooled and further processed.

The purified viral solution was inactivated by incubation with 0.02% formaldehyde over a period of ten days in a 22°C controlled-temperature incubator. The formaldehyde is neutralized by addition of sodium metabisulphite on the tenth day.

The sucrose gradient pool (~17mL after sampling) was further diluted 3-fold with PBS to a final volume of 51 mL in a PETG container. A volume of 1% formaldehyde (10,000 ppm) solution equivalent to 1/50 of the final volume of the pre-formaldehyde pool was added to this pool resulting in an effective concentration of 200 ppm. The formaldehyde-treated solution was mixed on a magnetic stirrer for 10 minutes. After sampling, the formaldehyde-treated viral solution was placed within a cooled incubator at 22°C ± 2°C. On Day 5 post addition of formaldehyde, the formaldehyde-treated viral solution was filtered through a 0.2 µm filter and then placed in the incubator at 22°C ± 2°C again. On Day 10, after removing the 10-Day inactivation final sample, a volume of 1 % (of the weight of the final formaldehyde-treated viral solution) of 200 mM-sodium metabisulphite solution (2mM final concentration) was aseptically transferred into the PETG container containing the formaldehyde-treated viral solution. After mixing for 5 minutes on a magnetic stirrer, the neutralized inactivated viral solution is held at room temperature (20 to 25°C) for a minimum of 30 minutes. After sampling, the neutralized inactivated viral solution is stored at 5°C ± 3°C until further processing.

Inactivation by formaldehyde

Critical parameters for this step are final formalin concentration, temperature, mixing and transfer into a new container. A preliminary acceptance criterion for maximum pfu/mL (determined by plaque assay) has been set on the diluted pool pre formaldehyde treatment.

The quality of the neutralized inactivated viral solution was monitored by the following parameters: Plaque assay on Day 10, SEC-HPLC, SDS-PAGE/Western Blot.

Interestingly, SEC-HPLC analysis of samples taken during the inactivation period followed by neutralization with bisulfite showed more or less constant peak area throughout the inactivation period. This is in contrast to JEV where losses of viral particles up to 60% are observed using the process disclosed by Srivastava et al. Vaccine 19 (2001) 4557-4565. In a scale-down model the viral losses were even much higher due to surface/area ratio at smaller scale and high losses due to unspecific adsorption. Differences of the ZikaV inactivation experiment and JEV inactivation were noticed as follows:

A) Much higher purity of ZikaV SGP pool with regard to residual PS ($<2\mu\text{g/mL}$) compared to JEV. The 3-fold ZikaV inactivated sample contained therefore $<<1\mu\text{g/mL}$ of residual PS. Commercial JEV SGP pool contains on average $\sim 120\mu\text{g/mL}$ (up to $152\mu\text{g/mL}$ possible). The average dilution to inactivation solution of ~ 14 -fold results in a residual PS content up to $\sim 11\mu\text{g/mL}$. It may be that higher amount of residual PS could cause virus precipitation due to cross-linking / reaction with formalin.

B) ZikaV inactivation sample contained $\sim 10\%$ sucrose (3-fold dilution of SGP pool containing ~ 30 - 35% sucrose). Sucrose might have stabilizing effect of viral ZikaV particles during treatment with formalin.

Dilution to DS and Formulation with Aluminium hydroxide (DP)

For preparation of ZikaV drug substance used in mouse potency assay an antigen content (expressed as total viral particles or SEC peak area) of 5 times higher compared to Ixiaro was targeted. The basis for determination of antigen content was SEC-HPLC. Briefly, a Superose 6 10/300 Increase column (GE Healthcare) equilibrated with PBS + 250 mM NaCl, pH 7.4 at 1 ml/min and 25°C , was used to detect ZikaV at 214 nm detection wavelength in harvest samples and throughout the downstream process. In the current JEV process the antigen content in NIV is determined by a specific ELISA. A good correlation was observed between antigen content determined by ELISA and SEC-HPLC. On average, the antigen content in commercial NIV samples is in the range of 33 AU/mL corresponding to $\sim 5.2\text{mAU}$ JEV peak area, see Figure 21.

ZikaV NIV day10 (Zika peak $\sim 36\text{ mAU}$, analysed on Waters HPLC/Superose6 Increase column) was diluted with PBS to a target of 6.3 ($\sim 5.7\text{x}$ dilution). Aluminium hydroxide was added to a final concentration of 0.5 mg/mL Aluminium (1/20 v/v Alum 2% stock solution added) to prepare ZikaV Drug Product (DP). The DP was gently mixed for 5 min. An aliquot of the DP was removed, Alum sedimented by centrifugation and the clear supernatant analysed by SEC-HPLC. No ZikaV peak was detected in the supernatant indicating complete adsorption (estimated as $>95\%$) of viral particles on the mineral adjuvant. Formulated ZikaV DP was stored at 2 - 8°C .

The impurity profile of the inactivated Zika virus DS is comparable to the profile of JEV DS with the exception of a lower PS content (Table 6).

5 **Table 6:** Determination of impurity profile in Zika and JEV DS samples:

	Specification (JEV DS)	JEV	Zika
HCP (ng/mL)	<100 LOQ 12 ng/mL	<LOQ	<LOQ
DNA (pg/mL)	<200 LOQ 40 pg/mL	<40	<40
Aggregates by SEC-MALLS (%)	Not specified, part of characterization LOQ 5%	<LOQ	<LOQ
PS (µg/mL)	Specification only at SGP pool to demonstrate consistent process performance (19-152µg/mL), *PS content in DS calculated based on PS content in SGP pool (~100 µg/mL) and average dilution factor (~28x) to DS; LOQ 2 µg/mL	~4*	<<LOQ

*Typical PS impurity in a JEV sample produced in accordance with protocol disclosed in Srivastava et al. Vaccine 19 (2001) 4557-4565.

SEC-MALLS Results

- 10 A representative SEC-HPLC elution profile of ZikaV NIV at 214 nm detection wave length is shown in Figure 16. Note that BSA (50µg/mL) was added to the sample to minimize losses in HPLC glass vial due to unspecific surface adsorption. ZikaV monomer content was estimated as ~98% with a multimer content of ~2%.
- 15 SEC-MALLS analysis (Figure 17) of the sample confirmed the radius R_z of the monomer ZikaV population peak 1 as 21.6 nm and ~49 nm for the multimer peak 2. Cumulative particle size distribution showed that 89% of all viral particles are within a radius range between 18 to 25nm (Figure 18).
- 20 Results confirm purity and homogeneity of ZikaV NIV.

Viral titer by plaque assay

Table 7: Active ZikaV pfus were quantified by plaque assay throughout the process.

Sample	Pfu/mL
Harvest day 2 (filtered)	6.4×10^7
Harvest day 3 (filtered)	1.0×10^8

Harvest day 5 (filtered)	1.5x10 ⁸
Harvest day 7 (filtered)	1.1x10 ⁸
PS treated harvest 300x concentrate (=SGP load)	9.0x10 ⁸
SGP pool	8.9x10 ⁸
Inactivation start (SGP pool 1:3 diluted)	3.4x10 ⁸
Inactivation day 5	<LOD
Inactivation day 10	<LOD

Comparison of PS and Benzonase on process performance

A direct comparison of DNA removal method of concentrated ZikaV harvest pool was done. One aliquot was treated with PS (2 mg/mL, 15min at room temperature), the other aliquot was treated with Benzonase (50 U/mL, 2 mM MgCl₂, 4h RT, 48h 2-8°C). Both samples were further purified by sucrose gradient as described in this report. Interestingly, the Benzonase treated samples did not yield any pure fractions after sucrose gradient centrifugation of the treated ZikaV harvest. In those fractions where the specific virus bands were detected, a high amount of host cell protein was detected throughout the collected fractions. The PS treated material resulted in pure ZikaV containing fractions as expected. This finding may suggest that PS is not only effective for DNA removal by precipitation; in addition it improves the recovery of virus particles in the gradient by disrupting interaction of DNA (fragments) and virus particles. Benzonase treatment does not remove DNA, it only results in its fragmentation. Residual DNA fragments might still interact with virus particles and residual HCPs resulting in cross-contamination and co-purification in the sucrose gradient. Pooled SGP fractions were also analysed by SEC-HPLC. Although a large peak was detected, SDS-PAGE confirmed that this sample was highly contaminated with HCPs. A large peak might be detected at UV214 and 280nm after SEC-HPLC analysis due to possible interaction of HCPs with large virus particles, changing the UV absorbance.

Immunogenicity of Vero grown Zika virus

Immunization of mice

Prior to immunization, groups of ten 6-week-old female CD1 mice were bled via vena facialis and pre-immune sera were prepared. One intraperitoneal immunizations of 200 µL were administered. A dose titration (12 µg, 3 µg, 1 µg, 0.33 µg, 0.11 µg, 0.037 µg and 0.012 µg, equivalent to the protein amount in IXIARO) of inactivated Zika virus formulated with aluminium hydroxide (Al(OH)₃) at a final concentration of 0.7%. Three weeks after immunization, blood was collected and immune sera were prepared. All animal experiments were conducted in accordance with Austrian law (BGB1 Nr. 501/1989) and approved by “Magistratsabteilung 58”.

Plaque reduction neutralization test (PRNT)

Twelve well plates were used for PRNT. Each well was seeded with 1 mL medium containing 4×10^5 Vero cells and incubated 35°C with 5% CO₂ overnight. Pools of heat inactivated sera from each dose group were tested in triplicate. The target viruses (H/PF/2013 (SEQ ID NO: 13) or MR766 (SEQ ID NO: 11)) were diluted to 100 pfu/165 µL. Equal volumes of target virus and serum dilution were incubated at 35°C with 5% CO₂ for 1 hour. The cell culture medium was aspirated from the Vero cells and 330 µL of the mixture target virus/serum dilution were added to each well and the plates were rocked back and forth 5 times before incubating for 2 hours at 35°C with 5% CO₂. To each well 1 mL of a 2% methylcellulose solution containing EMEM and nutrients was added, the plates were then incubated for 5 days at 35°C with 5% CO₂ before staining the cells for 1 hour with crystal violet/5% formaldehyde and subsequently washed 3 times with deionized water. The plates were air dried and the numbers of plaques in each well were manually counted.

Results

Neutralization was observed with serum pools from mice immunized with inactivated Zika virus vaccine (H/PF/2013) down to 37 ng (dosing equivalent to the amount protein in IXIARO®) against Zika viruses of both the Asian (H/PF/2013) and African (MR766) lineages (Figures 19 and 20, respectively). Complete inhibition was seen at the 1:20 serum dilution with an immunization dose down to 110 ng (dosing equivalent to the amount protein in IXIARO®). The neutralization of both the Asian (H/PF/2013) and African (MR766) lineages of the Zika virus was equivalent, which indicates high cross-neutralization between different Zika virus strains of the inactivated Zika virus vaccine (H/PF/2013).

Another neutralization assay was performed using the microneutralization assay as described by Larocca, et al. (2016, Nature doi:10.1038/nature18952). It was found that the inactivated Zika virus of the current invention had an MN50 (microneutralization) titer of 90 at 1 µg of inactivated purified virus.

Further methods: The immunogenicity of inactivated Zika virus preparations is assessed using a mouse model of Zika infection. Groups of adult mice are immunized subcutaneously (s.c.) with 500, 50, or 5 ng of inactivated Zika virus with adjuvant (*e.g.* aluminium hydroxide with or without IC31®), or without adjuvant. An additional group of mice receive PBS as a negative control. Each group is administered the indicated inoculum at $t=0$ and in some cases also at three to four weeks later ($t=3/4$).

Beginning approximately three weeks after administration of the last immunization, serum samples

are obtained from each of the mice at regular intervals. The serum samples are tested for the presence of neutralizing antibodies using PRNT.

The *in vivo* protective efficacy of the inactivated Zika virus preparations is also assessed using a mouse model of Zika infection, *i.e.* IFN-alpha/beta receptor knock-out mice (A129) (see *e.g.* Dowall et al., 4. March 2016, <http://dx.doi.org/10.1101/042358>) or blocking of the IFN-alpha/beta receptor by administration of anti-IFN-alpha/beta receptor monoclonal antibodies to C57BL/6 or BALB/c mice (see *e.g.* Pinto et al., 7. December 2011, DOI: 10.1371/journal.ppat.1002407). For protection assays, groups of 10 three- to eight-weeks-old A129, C57BL/6 or BALB/c mice are inoculated subcutaneously in the hindquarters with inactivated Zika virus with adjuvant (aluminium hydroxide) or without adjuvant at t=0. Age-matched controls are inoculated with PBS or non-specific antigens in alum. Mice are optionally boosted with a second administration of the indicated inoculation three to four weeks later. The mice are then challenged subcutaneously at three to eight weeks post immunization by inoculation with a deadly dose of live Zika virus. One day prior to challenge of C57BL/6 and BALB/c mice, they are passively administered (intraperitoneally) anti-IFN-alpha/beta receptor monoclonal antibodies. Challenged mice are monitored daily for morbidity and mortality for up to twenty-one days. Another alternative is to challenge intracranially adult vaccinated/non-vaccinated adult mice and observe protection.

It is expected that the Zika virus produced by the process of the invention will provide very similar functional read-outs in *in vitro*, *in vivo* and finally human trials as the currently licensed JEV vaccine in the EU and US and elsewhere, IXIARO®. The dosage may alter but due to the very similar impurity profile and almost identical manufacture, a very similar efficacy and safety result will be expected as was determined for the currently licensed JEV vaccine (licensed in the EU and US and elsewhere).

Discussion & Conclusion

The existing manufacturing platform for production of inactivated JEV vaccine IXIARO® was used as a basis for a manufacturing feasibility study of inactivated ZikaV vaccine candidate (Asian strain H/PF/2013). The virus was produced on Vero cells cultivated in roller bottles. The virus was purified by PS treatment followed by an optimized sucrose gradient. Inactivation was done by formalin treatment (0.02 %, 10 days at 22 °C). For exploratory immunization studies in mice, a DP formulated with Alum was prepared with an estimated 5-fold higher virus particle content compared to IXIARO®, the commercial JEV Vaccine. The impurity profile of the DS met all criteria as defined in the specification for IXIARO®, the commercial JEV vaccine. The neutralization of both the Asian

(H/PF/2013) and African (MR766) lineages of the Zika virus was equivalent, which indicates high cross-neutralization between different Zika virus strains of the inactivated Zika virus vaccine (H/PF/2013).

5 The in vivo data regarding immunogenicity of the inactivated Zika virus vaccine of the current invention indicates that the virus is surprisingly potently immunogenic and also highly cross-protective (very similar immunogenicity in African and Asian strains). Data indicate that immunogenicity was higher than the recently reported inactivated Zika virus vaccine candidate (Larocca, et. al, 2016, supra.). Inactivated viruses are among the safest vaccines and especially
10 preferred for deliver to populations where safety is especially concerning, such as pregnant women, children and immunocompromised individuals, which makes the herein disclosed inactivated Zika virus particularly suitable. Obtaining a high titer of inactivated virus is a challenge in the field. The herein disclosed process for purifying inactivated Zika virus results in not only a high yield, but also a very pure drug substance.

15 Further more detailed aspects of the invention:

A1. A Zika virus vaccine comprising an inactivated Zika virus particle, wherein the Zika virus particle is able to seroconvert a subject that is administered the Zika virus vaccine with at least a 70%
20 probability.

A2. The Zika virus vaccine of A1, wherein the Zika virus particle is able to seroconvert the subject that is administered the Zika virus vaccine with at least a 80%, 85%, 90%, or 95% probability.

25 A3. The vaccine of A1 or A2, wherein the Zika virus particle has a RNA genome corresponding to the DNA sequence provided by any one of the nucleic acid sequences of SEQ ID NOs: 2-13 or 72, or a variant nucleic acid sequence that is at least 88% identical to any one of SEQ ID NOs: 2-13 or 72 and able to pack a virulent Zika virus.

30 A4. The vaccine of any one of A1-A3, wherein the Zika virus particle has an E protein selected from the amino acid sequences provided by any one of SEQ ID NOs: 14-69, or a variant amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 14-69 and able to pack a virulent Zika virus.

A5. The vaccine of any one of A1-A4, wherein the Zika virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

5 A6. The vaccine of A5, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent to completely inactivate the Zika virus as measured by plaque assay.

A7. The vaccine of A6, wherein the chemical inactivation comprises contacting the Zika virus with formaldehyde.

10 A8. The vaccine of A7, wherein the formaldehyde inactivation comprises contacting the Zika virus with formaldehyde for between 2-10 days.

15 A9. The vaccine of any one of A5-A8, wherein the chemical activation is performed at about +4°C or about +22°C.

A10. The vaccine of any one of A1-A9, further comprising an adjuvant.

20 A11. The vaccine of A10, wherein the adjuvant is an aluminum salt adjuvant.

A12. The vaccine of A11, wherein the aluminum salt adjuvant is aluminium hydroxide or aluminium phosphate salt.

25 A13. The vaccine of any one of A10-A12, wherein the vaccine comprises or further comprises an adjuvant comprising a peptide and a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN).

A14. The vaccine of A13, wherein the peptide comprises the sequence KLKL5KLK (SEQ ID NO: 71) and the I-ODN comprises oligo-d(IC)13 (SEQ ID NO: 70).

30 A15. The vaccine of any one of A1-A14, further comprising one or more pharmaceutically acceptable excipient.

A16. The vaccine of any one of A1-A15, wherein the vaccine contains protamine sulphate or fragments or break-down products of PS at amounts too low to detect by HPLC, i.e., below 1 µg/mL, especially below 100 ng/mL.

5 A17. The vaccine of A16, wherein said protamine sulphate or fragments or break-down products of PS can be detected by mass spectroscopy or another sensitive method.

B1. A kit comprising a Zika virus vaccine of any one of A1-A15.

10

B2. The kit of B1, further comprising a second vaccine.

B3. The kit of B2, wherein the second vaccine is a West Nile virus vaccine, a Japanese Encephalitis virus vaccine, a Yellow Fever virus vaccine, a Dengue virus vaccine or a Chikungunya virus vaccine.

15

C1. A method, comprising administering a first dose of a therapeutically effective amount of the Zika virus vaccine of any one of A1-A15 to a subject in need thereof.

20

C2. The method of C1, further comprising administering a second dose of a therapeutically effective amount of the Zika virus vaccine.

C3. The method of C1 or C2, wherein the second dose of the Zika virus vaccine is administered about 7 days after the first dose of the Zika virus vaccine.

25

C4. The method of C1 or C2, wherein the second dose of the Zika virus vaccine is administered about 14 days after the first dose of the Zika virus vaccine.

C5. The method of C1 or C2, wherein the second dose of the Zika virus vaccine is administered about 28 days after the first dose of the Zika virus vaccine.

30

C6. The method of any one of C1-C5, wherein the administering results in production of Zika virus neutralizing antibodies.

35

- D1. A method of producing a Zika virus vaccine, comprising
- (i) passaging a Zika virus on Vero cells, thereby producing a culture supernatant comprising the Zika virus;
- 5 (ii) harvesting the culture medium of (i);
- (iii) precipitating the harvested culture medium of (ii), thereby producing a Zika virus supernatant; and
- (iv) optimally inactivating the Zika virus in the Zika virus supernatant of (iii) thereby producing an inactivated Zika virus.
- 10 D2. The method of D1, further comprising concentrating the culture medium of (ii) prior to step (iii).
- D3. The method of D1 or D2, wherein the precipitating of (iii) comprises contacting the culture
- 15 medium of (ii) with protamine sulfate or benzoate.
- D4. The method of any one of D1-D3, further comprising (v) dialyzing the inactivated Zika virus of (iv), thereby producing a dialyzed Zika virus.
- 20 D5. The method of D4, further comprising (vi) filtering the dialyzed Zika virus of (v).
- D6. The method of any one of D1-D5, wherein the inactivating is by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.
- 25 D7. The method of D6, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent for at least 4 days.
- D8. The method of D6 or D7, wherein the chemical inactivation agent comprises formaldehyde.
- 30 D9. The method of any one of D6-D8, wherein the chemical activation is performed at about +4°C or about +22°C.
- D10. The method of D8 or D9, further comprising neutralizing the formaldehyde.
- 35 D11. The method of D10, wherein the neutralizing is performed with sodium metabisulfite.

E1. The use of the optimally inactivated Zika virus vaccine of any one of A1-A15 for the treatment and/or prevention of a Zika virus infection.

5

E2. The use of E1, wherein the inactivated Zika virus vaccine is administered in a first dose of a therapeutically effective amount to a subject in need thereof.

10 E3. The use of E2, wherein the inactivated Zika virus vaccine is administered in a second dose of a therapeutically effective amount to the subject.

E4. The use of E3, wherein the second dose of the inactivated Zika virus vaccine is administered about 7 days after the first dose of the Zika virus vaccine.

15 E5. The use of E3, wherein the second dose of the Zika virus vaccine is administered about 14 days after the first dose of the Zika virus vaccine.

E6. The use of E3, wherein the second dose of the Zika virus vaccine is administered about 28 days after the first dose of the Zika virus vaccine.

20

E7. The use of any one of E1-E6, wherein the vaccine administration results in production of Zika virus neutralizing antibodies.

25 F1. A pharmaceutical composition for use in the treatment or prevention of a Zika virus infection, wherein said pharmaceutical composition comprises the optimally inactivated Zika virus vaccine of any one of A1-A15.

30 F2. The pharmaceutical composition of F1, wherein the inactivated Zika virus vaccine is administered in a first dose of a therapeutically effective amount to a subject in need thereof.

F3. The use of F2, wherein the inactivated Zika virus vaccine is administered in a second dose of a therapeutically effective amount to the subject.

F4. The use of F3, wherein the second dose of the inactivated Zika virus vaccine is administered about 7 days after the first dose of the Zika virus vaccine.

F5. The use of F3, wherein the second dose of the Zika virus vaccine is administered about 14 days after the first dose of the Zika virus vaccine.

F6. The use of F3, wherein the second dose of the Zika virus vaccine is administered about 28 days after the first dose of the Zika virus vaccine.

F7. The use of any one of F1-F6, wherein the vaccine administration results in production of Zika virus neutralizing antibodies.

G1. Use of an optimized sucrose gradient centrifugation for removal of protamine sulphate from purified infectious Zika virus particles.

G2. The use according to G1, wherein said optimized sucrose gradient centrifugation comprises a virus comprising fraction in a 10% +/- 1% (w/w) sucrose solution and three further layers of sucrose solutions with different densities, i.e. a first sucrose solution with 15% +/- 1% (w/w) sucrose, a second sucrose solution with 35% +/- 1% (w/w) sucrose, and a third sucrose solution with a 50% +/- 1% (w/w) sucrose.

G3. A process of purification of infectious Zika virus particles, comprising the steps of:

- a) providing a crude harvest (a) comprising virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate;
- b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising protamine, preferably a protamine salt, more preferably a protamine sulphate, even more preferably a recombinant protamine sulphate, to obtain a virus preparation (b);
- c) further purifying the virus preparation (b) by an optimized sucrose density gradient centrifugation, wherein the optimized sucrose gradient is provided such that the protamine can be completely or almost completely separated from the virus fraction; and wherein the protamine concentration is reduced by this step to the extent that the protamine concentration in the final drug substance is below 1 µg/ml, preferably below 0.5 µg/mL, more preferably below 0.1 µg/mL, most preferably below 0.05µg/mL.

G4. The process of G3, wherein said optimized sucrose density gradient centrifugation comprises a virus comprising fraction in a 10% +/- 1% (w/w) sucrose solution and three layers of sucrose with different densities, i.e. a first sucrose solution with 15% +/- 1% (w/w) sucrose, a second sucrose solution with 35% +/- 1% (w/w) sucrose, and a third sucrose solution with a 50% +/- 1% (w/w) sucrose.

G5. The process of any one of G3 to G4, additionally comprising a further purification step of: (d) a solid-phase matrix packed in a column comprising a ligand-activated core and an inactive shell comprising pores, wherein the molecular weight cut off of the pores excludes the virus particles from entering the ligand-activated core, and wherein a molecule smaller than the molecular weight cutoff of the pores can enter the ligand-activated core and collecting the virus particles.

G6. The process of any of G3 to G5, wherein the residual host cell DNA content of the Zika virus preparation (c) is less than 10 ng/mL and the residual host cell protein content of the final virus preparation (c) is less than 100 ng/mL.

G7. The process of any of G3 to G6, wherein said crude harvest (a) comprising Zika virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b).

G8. The process of G7, wherein the one or more pre-purification step(s) comprises
a) filtration using a filter having a pore size equal to or less than 0.2 μm ; and/or
b) digestion of host cell genomic DNA by enzymatic treatment; and/or
c) ultra/diafiltration using a hollow fiber membrane having a pore size equal to or greater than 300 kDa, preferably equal to or greater than 100 kDa.

G9. The process of any one of G3 to G8, wherein the concentration of protamine sulphate is 0.5 to 3 mg/ml, more preferably 1 to 2 mg/ml, more preferably 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml, most preferably 1.6 mg/ml or 2 mg/ml.

G10. The process of any one of G3 to G9, wherein the enrichment of infectious Zika virus particles in the virus preparation (c) or any final virus preparation relative to total virus products in the crude harvest (a) is in the range from at least 50% to 95%, preferably at least 80%.

G11. The process of any one of G7 to G10, wherein the one or more pre-purification step(s) prior to step (b) of any of G8 to G11 is performed using a filter having a pore size equal to or less than 1 μm , preferably 0.2 μm .

5 G12. The process of any one of G3 to G11, wherein the residual impurity of the Zika virus preparation (c) is less than 10%.

G13. The process of any one of G3 to G12, wherein the Zika virus is propagated in a cell line selected from the group consisting of an EB66 cell line, a Vero cell line, a Vero- α His cell line, a HeLa
10 cell line, a HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a diploid avian cell line.

G14. The process of G13, wherein said cell line is a Vero cell line.
15

G15. The process of any one of G3 to G14, wherein said infectious Zika virus particle is an infectious virus particle that is a live virus, a live attenuated virus, a chimeric virus, a modified live virus, or a recombinant live virus.

20 G16. The process of any one of G3 to G15, wherein said Zika virus is preferably a strain of the Asian lineage.

G17. The process of any one of G3 to G16, wherein said process resulting in final virus preparation (c) or (d) is followed by an inactivation step, wherein the virus is inactivated preferably by
25 formaldehyde.

G18. Use of the process according to any one of G3 to G17 for manufacturing a composition for immunization against a virus infection.

30 G19. The use according to G18, wherein said virus infection is an infection caused by a Zika virus.

Q1. A process of purification of infectious Zika virus particles, comprising the steps of:

(a) providing a crude harvest (a) comprising Zika virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate;

(b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising protamine, preferably a protamine salt, more preferably a protamine sulphate, even more preferably a recombinant protamine sulphate, to obtain a virus preparation (b);

(c) further purifying the virus preparation (b) by an optimized sucrose density gradient centrifugation, wherein the optimized sucrose gradient is provided such that the protamine can be completely or almost completely separated from the virus fraction; and wherein the protamine concentration is reduced by this step to the extent that the protamine concentration in the final drug substance is below 1 µg/ml, preferably below 0.5 µg/mL, more preferably below 0.1 µg/mL, most preferably below 0.05µg/mL.

Q2. The process of Q2, wherein the virus particles are from Zika virus.

Q3. The process of Q1 or Q2, additionally comprising the step of:

(d) a solid-phase matrix packed in a column comprising a ligand-activated core and an inactive shell comprising pores, wherein the molecular weight cut off of the pores excludes the virus particles from entering the ligand-activated core, and wherein a molecule smaller than the molecular weight cutoff of the pores can enter the ligand-activated core and collecting the virus particles.

Q4. The process of any of Q1 to 3, wherein the residual host cell DNA of the virus preparation (c) is less than 10 ng/mL and the residual host cell protein of the final virus preparation (c) is less than 100 ng/mL.

Q5. The process of any of Q1 to 4, wherein the crude harvest (a) comprising virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b).

Q6. The process of Q5, wherein the one or more pre-purification step(s) comprises

(a) filtration using a filter having a pore size equal to or less than 0.2 µm; and/or

(b) digestion of host cell genomic DNA by enzymatic treatment; and/or

(c) ultra/diafiltration using a hollow fiber membrane having a pore size equal to or greater than 300 kDa, preferably equal to or greater than 100 kDa.

Q7. The process of any one of Q1 to 6, wherein the concentration of protamine sulphate is 0.5 to 3 mg/ml, more preferably 1 to 2 mg/ml, more preferably 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml, most preferably 1.6 mg/ml or 2 mg/ml.

Q8. The process of any one of Q1 to 7, wherein the enrichment of infectious virus particles in the virus preparation (c) or any final virus preparation relative to total virus products in the crude harvest (a) is in the range from at least 50% to 95%, preferably at least 80%.

5 Q9. The process of any one of Q5 to 8, wherein the one or more pre-purification step(s) prior to step (b) of any of Q5 to 8 is performed using a filter having a pore size equal to or less than 1 μm , preferably 0.2 μm .

10 Q10. The process of any one of Q1 to 9, wherein the residual impurity of the virus preparation (c) is less than 10%.

15 Q11. The process of any one of Q1 to 10, wherein the virus is propagated in a cell line selected from the group consisting of an EB66 cell line, a Vero cell line, a Vero- α His cell line, a HeLa cell line, a HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a diploid avian cell line.

Q12. The process of Q11, wherein said cell line is a Vero cell line.

20 Q13. The process of any one of Q1 to 12, wherein the infectious virus particles is an infectious Zika virus particle that is a live virus, an attenuated live virus, a chimeric virus, a modified live virus, or a recombinant live virus.

25 Q14. The process of any one of Q1 to 13, wherein the Zika virus is a Zika virus strain of the Asian lineage or an immunogenic variant thereof.

30 Q15. The process of any one of Q1 to 14, wherein said process resulting in final virus preparation (c) or (d) is followed by an inactivation step, wherein the virus is inactivated preferably by formaldehyde.

Q16. Use of the process according to any one of Q1 to 15 for manufacturing a composition for immunization against a virus infection.

35 Q17. The use according to Q16, wherein the composition for immunization against a virus infection is an infection caused by Zika virus.

Q18. A composition comprising the virus particles obtainable or obtained by the process of any one of Q1 to 17 for treating and/or preventing an infection, such as e.g. a Zika virus infection.

5 Q19. A Zika virus vaccine comprising an inactivated Zika virus particle grown on vero cells, wherein the Zika virus particle is able to seroconvert a subject that is administered the Zika virus vaccine with at least a 70% probability and comprises minor amounts of protamine sulphate, preferably below the detection limit.

10 Q20. The Zika virus vaccine of Q19, wherein the Zika virus particle is able to seroconvert the subject that is administered the Zika virus vaccine with at least a 80%, 85%, 90%, or 95% probability, preferably a 80% probability.

15 Q21. The vaccine of Q19 or 20, wherein the Zika virus particle has a RNA genome corresponding to the DNA sequence provided by any one of the nucleic acid sequences of SEQ ID NOs: 2-13, or a variant nucleic acid sequence that is at least 88% identical to any one of SEQ ID NOs: 2-13 and able to pack a virulent Zika virus.

20 Q22. The vaccine of any one of Q19, 20 and 21, wherein the Zika virus particle has an E protein selected from the amino acid sequences provided by any one of SEQ ID NOs: 14-69 or 72, or a variant amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 14-69 or 72 and able to pack a virulent Zika virus.

25 Q23. The vaccine of any one of Q19, 20 to 22, wherein the Zika virus obtained by culturing on Vero cells is purified by protamine sulfate precipitation and sucrose gradient centrifugation.

Q24. The vaccine of Q23, wherein the sucrose gradient centrifugation is an optimized sucrose gradient centrifugation.

30 Q25. The vaccine of Q24, wherein the optimized sucrose gradient centrifugation comprises a virus comprising fraction in a 10% (w/w) sucrose solution and three layers of sucrose with different densities, i.e. a first sucrose solution with 15% (w/w) sucrose solution, a second sucrose solution with 35% (w/w) sucrose solution, and a third sucrose solution with a 50% (w/w) sucrose solution.

Q26. The vaccine of any one of Q19, 20 to 25, wherein the Zika virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

Q27. The vaccine of Q26, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent for longer than is required to completely inactivate the Zika virus as measured by plaque assay.

Q28. The vaccine of Q27, wherein the chemical inactivation comprises contacting the Zika virus with formaldehyde.

Q29. The vaccine of Q28, wherein the formaldehyde inactivation comprises contacting the Zika virus with formaldehyde for between 2-10 days.

Q30. The vaccine of any one of Q27-29, wherein the chemical activation is performed at about +4°C or about +22°C.

Q31. The vaccine of any one of Q19 to 30, further comprising an adjuvant.

Q32. The vaccine of Q31, wherein the adjuvant is an aluminum salt adjuvant.

Q33. The vaccine of Q32, wherein the aluminum salt adjuvant is aluminium hydroxide or aluminium phosphate salt.

Q34. The vaccine of Q32, wherein the aluminum salt adjuvant is aluminium hydroxide with less than 1.25ppb Cu based on the final pharmaceutical composition comprising the Zika virus, preferably the inactivated Zika virus.

Q35. The vaccine of any one of Q19 to 34, further comprising one or more pharmaceutically acceptable excipient.

R1. Use of protamine, preferably a protamine salt, to separate infectious and non-infectious Zika virus particles, host cell proteins and/or undefined low molecular weight materials.

R2. A process of purification of infectious Zika virus particles, comprising the steps of:

- (a) providing a crude harvest (a) comprising Zika virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate;
- (b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising protamine, preferably a protamine salt, more preferably a protamine sulphate, even more preferably a recombinant protamine sulphate, to obtain a virus preparation (b), wherein the enrichment of infectious virus particles in the virus preparation (b) relative to total virus products in the crude harvest (a) is in the range from at least 50% to 95%, preferably at least 80%.
- 5 R3. The use of R1 or the process of R2, wherein the virus particles are from Zika virus.
- R4. A process of purification of infectious Zika virus particles, comprising the steps of:
- 10 (a) providing a crude harvest (a) comprising Zika virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate;
- (b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising protamine, preferably a protamine salt, more preferably a protamine sulphate, even more preferably a recombinant protamine sulphate, to obtain a virus preparation (b);
- 15 (c) further purifying the virus preparation (b) by one or more size exclusion methods such as (i) a sucrose density gradient centrifugation, (ii) a solid-phase matrix packed in a column comprising a ligand-activated core and an inactive shell comprising pores, wherein the molecular weight cut off of the pores excludes the virus particles from entering the ligand-activated core, and wherein a molecule smaller than the molecular weight cutoff of the pores can enter the ligand-activated core and
- 20 collecting the virus particles, and/or (iii) size exclusion chromatography to obtain a virus preparation (c) comprising the infectious virus particles, wherein the residual host cell DNA of the virus preparation (c) is less than 100 ng/mL and the residual host cell protein and the residual aggregates of infectious virus particles of the final virus preparation (c) is less than 1 µg/mL.
- R5. The process of R4, wherein the residual host cell DNA of the virus preparation (c) is less than 25 10 ng/mL and the residual host cell protein of the final virus preparation (c) is less than 100 ng/mL.
- R6. The process of any of R2 to 5, wherein the crude harvest (a) comprising virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b).
- R7. The process of R6, wherein the one or more pre-purification step(s) comprises
- (a) filtration using a filter having a pore size equal to or less than 0.2 µm; and/or

(b) digestion of host cell genomic DNA by enzymatic treatment; and/or

(c) ultra/diafiltration using a hollow fiber membrane having a pore size equal to or greater than 300 kDa, preferably equal to or greater than 100 kDa.

5 R8. The process of any one of R2 to 7, wherein the concentration of protamine sulphate is 0.5 to 3 mg/ml, more preferably 1 to 2 mg/ml, more preferably 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml, most preferably 1.6 mg/ml.

R9. The process of any one of R2 to 8, wherein the enrichment of infectious virus particles in the virus preparation (c) or any final virus preparation relative to total virus products in the crude harvest (a) is in the range from at least 50% to 95%, preferably at least 80%.

10 R10. The process of any one of R6 to 9, wherein the one or more pre-purification step(s) prior to step (b) of any of R6 to 9 is performed using a filter having a pore size equal to or less than 1 μm , preferably 0.2 μm .

R11. The process of any one of R2 to 10, wherein the residual impurity of the virus preparation (c) is less than 10%.

15 R12. The process of any one of R2 to 11, wherein the virus is propagated in a cell line selected from the group consisting of an EB66 cell line, a Vero cell line, a Vero- α His cell line, a HeLa cell line, a HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a diploid avian cell line.

20 R13. The process of R12, wherein said cell line is a Vero cell line.

R14. The process of any one of R2 to 13, wherein the Zika virus is a live virus, an attenuated live virus, a chimeric virus, a modified live virus, or a recombinant live virus.

R15. The process of any one of R2 to 14, wherein the Zika virus is a Zika virus strain of the Asian lineage or an immunogenic variant thereof.

25 R16. The process of any one of R2 to 15, wherein said process resulting in final virus preparation (c) is followed by an inactivation step, wherein the virus is inactivated preferably by formaldehyde.

R17. Use of the process according to any one of R1 to 16 for manufacturing a composition for immunization against a virus infection.

R18. The use according to R17, wherein the composition for immunization against a virus infection is an infection caused by a Zika virus.

R19. A composition comprising the virus particles obtainable or obtained by the process of any one of R2 to 16 for treating and/or preventing an infection.

CLAIMS

1. A Zika virus vaccine comprising inactivated Zika virus particles, in which the Zika virus vaccine contains protamine sulphate (PS) or fragments thereof, in which PS or fragments of PS are present at amounts below 1 µg/mL and in which the vaccine is able to confer
5 seroprotection on at least 70% of subjects that are administered the Zika virus vaccine.
2. A Zika virus vaccine according to Claim 1, in which the Zika virus vaccine is able to confer seroprotection on at least 80% of subjects that are administered the Zika virus vaccine.
3. A Zika virus vaccine according to Claim 1, in which the Zika virus vaccine is able to confer seroprotection on at least 90% of subjects that are administered the Zika virus vaccine.
- 10 4. A Zika virus vaccine according to Claim 1, in which the Zika virus vaccine is able to confer seroprotection on at least 95% of subjects that are administered the Zika virus vaccine.
5. A vaccine according to any preceding claim, in which the Zika virus particles comprise an RNA genome corresponding to the DNA sequence provided by any one of the nucleic acid sequences of SEQ ID NOs: 2-13 or 72, or a variant nucleic acid sequence that is at least 88%
15 identical to any one of SEQ ID NOs: 2-13 or 72 and able to pack a virulent Zika virus.
6. A Zika virus vaccine according to any preceding claim, in which the Zika virus particles comprise an E protein selected from the amino acid sequences provided by any one of SEQ ID NOs: 14-69, or a variant amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 14-69 and able to pack a virulent Zika virus.
- 20 7. A Zika virus vaccine according to any preceding claim, in which the Zika virus particles are chemically inactivated, thermally inactivated, pH inactivated, or UV inactivated.
8. A Zika virus vaccine according to Claim 7, in which the chemical inactivation comprises contacting the Zika virus particles with a chemical inactivation agent for longer than is required to completely inactivate the Zika virus as measured by plaque assay.
- 25 9. A Zika virus vaccine according to Claim 7 or 8, in which the chemical inactivation comprises contacting the Zika virus particles with formaldehyde.

10. A Zika virus vaccine according to Claim 9, in which the formaldehyde inactivation comprises contacting the Zika virus particles with formaldehyde for between 2-10 days.
11. A Zika virus vaccine according to any of Claims 7 to 10, in which the chemical inactivation is performed at about +4°C or about +22°C.
- 5 12. A Zika virus vaccine according to any preceding claim, further comprising an adjuvant and/or one or more pharmaceutically acceptable excipients.
13. A Zika virus vaccine according to Claim 12, in which the adjuvant is an aluminium salt adjuvant.
14. A Zika virus vaccine according to Claim 13, in which the aluminium salt adjuvant is
10 aluminium hydroxide or aluminium phosphate salt.
15. The Zika virus vaccine according to Claim 14, in which the aluminium salt adjuvant is aluminium hydroxide with less than 1.25 ppb Cu based on the final pharmaceutical composition comprising the virus.
16. A Zika virus vaccine according to any of Claims 12 to 15, in which the Zika virus
15 vaccine comprises or further comprises an adjuvant comprising a peptide and a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN).
17. A Zika virus vaccine according to Claim 16, in which the peptide comprises the sequence KLKL5KLLK (SEQ ID NO: 71) and the I-ODN comprises oligo-d(IC)13 (SEQ ID NO: 70).
- 20 18. A Zika virus vaccine according to any preceding claim, in which the vaccine contains protamine sulphate or fragments thereof at amounts below 100 ng/mL.
19. A Zika virus vaccine according to Claim 18, in which the protamine sulphate or fragments thereof can be detected only by a highly sensitive method, in which the highly sensitive method is selected from mass spectroscopy and nuclear magnetic resonance.
- 25 20. A process for purification of inactivated Zika virus particles, comprising the steps of:

- (a) providing a crude harvest (a) comprising Zika virus particles and impurities, in which the impurities are generated from growing the Zika virus particles on a cell substrate;
- 5 (b) reducing impurities from crude harvest (a) by precipitation with an agent comprising a protamine salt, preferably a protamine sulphate, to obtain a Zika virus preparation (b);
- 10 (c) further purifying Zika virus preparation (b) by centrifugation on an optimized sucrose density gradient to obtain a Zika virus preparation (c) comprising the infectious Zika virus particles, in which the optimized sucrose density gradient is provided such that the protamine can be completely or almost completely separated from the virus fraction; and in which the protamine concentration is reduced by this step to the extent that the protamine concentration in the final drug substance is less than 1 µg/ml, preferably less than 900, 800, 700, 600, 500, 400, 300 or 200 ng/mL, preferably less than 100 ng/mL, as measured by a sensitive method selected from mass spectroscopy and nuclear magnetic resonance, in which the optimized sucrose density gradient comprises a Zika virus comprising fraction in a 10% +/- 1% (w/w) sucrose solution and three layers of sucrose with different densities, i.e. a first sucrose solution with 15% +/- 1% (w/w) sucrose, a second sucrose solution with 35% +/- 1% (w/w) sucrose, and a third sucrose solution with a 50% +/- 1% (w/w) sucrose; and
- 20 (d) subjecting Zika virus preparation (c) to one or more inactivation steps.